0001493152-16-009703.txt : 20160512 0001493152-16-009703.hdr.sgml : 20160512 20160512173250 ACCESSION NUMBER: 0001493152-16-009703 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 60 CONFORMED PERIOD OF REPORT: 20160331 FILED AS OF DATE: 20160512 DATE AS OF CHANGE: 20160512 FILER: COMPANY DATA: COMPANY CONFORMED NAME: eWELLNESS HEALTHCARE Corp CENTRAL INDEX KEY: 0001550020 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOME HEALTH CARE SERVICES [8082] IRS NUMBER: 451560906 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-55203 FILM NUMBER: 161645124 BUSINESS ADDRESS: STREET 1: 605 WEST KNOX ROAD, SUITE 202 CITY: TEMPE STATE: AZ ZIP: 85284 BUSINESS PHONE: 480-588-3333 MAIL ADDRESS: STREET 1: 605 WEST KNOX ROAD, SUITE 202 CITY: TEMPE STATE: AZ ZIP: 85284 FORMER COMPANY: FORMER CONFORMED NAME: Dignyte, Inc. DATE OF NAME CHANGE: 20120515 10-Q 1 form10-q.htm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 10-Q

 

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2016

 

[  ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission file number 000-55203

Description: Description: logo-ewellness (3)

 

eWELLNESS HEALTHCARE CORPORATION

(Exact name of registrant as specified in its charter)

 

Nevada   45-1560906
(State or other jurisdiction of
incorporation or organization)
  (I.R.S. Employer
Identification No.)
     
11825 Major Street, Culver City, California   90230
(Address of principal executive offices)   (Zip Code)

 

(310) 915-9700

(Registrant’s telephone number, including area code)

 

Copies of Communications to:

Louis Taubman, Esq.

Hunter Taubman Fischer

1450 Broadway, 26th Floor

New York, NY 10018

P: 917-512-0828

F: 212-202-6380

 

Indicate by check mark whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes [X] No [  ]

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes [X] No [  ]

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Ruble 12b-2 of the Exchange Act.

 

Large accelerated filer [  ] Accelerated filer [  ]
   
Non-accelerated filer [  ] (Do not check if a smaller reporting company) Smaller reporting company [X]

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [  ] No [X]

 

The number of shares of Common Stock, $0.001 per share par value, outstanding on May 12, 2016 was 18,697,770 shares.

 

 

 

  
 

 

TABLE OF CONTENTS

 

PART I - FINANCIAL INFORMATION  
Item 1 Financial Statements F-1
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 3
Item 3 Quantitative and Qualitative Disclosures About Market Risk 8
Item 4 Controls and Procedures 8
PART II - OTHER INFORMATION  
Item 1 Unregistered Sales of Equity Securities and Use of Proceeds 9
Item 2 Exhibits 9
Signatures   11

 

2
 

 

PART I - FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS

 

eWELLNESS HEALTHCARE CORPORATION
CONDENSED BALANCE SHEETS

 

   March 31, 2016   December 31, 2015 
   (unaudited)     
ASSETS          
CURRENT ASSETS          
Cash  $13,582   $41,951 
Prepaid Expenses   42,824    4,053 
           
Total current assets   56,406    46,004 
           
Property & equipment, net   5,543    5,964 
Intangible assets, net   19,123    19,862 
           
TOTAL ASSETS  $81,072   $71,830 
           
LIABILITIES AND STOCKHOLDERS’ DEFICIT          
           
CURRENT LIABILITIES          
Accounts payable and accrued expenses  $354,693   $248,305 
Accounts payable - related party   50,362    43,717 
Accrued expenses - related party   49,226    33,090 
Accrued compensation   767,000    677,000 
Contingent liability   90,000    90,000 
Convertible debt, net of discount   261,727    309,945 
Derivative liability   2,802    2,802 
Short term note and liabilities   112,048    71,605 
           
Total current liabilities   1,687,858    1,476,464 
           
Total Liabilities   1,687,858    1,476,464 
           
STOCKHOLDERS’ DEFICIT          
Preferred stock, authorized, 10,000,000 shares, $.001 value, 0 shares issued and outstanding   -    - 
Common stock, authorized 100,000,000 shares, $.001 par value, 18,697,770 and 18,170,538 issued and outstanding, respectively   18,698    18,171 
Shares to be issued   10,000    - 
Additional paid in capital   2,246,311    2,033,383 
Accumulated deficit   (3,881,795)   (3,456,187)
           
Total Stockholders’ Deficit   (1,606,786)   (1,404,634)
           
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT  $81,072   $71,830 

 

The accompanying notes are an integral part of these condensed financial statements

 

  F-1 

 

 

e WELLNESS HEALTHCARE CORPORATION
CONDENSED STATEMENTS OF OPERATIONS

(unaudited)

 

   Three Months Ended 
   March 31, 2016   March 31, 2015 
OPERATING EXPENSES          
Executive compensation  $190,633   $186,000 
General and administrative   51,526    34,588 
Professional fees   111,288    90,394 
           
Total Operating Expenses   353,447    310,982 
           
Loss from Operations   (353,447)   (310,982)
           
OTHER INCOME (EXPENSE)          
Gain on extinguishmment of debt   -    11,323 
Interest expense, related parties   (897)   (1,078)
Interest expense   (71,264)   (16,142)
           
Net Loss before Income Taxes   (425,608)   (316,879)
           
Income tax expense   -    - 
           
Net Loss  $(425,608)  $(316,879)
           
Basic and diluted (loss) per share  $(0.02)  $(0.02)
           
Basic and diluted weighted average shares outstanding   18,352,696    16,740,778 

 

The accompanying notes are an integral part of these condensed financial statements

 

  F-2 

 

 

e WELLNESS HEALTHCARE CORPORATION

CONDENSED STATEMENTS OF CASH FLOWS

(unaudited)

 

   For Three Months Ended 
   March 31, 2016   March 31, 2015 
Cash flows from operating activities          
Net loss  $(425,608)  $(316,879)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization   1,160    950 
Contributed services   96,000    97,500 
Shares issued for consulting services   -    9,389 
Imputed interest - related party   897    1,078 
Option expense   4,633    - 
Interest on debt extension   22,494    7,153 
Amortization of debt discount to interest expense   37,470    8,726 
Rent contributed by officer   1,500    - 
Changes in operating assets and liabilities          
Advances - related parties   -    7,054 
Prepaid expense   1,329    16,074 
Accounts payable and accrued expenses   118,974    (34,880)
Accounts payable - related party   6,645    (13,100)
Accrued expenses - related party   16,137    (5,105)
Accrued compensation   90,000    85,000 
           
Net cash used in operating activities   (28,369)   (137,040)
           
Cash flows from investing activities          
Purchase of equipment   -    (4,207)
Net cash used in investing activities   -    (4,207)
           
Cash flows from financing activities          
Convertible loan payable proceeds   -    20,000 
Common stock subscribed   -    146,100 
           
Net cash provided by financing activities   -    166,100 
           
Net increase in cash   (28,369)   24,853 
           
Cash, beginning of period   41,951    900 
           
Cash, end of period  $13,582   $25,753 
           
Supplemental Information:          
Cash paid for:          
Taxes  $-    - 
Interest Expense  $-   $- 

 

The accompanying notes are an integral part of these condensed financial statements

 

  F-3 

 

 

eWellness Healthcare Corporation

Notes to Condensed Financial Statements

(unaudited)

 

Note 1. The Company

 

The Company and Nature of Business

 

eWellness Healthcare Corporation (f/k/a Dignyte, Inc.), (the “Company”, “we”, “us”, “our”) was incorporated in the State of Nevada on April 7, 2011, to engage in any lawful corporate undertaking, including, but not limited to, selected mergers and acquisitions. The Company has generated no revenues to date. Prior to the Share Exchange Agreement discussed below, other than issuing shares to its original shareholder, the Company never commenced any operational activities.

 

The eWellness strategy as a first-to-market enterprise in the Physical Therapy based telemedicine industry is to deliver a telemedicine physical therapy service augmenting corporate wellness programs and also expand nationally through a Software as a Service (SaaS) business model that enables existing physical therapy practices to extend their offerings via our telemedicine solution. Our objective is to provide Distance Monitored Physical Therapy (PHZIO) Programs to pre diabetic, cardiac and health challenged patients and knee and hip surgery rehabilitation. For corporate wellness programs, our services are designed to deliver significant healthcare savings to the company while charging a very small relative incremental cost.

 

Share Exchange Agreement

 

On April 11, 2014, Digntye, Inc. (“Dignyte”), a publicly held Nevada corporation and eWellness Corporation (“Private Co”), a privately held company incorporated in Nevada, executed a Share Exchange Agreement (or “Initial Exchange Agreement”). Prior to the execution and delivery of the final Amended and Restated Share Exchange Agreement (the “Agreement”), the Board of Directors of Dignyte approved the Agreement and the transactions contemplated thereby. Similarly, the Board of Directors of the Private Co. approved the exchange. On April 25, 2014, immediately prior to the execution and delivery of the Agreement, Dignyte amended its certificate of incorporation to change its corporate name from “Dignyte, Inc.” to “eWellness Healthcare Corporation.”

 

Pursuant to the Agreement, eWellness Healthcare Corporation issued 9,200,000 shares of unregistered common stock, $.001 par value per share (the “common stock”) to the shareholders of the Private Co. in exchange for all outstanding shares of the Private Co.’s common stock. In addition, our former chief executive officer agreed: (i) to tender 5,000,000 shares of common stock of Dignyte back to the Company for cancellation; (ii) assign from his holdings, an additional 2,500,000 shares of Dignyte to the shareholders of the Private Co. resulting in a total of 11,700,000 shares owned by those shareholders; and, (iii) to a further assignment of an additional 2,100,000 shares of Dignyte to other parties as stated therein (collectively, the “CEO Stock Actions”).

 

As the parties satisfied all of the closing conditions, on April 30, 2014, we closed the Share Exchange. As a result, the Private Co. shareholders own approximately 76.97% of our issued and outstanding common stock, after giving effect to CEO Stock Actions.

 

Following the Share Exchange, we abandoned our prior business plan and we are now pursuing the Private Co.’s historical businesses and proposed businesses. The Private Co. is the surviving company under the share exchange and became a wholly owned subsidiary of the Company.

 

  F-4 

 

 

eWellness Healthcare Corporation

Notes to Condensed Financial Statements

(unaudited)

 

For financial reporting purposes, the Share Exchange represents a “reverse merger” rather than a business combination. Consequently, the transaction is accounted for as a reverse-merger and recapitalization. eWellness Corporation is the acquirer for financial reporting purposes and Dignyte, Inc. is the acquired company. Consequently, the assets and liabilities and the operations that are reflected in the historical financial statements prior to the transactions are those of eWellness Corporation and are recorded at the historical cost basis of eWellness

Corporation,and the consolidated financial statements after completion of the transaction include the assets, liabilities and operations of eWellness Healthcare Corporation, and eWellness Corporation from the closing date of the transaction. Additionally all historical equity accounts and awards of eWellness Corporation, including par value per share, share and per share numbers, have been adjusted to reflect the number of shares received in the transaction.

 

The foregoing description of the Share Exchange Agreement does not purport to be complete and is qualified in its entirety by the Share Exchange Agreement, a copy of which is attached to the Company’s Current Report on Form 8-K/A as filed with the Securities and Exchange Commission on August 6, 2014. At the execution of the Share Exchange Agreement, the number of total shares of common stock outstanding was 15,200,000.

 

On July 22, 2015, the Company’s wholly owned subsidiary, eWellness Corporation, was merged into the Company and, therefore, no longer exists as a separate entity.

 

Note 2. Summary of Significant Accounting Policies

 

Basis of Presentation

 

The interim financial information of the Company as of periods ended March 31, 2016 and March 31, 2015 is unaudited. The balance sheet as of December 31, 2015 is derived from audited financial statements of eWellness Healthcare Corporation. The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial statements. Accordingly, they omit or condense footnotes and certain other information normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles. The accounting policies followed for quarterly financial reporting conform to the accounting policies disclosed in ASU 2014-10. In the opinion of management, all adjustments which are necessary for a fair presentation of the financial information for the interim periods reported have been made. All such adjustments are of a normal recurring nature. The results of operations for the three months ended March 31, 2016 are not necessarily indicative of the results that can be expected for the entire year ending December 31, 2016. The unaudited financial statements should be read in conjunction with the financial statements and the notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2015.

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from these good faith estimates and judgments.

 

Going Concern

 

For the period ended March 31, 2016, the Company has no revenues and no operations. The Company has an accumulated loss of $3,881,795. In view of these matters, there is substantive doubt about the Company’s ability to continue as a going concern. The Company’s ability to continue operations is dependent upon the Company’s ability to raise additional capital and to ultimately achieve sustainable revenues and profitable operations, of which there can be no guarantee. The Company intends to finance its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

 

  F-5 

 

 

eWellness Healthcare Corporation

Notes to Condensed Financial Statements

(unaudited)

 

Deferred Offering and Acquisition Costs

 

The Company defers as other assets the direct incremental costs of raising capital until such time as the offering is completed. At the time of the completion of the offering, the costs will be charged against the capital raised. Should the offering be terminated, the deferred offering costs will be charged to operations during the period in which the offering is terminated. Direct acquisition costs will be expensed as incurred.

 

Fair Value of Financial Instruments

 

The Company complies with the accounting guidance under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820-10, Fair Value Measurements, as well as certain related FASB staff positions. This guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact business and considers assumptions that marketplace participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance.

 

The guidance also establishes a fair value hierarchy for measurements of fair value as follows:

 

Level 1 – quoted market prices in active markets for identical assets or liabilities.

 

Level 2 – inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

 

Level 3 – unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

 

As of March 31, 2016, the Company had the following assets and liabilities measured at fair value on a recurring basis.

 

    Total     Level 1     Level 2     Level 3  
Derivative liability   $ 2,802     $ -     $ -     $ 2,802  
Total liabilities measure at fair value   $ 2,802     $ -     $ -     $ 2,802  

 

Cash and Cash Equivalents

 

Cash and cash equivalents includes all cash deposits and highly liquid financial instruments with an original maturity to the Company of three months or less.

 

  F-6 

 

 

eWellness Healthcare Corporation

Notes to Condensed Financial Statements

(unaudited)

 

Property and Equipment

 

Property and equipment are recorded at historical cost. Minor additions and renewals are expensed in the year incurred. Major additions and renewals are capitalized and depreciated over their estimated useful lives. Depreciation is recorded over the estimated useful lives of the related assets using the straight-line method for financial statement purposes. The Company uses other depreciation methods (generally accelerated) for tax purposes where appropriate. The estimated useful lives for significant property and equipment categories are as follows:

 

Furniture and Fixtures   5-7 Years
Computer Equipment   5-7 Years
Software   3 Years

 

The Company regularly evaluates whether events or circumstances have occurred that indicate the carrying value of long-lived assets may not be recoverable. If factors indicate the asset may not be recoverable, we compare the related undiscounted future net cash flows to the carrying value of the asset to determine if impairment exists. If the expected future net cash flows are less than the carrying value, an impairment charge is recognized based on the fair value of the asset.

 

Revenue Recognition

 

The Company has yet to realize revenues from operations. Once the Company has commenced operations, it will recognize revenues when delivery of goods or completion of services has occurred provided there is persuasive evidence of an agreement, acceptance has been approved by its customers, the fee is fixed or determinable based on the completion of stated terms and conditions, and collection of any related receivable is probable.

 

Loss per Common Share

 

The Company follows ASC Topic 260 to account for the loss per share. Basic loss per common share calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per common share calculations are determined by dividing net loss by the weighted average number of common shares and dilutive common share equivalents outstanding. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation. As the Company has no common stock equivalents and has incurred losses for the periods ended March 31, 2016 and 2015, no dilutive shares are added into the loss per share calculations.

 

Recent Accounting Pronouncements

 

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) that are adopted by the Company as of the specified date. The Company has elected to the early adoption of ASU 2015-03 that simplifies the presentation of debt issuance costs. The Company had previously used the methodology in this standard and has adopted the pronouncement for current and future debt instruments.

 

Note 3. Property and Equipment

 

Property and equipment consists of computer equipment that is stated at cost $8,421 and $8,421 less accumulated depreciation of $2,878 and $2,457 at March 31, 2016 and December 31, 2015, respectively. Depreciation expense was $421 for the three months ended March 31, 2016 and $211 for the three months ended March 31, 2015, respectively.

 

  F-7 

 

 

eWellness Healthcare Corporation

Notes to Condensed Financial Statements

(unaudited)

 

Note 4. Intangible Assets

 

The Company recognizes the cost of a software license and a license for use of a programming code as intangible assets. The stated cost of these assets were $24,770 and $24,770 less accumulated amortization of $5,647 and $4,908 for the periods ended March 31, 2016 and December 31, 2015, respectively. For the periods ended March 31, 2016 and March 31, 2015, the amortization expense recorded was $739 and $739, respectively.

 

Note 5. Related Party Transactions

 

Through the period ended March 31, 2016, a related party, a company for which the Company’s former Secretary-Treasurer and CFO is also serving as CFO, has paid $96,831 on the Company’s behalf for various operating expenses. The amount outstanding as of March 31, 2016 and December 31, 2015 was $50,362 and $43,717, respectively. The Company recorded $897 and $1,078 imputed interest on the amount owed to the related party based on an interest rate of 8% for the three months ended March 31, 2016 and March 31, 2015, respectively.

 

During 2014, the Company entered into a license agreement with a programming company in which one of our directors is Chief Marketing Officer. Through the licensing agreement, we obtained a perpetual license to use the programming code created by a video management platform as a base to develop our telemedicine video service for a license fee of $20,000. The license fee is recorded as an Intangible Asset and Accounts Payable on the Balance Sheet at March 31, 2016 and December 31, 2015.

 

On April 1, 2015, the Company entered into an operating agreement with a physical therapy company (“EPT”) which is owned by the Company’s President and Chief Executive Officer. Through the agreement the Company agrees to provide operating capital advances in order for EPT to offer the Company’s PHIZIO platform to physical therapy patients. For accounting and tax purposes, the net profits or losses generated by EPA shall be allocated on a monthly basis. The Company will receive 75% of the net patient insurance reimbursements associated with the operation of the PHIZIO platform.

 

The Company rents its Culver City, CA office space from a company owned by our CEO. The imputed rent expense of $500 per month is recorded in the Consolidated Statement of Operations and Additional Paid in Capital in the Balance Sheet.

 

The officers of the Company incur business expenses on behalf of the Company. The amounts outstanding as of March 31, 2016 and December 31, 2015 were $49,226 and $33,090, respectively.

 

Note 6. Income Taxes

 

The tax provision for interim periods is determined using an estimate of the Company’s effective tax rate for the full year adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter the Company updates its estimate of the annual effective tax rate, and if the estimated tax rate changes, the Company makes a cumulative adjustment.

 

At March 31, 2016 and December 31, 2015, the Company had a full valuation allowance against its deferred tax assets, net of expected reversals of existing deferred tax liabilities, as it believes it is more likely than not that these benefits will not be realized.

 

The Company does not identify any material uncertain tax positions of the Company on returns that have been filed or that will be filed. The Company has not had operations and has deferred items consisting entirely of unused Net Operating Losses. Since the Company does not believe that this Net Operating Loss will ever produce a tax benefit, even if examined by taxing authorities and disallowed entirely, there would be no effect on the financial statements.

 

  F-8 

 

 

eWellness Healthcare Corporation

Notes to Condensed Financial Statements

(unaudited)

 

The Company’s policy is to recognize potential interest and penalties accrued related to unrecognized tax benefits within income tax expense. For the periods ended March 31, 2016, and March 31, 2015, the Company did not recognize nor accrue for any interest or penalties.

 

Note 7. Non-Convertible Notes Payable

 

On March 14, 2016, the Company issued a 45-day promissory note to a shareholder of $112,550 as an extension for notes with a shareholder dated May 30 2015, July 15, 2015, September 16, 2015, October 11, 2015, and December 6, 2015. The amount of the note includes interest accrued on the previous notes, risky loan fee and a default fee. The note has an annual interest rate of 12% due and payable on May 1, 2016. As an inducement for this promissory note, the Company issued 400,000 warrants to purchase Company common stock at $.80 per share. The fair value of the warrants is $794. For the period ended March 31, 2016, the Company recorded $2,470 of interest expense for this note.

  

Note 8. Convertible Notes Payable

 

On February 20, 2016, a convertible promissory note with the principal value of $69,500 was converted to 227,332 shares of common stock at a conversion price of $.35 per share. The warrants associated with this note were not exercised. See Note 9 below – Equity Transactions.

  

Note 9. Equity Transactions

 

Preferred Stock

 

The total number of shares of preferred stock which the Company shall have authority to issue is 10,000,000 shares with a par value of $0.001 per share. There have been no preferred shares issued as of March 31, 2016.

 

Common Stock

 

The total number of shares of common stock which the Company shall have authority to issue is 100,000,000 shares with a par value of $0.001 per share.

 

Holders of shares of common stock are entitled to cast one vote for each share held at all stockholders’ meetings for all purposes including the election of directors. The common stock does not have cumulative voting rights.

 

No holder of shares of stock of any class is entitled as a matter of right to subscribe for or purchase or receive any part of any new or additional issue of shares of stock of any class or of securities convertible into shares of stock of any class, whether now hereafter authorized or whether issued for money, for consideration other than money, or by way of dividend.

 

  F-9 

 

 

eWellness Healthcare Corporation

Notes to Condensed Financial Statements

(unaudited)

 

On January 20, 2016, the Company authorized the issuance of 50,000 shares for consulting services for a value of $5,000 that is being amortized over twelve months.

 

On February 29, 2016, the Company authorized the issuance of 227,232 shares for conversion of convertible debt of $69,500.

 

On March 3, 2016, the Company authorized the issuance of 100,000 shares for consulting services for a value of $10,100 that is being amortized over six months.

 

On March 11, 2016, the Company authorized the issuance of 150,000 shares for consulting services for a value of $15,000 that is being amortized over twelve months.

 

Stock Options

 

On August 6, 2015, the Board of Directors approved the 2015 Stock Option Plan, pursuant to which certain directors, officers, employees and consultants will be eligible for certain stock options and grants. The Plan is effective as of August 1, 2015 and the maximum number of shares reserved and available for granting awards under the Plan shall be an aggregate of 3,000,000 shares of common stock, provided however that on each January 1, starting with January 1, 2016, an additional number of shares equal to the lesser of (A) 2% of the outstanding number of shares (on a fully-diluted basis) on the immediately preceding December 31 and (B) such lower number of shares as may be determined by the Board or committee charged with administering the plan. This plan may be amended at any time by the Board or appointed plan Committee.

 

On February 19, 2016, the Board of Directors authorized the issuance of stock options under this plan to selected employees, directors and consultants. The stock options vest immediately upon the grant date and authorize the recipient to purchase shares of common stock at $.80 per share within five years of the grant date.. The Company valued the issuance of these warrants using the Black Scholes valuation model assuming a 2.0% risk free rate and an 61.4% volatility. At March 31, 2016, the vested value of the options was $4,633. This was recorded as compensation expense.

 

The following is a summary of the status of all Company’s stock options as of March 31, 2016 and changes during the three months ended on that date:

 

    Number     Weighted  
    of Stock
Options
    Average Exercise Price  
Oustanding at January 1, 2016     0     $ -  
Granted     2,850,000     $ 0.80  
Exercised     0     $ -  
Cancelled     0     $ -  
Outstanding at March 31, 2016     2,850,000     $ 0.80  
Options exercisable at March 31, 2016     2,850,000     $ 0.80  

 

Warrants

 

On March 14, 2016, the Company authorized the issuance of 400,000 warrants that were issued as part of the extension of a promissory note dated December 6, 2015. The fair value of the warrants is $794.

 

The following is a summary of the status of all of the Company’s warrants as of March 31, 2016 and changes during the three months ended on that date:

 

  F-10 

 

 

eWellness Healthcare Corporation

Notes to Condensed Financial Statements

(unaudited)

 

            Weighted  
      Number of     Average  
      Warrants     Exercise Price  
Outstanding at January 1, 2015       609,533     $ 0.35  
Granted       5,021,658     $ 0.63  
Exercised       -     $ -  
Cancelled       -     $ -  
Outstanding at December 31, 2015       5,631,191     $ 0.61  
Granted       400,000     $ 0.80  
Exercised       -     $ -  
Cancelled       -     $ -  
Outstanding at March 31, 2016       6,031,191     $ 0.62  

 

For purpose of determining the fair market value of the warrants and options issued during the three months ended March 31, 2016, we used the Black Scholes option valuation model. These valuations were done throughout the period at the date of issuance and not necessary as of the reporting date. As there is no current market for the Company’s shares, we used $0.10 as the stock price at valuation date to be consistent with prior issuances and the stock prices of comparable companies to determine volatility. The significant assumptions used in the Black Scholes valuation of the date of issuance are as follows:

 

Stock price on the valuation date   $ 0.10  
Exercise price of warrants   $ .35 and .80  
Dividend yield     0.00 %
Years to maturity      2.5  
Risk free rate     2.0%  
Expected volatility     61%  

 

Note 10. Commitments, Contingencies

 

The Company may be subject to lawsuits, administrative proceedings, regulatory reviews or investigations associated with its business and other matters arising in the normal conduct of its business. The following is a description of an uncertainty that is considered other than ordinary, routine and incidental to the business.

 

The closing of the Initial Exchange Agreement with Private Co. was conditioned upon certain, limited customary representations and warranties, as well as, among other things, our compliance with Rule 419 (“Rule 419”) of Regulation C under the Securities Act of 1933, as amended (the “Securities Act”) and the consent of our shareholders as required under Rule 419. Accordingly, we conducted a “Blank Check” offering subject to Rule 419 (the “Rule 419 Offering”) and filed a Registration Statement on Form S-1 to register the shares of such offering; the Registration Statement was declared effective on September 14, 2012. We used 10% of the subscription proceeds as permitted under Rule 419 and the amount remaining in the escrow trust as of the date of the closing of the Share Exchange was $90,000 (the “Trust Account Balance”).

 

  F-11 

 

 

eWellness Healthcare Corporation

Notes to Condensed Financial Statements

(unaudited) 

 

Rule 419 required that the Share Exchange occur on or before March 18, 2014, but due to normal negotiations regarding the transactions and the parties’ efforts to satisfy all of the closing conditions, the Share Exchange did not close on such date. Accordingly, after numerous discussions with management of both parties, they entered into an Amended and Restated Share Exchange Agreement (the “Share Exchange Agreement”) to reflect a revised business combination structure, pursuant to which we would: (i) file a registration statement on Form 8-A (“Form 8A”) to register our common stock pursuant to Section 12(g) of the Exchange Act, which we did on May 1, 2014 and (ii) seek to convert the participants of the Rule 419 Offering into participants of a similarly termed private offering (the “Converted Offering”), to be conducted pursuant to Regulation D, as promulgated under the Securities Act.

 

Fifty-two persons participated in the Rule 419 Offering and each of them gave the Company his/her/its consent to use his/her/its escrowed funds to purchase shares of the Company’s restricted common stock in the Converted Offering (the “Consent”) rather than have their funds returned. To avoid further administrative work for the investors, we believe that we took reasonable steps to inform investors of the situation and provided them with an appropriate opportunity to maintain their investment in the Company, if they so choose, or have their funds physically returned. Management believed the steps it took constituted a constructive return of the funds and therefore met the requirements of Rule 419.

 

However, pursuant to Rule 419(e)(2)(iv), “funds held in the escrow or trust account shall be returned by first class mail or equally prompt means to the purchaser within five business days [if the related acquisition transaction does not occur by a date that is 18 months after the effective date of the related registration statement].” As set forth above, rather than physically return the funds, we sought consent from the investors of the Rule 419 Offering to direct their escrowed funds to the Company to instead purchase shares in the Converted Offering. The consent document (which was essentially a form of rescission) was given to the investors along with a private placement memorandum describing the Converted Offering and stated that any investor who elected not to participate in the Converted Offering would get 90% of their funds physically returned. Pursuant to Rule 419(b)(2)(vi), a blank check company is entitled to use 10% of the proceed/escrowed funds; therefore, if a return of funds is required, only 90% of the proceed/escrowed funds need be returned. The Company received $100,000 proceeds and used $10,000 as per Rule 419(b)(2)(vi); therefore, only $90,000 was subject to possible return.

 

As disclosed therein, we filed the amendments to the initial Form 8-K in response to comments from the SEC regarding the Form 8-K and many of those comments pertain to an alleged violation of Rule 419. The Company continued to provide the SEC with information and analysis as to why it believes it did not violate Rule 419, but was unable to satisfy the SEC’s concerns. Comments and communications indicate that Rule 419 requires a physical return of funds if a 419 offering cannot be completed because a business combination was not consummated within the required time frame; constructive return is not permitted.

 

As a result of these communications and past comments, we are disclosing that we did not comply with the requirements of Rule 419, which required us to physically return the funds previously submitted to escrow pursuant to the Rule 419 Offering. As a result of our failure to comply with Rule 419, the SEC may bring an enforcement action or commence litigation against us for failure to strictly comply with Rule 419. If any claims or actions were to be brought against us relating to our lack of compliance with Rule 419, we could be subject to penalties (including criminal penalties), required to pay fines, make damages payments or settlement payments. In addition, any claims or actions could force us to expend significant financial resources to defend ourselves, could divert the attention of our management from our core business and could harm our reputation.

 

  F-12 

 

 

eWellness Healthcare Corporation

Notes to Condensed Financial Statements

(unaudited) 

 

Ultimately, the SEC determined to terminate its review of the Initial Form 8-K and related amendments, rather than provide us with additional opportunities to address their concerns and therefore, we did not clear their comments. It is not possible at this time to predict whether or when the SEC may initiate any proceedings, when this issue may be resolved or what, if any, penalties or other remedies may be imposed, and whether any such penalties or remedies would have a material adverse effect on our consolidated financial position, results of operations, or cash flows. Litigation and enforcement actions are inherently unpredictable, the outcome of any potential lawsuit or action is subject to significant uncertainties and, therefore, determining at this time the likelihood of a loss, any SEC enforcement action and/or the measurement of the amount of any loss is complex. Consequently, we are unable to estimate the range of reasonably possible loss. Our assessment is based on an estimate and assumption that has been deemed reasonable by management, but the assessment process relies heavily on an estimate and assumption that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change that estimate and assumption. In light of the uncertainty of this issue and while Management evaluates the best and most appropriate way to resolve same, management determined to create a reserve on the Company’s Balance Sheet for the $90,000 that was subject to the Consent.

 

The Company rents its Culver City, CA office space from a company owned by our CEO. The rental agreement provides for the value of the rent of $500 per month be recorded as contributed towards the founding eWellness and its operations. During the period ended March 31, 2016, we have recorded this rent payment in the Consolidated Statements of Operations and Additional Paid in Capital on the Balance Sheet.

 

On April 1, 2015, the Company entered into an Operating Agreement with Evolution Physical Therapy (“EPT”), a company owned by one of the Company’s officers, wherein it is agreed that EPT would be able to operate the Company’s telemedicine platform www.phzio.com and offer it to selected physical therapy patients of EPT. The Company is to receive 75% of the net insurance reimbursements from the patient for use of the platform. The Company will advance capital requested by EPT for costs specifically associated with operating the www.phzio,com platform and associated physical therapy treatments – computer equipment, office or facilities rental payments, physical therapist or physical therapy assistant, administrative staff, patient induction equipment, office supplies, utilities and other associated operating costs. It is anticipated that the operation of the platform by EPT will generate positive cash flow within 90 days from the start of patient induction.

 

On May 20, 2015, the Company entered into an agreement with Mavericks Capital Securities LLC (“Mavericks”). The term of the contract begins on the effective date and can be terminated within 30 days upon written notice by either party. The Company is to pay Mavericks a monthly retainer fee of $10,000 that is deferred until the Company raises $250,000 in new investor funds from the effective date. In addition, the Company granted Mavericks 250,000 warrants to purchase Company common stock at $.35 per share. On September 28, 2015, the Company and Mavericks entered into an amendment to the consultant agreement pursuant to which Mavericks will also assist the Company in the acquisition of new customers, for which the Company shall pay Mavericks 10% of the revenue received by the Company, net of any pass through costs, from any such customers introduced to the Company by Mavericks; payment shall be made upon the Company’s receipt of such revenues. In the amendment, the parties also further clarified the definition of Customer Acquisition.

 

On January 20, 2016, the Company entered into a one year agreement with a consulting firm to provide marketing and financial media awareness services. Compensation for this agreement is the issuance of 100,000 shares of common stock – 50,000 were issued at the signing of the agreement and the other 50,000 are to be issued in July, 2016. The value of these shares is $5,000 for each issuance which is being amortized over the term of the contract.

 

  F-13 

 

 

eWellness Healthcare Corporation

Notes to Condensed Financial Statements

(unaudited)

 

On February 1, 2016, the Company entered into a six month agreement with a consulting firm for services including introductions to brokers, investment bankers, market makers and business development opportunities. Compensation for his agreement is the issuance of 100,000 shares of common stock. The value of these shares is $10,000 and is being amortized over the term of the contract. At the end of the period ending March 31, 2016, the shares had not yet been issued.

 

On March 3, 2016, the Company entered into a six month agreement with a consulting firm for management consulting, business advisory and public relations services. Compensation for this agreement is the issuance of 100,000 shares of common stock for the purchase price of $100 and a $2,500 monthly fee that is to be accrued and not payable until the Company closes a qualified financing.

 

On March 14, 2016, the Company entered into a 45-day Promissory Note Extension at an interest rate of 12% per annum. As an inducement for this extension of previous promissory notes, the Company issued 400,000 warrants to purchase Company common stock at $.80 per share. The fair value of the warrants is $794. For the period ended March 31, 2016, the Company recorded $629 of accrued interest for this note.

 

From time to time the Company may become a party to litigation matters involving claims against the Company. Except as may be outlined above, management believes that there are no current matters that would have a material effect on the Company’s financial position or results of operations.

 

Note 11. Segment Reporting

 

The Company has one operating segment, which was identified based upon the availability of discrete financial information and the chief operating decision makers’ regular review of financial information.

 

Note 12. Derivative Valuation

 

The warrants granted with the $275,000 senior convertible promissory note (the “Note”) issued on December 7, 2015 have a Most Favored Nation clause resulting in the exercise price of the warrants not being fixed. Therefore, this feature has been characterized as a derivate liability to be re-measured at the end of every reporting period with the change in value reported in the statement of operations. At March 31, 2016, the outstanding fair value of the warrants accounted for as a derivative liability amounted to $2,802. As of March 31, 2016, no gain or loss was recognized in the statement of operations as the change in valuation from inception was clearly trivial to the financial statements.

 

For purposes of determining the fair market value of the derivative liability for the warrants, the Company used Black Scholes option valuation model. The significant assumptions used in the Black Scholes valuation of the derivative are as follows:

 

Stock price at valuation date   $ .10  
Exercise price of warrants   $ .80  
Risk free interest rate     1.67 %
Stock volatility factor     62.82 %
Years to Maturity     5  
Expected dividend yield     None  

 

  F-14 

 

 

eWellness Healthcare Corporation

Notes to Condensed Financial Statements

(unaudited)

 

Note 13. Subsequent Events

 

On April 13, 2016, we entered into a one-year renewable advisory agreement with Dan Mills, MPT to become the Company’s chairman of the to-be-formed committee known as the eWellness Physical Therapy Clinical Advisory Board and to act as the Company’s national spokesperson at the American Physical Therapy Association (“APTA”).

 

As inducement for Mr. Mills to enter the Agreement, we agreed to issue to 250,000 immediately vesting common stock purchase warrants at a price of $1.00 per share. The common stock underlying the Warrants has piggy-back registration rights. In addition, 10,000 shares of common stock are to be issued to Mr. Mills upon the signing of the Agreement. Per the agreement Mr. Mills will receive $0.50 cents per PHZIO session that an APTA members uses, $500 per month in consulting fees and $2,500 paid within ten days of signing the Agreement.

 

On May 2, 2016, the Company entered into a 45-day Promissory Note Extension at an interest rate of 12% per annum. As an inducement for this extension of previous promissory notes, the Company issued 400,000 warrants to purchase Company common stock at $.80 per share.

 

  F-15 

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

FORWARD-LOOKING STATEMENTS

 

This Quarterly Report on Form 10-Q, including “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Item 2 of Part I of this report include forward-looking statements. These forward looking statements are based on our management’s current expectations and beliefs and involve numerous risks and uncertainties that could cause actual results to differ materially from expectations. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “proposed,” “intended,” or “continue” or the negative of these terms or other comparable terminology. You should read statements that contain these words carefully, because they discuss our expectations about our future operating results or our future financial condition or state other “forward-looking” information. Many factors could cause our actual results to differ materially from those projected in these forward-looking statements, including but not limited to: variability of our future revenues and financial performance; risks associated with product development and technological changes; the acceptance of our products in the marketplace by potential future customers; general economic conditions. You should be aware that the occurrence of any of the events described in this Quarterly Report could substantially harm our business, results of operations and financial condition, and that upon the occurrence of any of these events, the trading price of our securities could decline. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, growth rates, levels of activity, performance or achievements. We are under no duty to update any of the forward-looking statements after the date of this Quarterly Report to conform these statements to actual results.

 

The following discussion and analysis of financial condition and results of operations relates to the operations and financial condition reported in the financial statements of eWellness Healthcare Corporation for the three-months ended March 31, 2016 and 2015 and should be read in conjunction with such financial statements and related notes included in this report and the Company’s Annual Report on Form 10-K for the year ended December 31, 2015.

 

THE COMPANY

 

Business Overview

 

Our business model is to license our PHZIO (“PHZIO”) telemedicine platform to any physical therapy (“PT”) clinic in the U.S. and or have large-scale employers use our PHZIO platform as a fully PT monitored corporate wellness program.

 

As shown in the financial statements accompanying this Quarterly Report, the Company has had no revenues to date and has incurred only losses since its inception. The Company has operations currently only in Culver City, California and has been issued a “going concern” opinion from our accountants, based upon the Company’s reliance upon the sale of our common stock as the sole source of funds for our future operations.

 

The Company’s operations and corporate offices are located at 11825 Major Street Culver City, CA, 90230, with a telephone number of (310) 915-9700.

 

The Company’s fiscal year end is December 31.

 

Plan of Operations

 

The Company’s initial licensee is Evolution Physical Therapy (“EPT”), which is owned by our CEO, Darwin Fogt, MPT. All treatment revenue for the first quarter of 2016 was reimbursed to EPT, but was not sufficient to generate sales for the Company. The Company is in the process of developing marketing channel partnerships with industry association members, existing software-based telemedicine providers and physical therapy billing and practice management providers. These partnerships, if completed, are anticipated to begin adding third party PT licensee revenue during the second or third quarters of 2016.

 

3 

 

 

The Company’s PHZIO home physical therapy exercise platform has been designed to disrupt the $30 billion physical therapy and the $8 billion corporate wellness industries. PHZIO re-defines the way physical therapy can be delivered. PHZIO is the first real-time remote monitored 1-to-many physical therapy platform for home use. Due to the real-time patient monitoring feature, the PHZIO platform is insurance reimbursable by payers such as: Anthem Blue Cross and Blue Shield.

 

The PHZIO Solution: A New Physical Therapy Delivery System

 

  SaaS technology platform solution for providers bundling rehabilitation services and employer wellness programs;
     
  First real-time remote monitored 1-to-many physical therapy treatment platform for home use;
     
  Ability for physical therapists to observe multiple patients simultaneously in real-time;
     
  Solves what has been a structural problem and limitation in post-acute care practice growth.
     
  PT practices can experiencing 20% higher adherence & compliance rates versus industry standards; and
     
  Tracking to 30% increase in net income for a PT practice.

 

Patient program adherence in 2015 was nearly 85 percent due to the real-time patient monitoring and the at-home use of the platform. Now physical therapy practices have a way to scale profitably using a technology platform that can help them grow beyond the limits of the typical brick and mortar PT clinic.

 

Additional Treatment Protocols: The Company’s initial PHZIO application is a 6-month exercise program for patients with back, knee or hip pain. The next two platforms are anticipated to be released in the second quarter of 2016 include a total knee and hip replacement exercise program. These hip and knee programs have been designed to be integrated into any hospital or medical group’s Medicare CMS bundled payment model for post-acute care physical therapy. These two programs are anticipated to be followed by woman’s health and geriatric programs by the end of the third quarter of 2016.

 

Our PHZIO platform enables employees or patients to engage with live or on-demand video based physical therapy telemedicine treatments from their home or office. Following a physician’s exam and prescription for physical therapy to treat back, knee or hip pain, a patient can be examined by a physical therapist and if found appropriate inducted in the Company’s PHZIO program that includes a progressive 6-month telemedicine exercise program (including monthly in-clinic checkups). All PHZIO treatments are monitored by a licensed therapist that sees everything the patient is doing while providing their professional guidance and feedback in real-time. This ensures treatment compliance by the patient, maintains the safety and integrity of the prescribed exercises, tracks patient metrics and captures pre and post treatment evaluation data. PHZIO unlocks a host of potential for revolutionizing patient treatment models and directly links back to the established brick and mortar physical therapy clinic. This unique model enables any physical therapy practice to be able to execute more patient care while utilizing their same resources, and creates more value than was ever before possible.

 

During 2015 our PHZIO platform achieved the following metrics:

 

  The total (insurance reimbursed) monitored PHZIO visits in 2015: 699 patient visits (267 paid patient visits total).
     
  The average insurance reimbursement per PHZIO session in 2015: $46.87 (excluding co-payments).
     
  The top line wellness goals of our PHZIO program are to graduate at least 80% of inducted patients through our 6-month program. Patients should expect to experience an average of a 20% reduction in BMI, a 4-inch reduction in waist size, weight loss of at least 20 pounds, significant overall improvement in balance, coordination, flexibility, strength, and lumbopelvic stability. Patients also should score better on Functional Outcomes Scales (Oswestry and LEFS), which indicates improved functional activity levels due to reduced low back, knee and hip pain.

 

4 

 

 

Our PHZIO platform, including: design, testing, exercise intervention, follow-up, and exercise demonstration, has been developed by accomplished Los Angeles based physical therapist Darwin Fogt. Mr. Fogt has extensive experience and education working with diverse populations from professional athletes to morbidly obese. He understands the most beneficial exercise prescription to achieve optimal results and has had great success in motivating all patient types to stay consistent in working toward their goals. Additionally, his methods have proven effective and safe as he demonstrates exercises with attention to proper form to avoid injury. Mr. Fogt has established himself as a national leader in his field and has successfully implemented progressive solutions to delivering physical therapy: he has consulted with and been published by numerous national publications including Runner’s World, Men’s Health, Men’s Journal, and various Physical Therapy specific magazines; his 13 plus years of experience include rehabilitating the general population, as well as professional athletes, Olympic gold medalists, and celebrities. He has bridged the gap between physical therapy and fitness by opening Evolution Fitness, which uses licensed physical therapists to teach high intensity circuit training fitness classes. He also founded one of the first exclusive prenatal and postnatal physical therapy clinics in the country. Mr. Fogt is a leader in advancing the profession to incorporate research-based methods and focus on, not only rehabilitation but also wellness, functional fitness, performance, and prevention. He is able to recognize that the national healthcare structure (federal and private insurance) is moving toward a model of prevention and that the physical therapy profession will take a larger role in providing wellness services to patients.

 

Innovators in other industries have solved access, cost and quality inefficiencies through the implementation of technology platforms and business models that deliver products and services on-demand and create new economies by connecting and empowering both consumers and businesses. We have taken the same approach to solving the pervasive access, cost and quality challenges facing the current access to physical therapy clinics.

 

Our underlying technology platform is complex, deeply integrated and purpose-built over the three years for the evolving physical therapy marketplace. Our PHZIO platform is highly scalable and can support substantial growth of third party licensees. Our PHZIO platform provides for broad interconnectivity between PT practitioners and their patients and, we believe, uniquely positions us as a focal point in the rapidly evolving PT industry to introduce innovative, technology-based solutions, such as remote patient monitoring, post-discharge treatment plan adherence and in-home care.

 

We plan to generate revenue from third-party PT and corporate wellness licensees on a contractually recurring per PHZIO session fee basis. Our PHZIO platform is anticipated to transform the access, cost and quality dynamics of physical therapy delivery for all of the market participants. We further believe any patient, employer, health plan or healthcare professional interested in a better approach to physical therapy is a potential PHZIO platform user.

 

We have developed various key performance indicators that we anticipate using to assess our business after we on-board third party PT licensees later in the year:

 

Before even launching, we have received a high indication of interest in our service. We think the demand is warranted, but recognize that in the early stages of our services, we may experience bottlenecks in our ability to meet the demand for same. Under this type of environment it is critical to maintain awareness of the Company’s operational budget goals and how they are being met in our attempts to address demand. Because the Company is “early stage” and launching with a minimum of capital, monitoring cash flow on a constant basis will be essential to growth.

 

During the third quarter of 2015, we pivoted our business model to focus on licensing our PHZIO platform to any physical therapy clinics in the U.S. and or to have large scale employers use our platform as a corporate wellness program. The Physical Therapy industry has remained disconnected and unscalable throughout the technological revolution of the past twenty years. Over 200,000 Physical Therapists are limited to one-on-one patient treatments within a traditional clinic setting. The Physical Therapy industry measures $33 Billion in size with over 270 Million one-on-one treatments delivered annually. This technology gap and market size is the opportunity that the Company is focused on with the recent launch of its PHZIO telemedicine platform.[1]

 

1 Sources: Harris Williams & Co., Physical Therapy Market Overview, Feb 2014 IBIS World, Physical Therapists in the US (Report 62134), May 2015

 

5 

 

 

Our PHZIO platform enables patients to engage with live or on-demand video based physical therapy telemedicine treatments from their home or office. Following a physician’s exam and prescription for physical therapy to treat back, knee or hip pain, a patient can be examined by a physical therapist and if found appropriate inducted in eWellness’ PHZIO program that includes a progressive 6-month telemedicine exercise program (including weekly in-clinic exercise sessions and monthly in-clinic checkups. All PHZIO treatments are monitored by a licensed therapist that sees everything the patient is doing while providing their professional guidance and feedback in real-time. This ensures treatment compliance by the patient, maintains the safety and integrity of the prescribed exercises, tracks patient metrics and captures pre and post treatment evaluation data. PHZIO unlocks a host of potential for revolutionizing patient treatment models and directly links back to the established brick and mortar Physical Therapy clinic. This unique model enables any physical therapy practice to be able to execute more patient care while utilizing their same resources, and creates more value than was ever before possible.

 

Through our Cooperative Operating Agreement with Evolution Physical Therapy (“EPT”) their Marina del Rey, California patient induction office (“PIO”) is effectively a laboratory for us to support the licensing of our platform to the entire Physical Therapy (“PT”) industry. In April we moved the PIO to EPT’s Culver City location as we could not extend the lease at that location. Active PT licensing of our PHZIO platform is anticipated to begin in the second quarter of 2016. We have also developed a separate vertical for our PHZIO platform that focuses on the marketing of our platform as a robust Corporate Wellness program. Active marketing to the large scale employers in the Los Angeles area began in the October 2015 with the expectation of beginning at least pilot program for our Corporate Wellness program during the second quarter of 2016.

 

We are also actively seeking corporate partnership relationships with other telemedicine companies that if completed, would create a new channel for our corporate wellness PHZIO program. Amid ongoing challenges and changes within the healthcare industry, telemedicine is emerging as an increasingly attractive tool for delivering quality medical & wellness services.

 

In early 2016, we began offering our PHZIO program that has been designed to be the most productive physical exercise program available to corporate wellness programs and their employees. We anticipate that employers using our system can significantly improve employee wellness and decrease costs associated with workman’s compensation claims. PHZIO is a comprehensive lifestyle management intervention. Our PHZIO exercise program documents an employee’s success or failure. We can provision highly reliable Return On Investment (“ROI”) metrics displayed on an easy to use HIPAA compliant dashboard for any organization using our PHZIO system.

 

The Current State of Workplace Wellness Programs:

 

Broadly, a workplace wellness program is an employment-based activity or employer-sponsored benefit aimed at promoting health-related behaviors (primary prevention or health promotion) and disease management (secondary prevention). It may include a combination of data collection on employee health risks and population-based strategies paired with individually focused interventions to reduce those risks. A formal and universally accepted definition of a workplace wellness program has yet to emerge, and employers define and manage their programs differently. Programs may be part of a group health plan or be offered outside of that context; they may range from narrow offerings, such as free gym memberships, to comprehensive counseling and lifestyle management interventions4.

 

Wellness programs have become very common, as 92 percent of employers with 200 or more employees reported offering them in 2009. Survey data indicate that the most frequently targeted behaviors are exercise, addressed by 63 percent of employers with programs; smoking (60 percent); and weight loss (53 percent). In spite of widespread availability, the actual participation of employees in such programs remains limited. While no nationally representative data exist, a 2010 non-representative survey suggests that typically fewer than 20 percent of eligible employees participate in wellness interventions.

 

6 

 

 

Wellness Program Impact: In industry surveys, employers typically express their conviction that workplace wellness programs are delivering on their promise to improve health and reduce costs. Numerous anecdotal accounts of positive program effects are consistent with this optimistic view. Further, several evaluations of individual programs and summative reviews in the scientific literature provide corroborating evidence for a positive impact.

 

In “A Review of the U.S. Workplace Wellness Market “, the most recent scientific literature evaluating the impact of workplace wellness programs on health-related behavior and medical cost outcomes identified 33 peer-reviewed publications that met their standards for methodological rigor. They found, consistent with previous reviews, evidence for positive effects on diet, exercise, smoking, alcohol use, physiologic markers, and health care costs, but limited evidence for effects on absenteeism and mental health. They could not conclusively determine whether or not program intensity was positively correlated with impact. Positive results found in this and other studies should be interpreted with caution, as many of these programs were not evaluated with a rigorous approach, and published results may not be representative of the typical experience of a U.S. employer.

 

The Company intends to close on a private financing of up to $2.5 million by the end of the second quarter of 2016, pursuant to Rule 506 (c) promulgated pursuant to the Securities Act of 1933, as amended, although there can be no guarantee we will receive any such financing.

 

Results of Operations for the three months ended March 31, 2016 and March 31, 2015.

 

The following discussion should be read in conjunction with our financial statements and the related notes that appear elsewhere in this Quarterly Report.

 

Operating Expenses

 

Operating expenses during the three months ended March 31, 2016 were $353,447 compared to $310,982 for the three months ended March 31, 2015. Operating expenses increased for the period primarily as a result of an increase in professional fees for consulting services.

 

Interest Expense.

 

Interest expense, including interest expense–related parties, was $72,161 and $17,220 for the three months ended March 31, 2016 and March 31, 2015, respectively. The increase was related to costs of convertible debt with unrelated parties.

 

Net Loss

 

Net loss during the three months ended March 31, 2016 was $425,608 compared to $316,879 for the three months ended March 31, 2015. The increase in the net loss is a result of increased operating and interest expenses as discussed above.

 

Liquidity and Capital Resources

 

The Company had $13,582 and $42,951 cash as of March 31, 2016 and December 31, 2015, respectively.

 

Net cash used in operating activities was $28,369 for the three months ended March 31, 2016, compared to $137,040 for the three months ended March 31, 2015.

 

Net cash provided by financing activities during the three months ended March 31, 2016, was zero compared to $166,100 for the three months ended March 31, 2015.

 

We had not yet earned any revenues as of the period ending March 31, 2016. Our current cash position is not sufficient to fund our cash requirements during the next twelve months including operations and capital expenditures. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

 

We had assets at March 31, 2016 of $81,072. We will be reliant upon shareholder loans, private placements or public offerings of equity to fund any kind of operations, although there can be no guarantee we will be able to secure such finding on beneficial terms, if at all.

 

7 

 

 

Off-Balance Sheet Arrangements

 

There are no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

 

Critical Accounting Policies and Estimates

 

Please refer to “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in our Annual Report on Form 10-K for the year ended December 31, 2015, for disclosures regarding the Company’s critical accounting policies and estimates, as well as any updates further disclosed in our interim financial statements as described in this Form 10-Q.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

As a “smaller reporting company”, we are not required to provide the information under Item 3.

 

ITEM 4. CONTROLS AND PROCEDURES.

 

Evaluation of Disclosure Controls and Procedures

 

Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures as defined in Rule 13a-15(e) under the Exchange Act as of the end of the period covered by this Quarterly Report on Form 10-Q. In designing and evaluating the disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

 

8 

 

 

Based on that evaluation, our chief executive officer and chief financial officer concluded that, as of March 31, 2016, our disclosure controls and procedures were not effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules, regulations and forms, and (ii) that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.

 

Changes in Internal Controls Over Financial Reporting

 

There were no changes in the Company’s internal controls over financial reporting that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

PART II - OTHER INFORMATION

 

ITEM 1. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

 

On April 13, 2016, the Company entered into a one year renewable advisory agreement with Dan Mills, MPT to become the Company’s chairman of the to-be-formed committee known as the eWellness Physical Therapy Clinical Advisory Board and to act as the Company’s national spokesperson at the American Physical Therapy Association (“APTA”).

 

As inducement to enter the Agreement, we agreed to issue to Mr. Mills 250,000 immediately vesting common stock purchase warrants at a price of $1.00 per share . The common stock underlying the Warrants has piggy-back registration rights. In addition, 10,000 shares of common stock are to be issued to Mr. Mills upon the signing of the Agreement. Per the Agreement, Mr. Mills will receive $0.50 cents per PHZIO session that an APTA members uses, $500 per month in consulting fees and $2,500 paid within ten days of signing the Agreement.

 

ITEM 2. EXHIBITS.

 

Exhibit No.   Description
3.1   Amended & Restated Certificate of Incorporation of Registrant. (Incorporated by reference to Exhibit 4.1 to the Form 8-K/A filed on August 6, 2014)
     
3.2   Bylaws of the Company. (Incorporated by reference to Exhibit 3(b) to the Registration Statement on Form S-1 filed on May 15, 2012)
     
10.1   Securities Purchase Agreement dated December 23, 2014 (Incorporated by reference to the Company’s Current Report on Form 8-K filed on January 6, 2015)
     
10.2   Form of 12% Senior Convertible Promissory Note (Incorporated by reference to the Company’s Current Report on Form 8-K filed on January 6, 2015)
     
10.3   Form of Series A Warrant Agreement (Incorporated by reference to the Company’s Current Report on Form 8-K filed on January 6, 2015)

 

9 

 

 

10.4   Form of Registration Rights Agreement (Incorporated by reference to the Company’s Current Report on Form 8-K filed on January 6, 2015)
     
10.5   Form of Security Agreement (Incorporated by reference to the Company’s Current Report on Form 8-K filed on January 6, 2015)
     
10.6   Operating Agreement with Evolution Physical Therapy (Incorporated by reference to Exhibit 10.6 of the Company’s Quarterly Report on Form 10-Q filed on May 12, 2015)
     
10.7  

Medical Advisory Agreement with Akash Bajaj M.D., M.P.H. (Incorporated by reference to Exhibit 10.7 of the Company’s Quarterly Report on Form 10-Q filed on May 12, 2015)

     
10.8  

Advisory Agreement *

     
31.1   Rule 13a-14(a)/15d-14(a) Principal Executive Officer Certification*
     
31.2   Rule 13a-14(a)/15d-14(a) Principal Financial and Accounting Officer Certification*
     
32.1   Certifications under Section 906 of the Sarbanes-Oxley Act (18 U.S.C. Section 1350)*
     
32.2   Certification under Section 906 of the Sarbanes-Oxley Act (18 U.S.C. Section 1350)*
     
101.INS   XBRL INSTANCE DOCUMENT *
     
101.SCH   XBRL TAXONOMY EXTENSION SCHEMA *
     
101.CAL   XBRL TAXONOMY EXTENSION CALCULATION LINKBASE *
     
101.DEF   XBRL TAXONOMY EXTENSION DEFINITION LINKBASE *
     
101.LAB   XBRL TAXONOMY EXTENSION LABEL LINKBASE *
     
101.PRE   XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE *

 

* Filed herewith

 

10 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  eWellness Healthcare Corporation
     
Date: May 12, 2016 By: /s/ Darwin Fogt
    Darwin Fogt
    Director and Chief Executive Officer
    (Principal Executive Officer)
     
Date: May 12, 2016 By: /s/ David Markowski
    David Markowski, Chief Financial Officer
    (Principal Financial and Accounting Officer)

 

11 

 

 

EX-31.1 2 ex31-1.htm

 

EXHIBIT 31.1

 

Exhibit 31.1 Certification of the Chief Executive Officer of eWellness Healthcare Corporation., pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Darwin Fogt, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2016 of eWellness Healthcare Corporation (the “registrant”);

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15-d-15(f)) for the registrant and have:

 

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the Audit Committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 12, 2016  
   
/s/ Darwin Fogt  
Darwin Fogt,  
Chief Executive Officer (Principal Executive Officer)  

 

  
 

 

EX-31.2 3 ex31-2.htm

 

EXHIBIT 31.2

 

Exhibit 31.2 Certification of the Chief Financial Officer of eWellness Healthcare Corporation, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, David Markowski, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2016 of eWellness Healthcare Corporation (the “registrant”);

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15-d-15(f)) for the registrant and have:

 

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the Audit Committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 12, 2016  
   
/s/ David Markowski  
David Markowski,  
Chief Financial Officer  
(Principal Financial and Accounting Officer)  

 

  
 

 

EX-32.1 4 ex32-1.htm

 

EXHIBIT 32.1

 

Exhibit 32.1 Certification of the Chief Executive Officer of eWellness Healthcare Corporation pursuant to Section 906 of the Sarbanes Oxley Act of 2002

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report on Form 10-Q of eWellness Healthcare Corporation (the “Company”) for the quarterly period ended March 31, 2016 as filed with the Securities and Exchange Commission (the “Report”), the undersigned Darwin Fogt, Chief Executive Officer of the Company certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

 

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

  eWellness Healthcare Corporation.
     
Date: May 12, 2016 By: /s/ Darwin Fogt
    Darwin Fogt, Director and Chief Executive Officer
    (Principal Executive Officer)

 

This certification accompanies this Quarterly Report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.

 

  
 

 

EX-32.2 5 ex32-2.htm

 

EXHIBIT 32.2

 

Exhibit 32.2 Certification of the Chief Financial Officer of eWellness Healthcare Corporation pursuant to Section 906 of the Sarbanes Oxley Act of 2002

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report on Form 10-Q of eWellness Healthcare Corporation (the “Company”) for the quarterly period ended March 31, 2016 as filed with the Securities and Exchange Commission (the “Report”), the undersigned David Markowski, Chief Financial Officer of the Company, certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

 

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

  eWellness Healthcare Corporation
   
Date: May 12, 2016 /s/ David Markowski
  David Markowski, Chief Financial Officer
  (Principal Financial and Accounting Officer)

 

This certification accompanies this Quarterly Report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.

 

  
 

 

 

GRAPHIC 6 image_001.jpg GRAPHIC begin 644 image_001.jpg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dgt-20160331.xml XBRL INSTANCE FILE 0001550020 2016-01-01 2016-03-31 0001550020 2015-12-31 0001550020 2016-03-31 0001550020 us-gaap:ChiefFinancialOfficerMember 2016-03-31 0001550020 2015-01-01 2015-03-31 0001550020 us-gaap:ConvertibleNotesPayableMember 2014-12-22 2014-12-23 0001550020 DGT:EscrowTrustMember 2016-03-31 0001550020 us-gaap:ConvertibleNotesPayableMember 2014-12-23 0001550020 DGT:ShareExchangeAgreementMember 2014-04-11 0001550020 DGT:ShareExchangeAgreementMember 2014-04-10 2014-04-11 0001550020 DGT:ShareExchangeAgreementMember 2014-04-29 2014-04-30 0001550020 us-gaap:ComputerEquipmentMember 2016-03-31 0001550020 us-gaap:ComputerEquipmentMember 2015-12-31 0001550020 us-gaap:ComputerSoftwareIntangibleAssetMember 2015-12-31 0001550020 us-gaap:ComputerSoftwareIntangibleAssetMember 2016-03-31 0001550020 us-gaap:ConvertibleNotesPayableMember us-gaap:WarrantMember 2014-12-19 2014-12-23 0001550020 us-gaap:WarrantMember us-gaap:ConvertibleNotesPayableMember 2014-12-23 0001550020 DGT:ChiefMarketingOfficerMember 2014-01-01 2014-12-31 0001550020 us-gaap:WarrantMember 2014-12-31 0001550020 2015-01-23 2015-01-24 0001550020 2015-02-22 2015-02-23 0001550020 us-gaap:WarrantMember 2015-01-01 2015-12-31 0001550020 us-gaap:WarrantMember 2015-12-31 0001550020 2016-05-12 0001550020 2015-01-26 2015-01-27 0001550020 2015-01-27 0001550020 2015-04-09 0001550020 2015-04-07 2015-04-09 0001550020 us-gaap:ConvertibleNotesPayableMember 2016-03-31 0001550020 DGT:ConvertibleNotesPayableOneMember 2016-03-31 0001550020 2015-03-28 2015-04-02 0001550020 DGT:MavericksCapitalSecuritiesLlcMember 2015-05-18 2015-05-20 0001550020 DGT:MavericksCapitalSecuritiesLlcMember 2015-05-20 0001550020 DGT:NonConvertibleNotePayableOneMember 2015-05-29 2015-05-30 0001550020 DGT:NonConvertibleNotePayableOneMember 2015-05-30 0001550020 DGT:NonConvertibleNotePayableOneMember 2015-08-25 2015-08-26 0001550020 DGT:NonConvertibleNotePayableOneMember 2015-07-13 2015-07-15 0001550020 DGT:NonConvertibleNotePayableOneMember 2015-07-15 0001550020 DGT:NonConvertibleNotePayableOneMember 2015-09-15 2015-09-16 0001550020 DGT:NonConvertibleNotePayableOneMember 2015-09-16 0001550020 DGT:NonConvertibleNotePayableTwoMember 2015-09-15 2015-09-16 0001550020 DGT:NonConvertibleNotePayableTwoMember 2015-09-16 0001550020 DGT:NonConvertibleNotePayableThreeMember 2015-09-15 2015-09-16 0001550020 us-gaap:ConvertibleNotesPayableMember 2016-02-20 0001550020 us-gaap:ConvertibleNotesPayableMember 2016-02-18 2016-02-20 0001550020 us-gaap:ConvertibleNotesPayableMember 2015-04-08 2015-04-09 0001550020 us-gaap:ConvertibleNotesPayableMember 2015-04-09 0001550020 us-gaap:ConvertibleNotesPayableMember us-gaap:WarrantMember 2015-04-08 2015-04-09 0001550020 us-gaap:ConvertibleNotesPayableMember us-gaap:WarrantMember 2015-04-09 0001550020 us-gaap:ConvertibleNotesPayableMember 2016-01-01 2016-03-31 0001550020 DGT:ConvertibleNotesPayableThreeMember 2016-03-31 0001550020 2015-07-12 2015-07-14 0001550020 2015-08-17 2015-08-19 0001550020 2015-09-08 2015-09-10 0001550020 DGT:StockOptionPlanMember 2015-08-06 0001550020 us-gaap:SubsequentEventMember DGT:MrMillsMember 2016-04-12 2016-04-13 0001550020 us-gaap:SubsequentEventMember DGT:PromissoryNoteExtensionMember 2016-05-02 0001550020 us-gaap:FurnitureAndFixturesMember us-gaap:MinimumMember 2016-01-01 2016-03-31 0001550020 us-gaap:FurnitureAndFixturesMember us-gaap:MaximumMember 2016-01-01 2016-03-31 0001550020 us-gaap:ComputerEquipmentMember us-gaap:MinimumMember 2016-01-01 2016-03-31 0001550020 us-gaap:ComputerEquipmentMember us-gaap:MaximumMember 2016-01-01 2016-03-31 0001550020 us-gaap:SoftwareDevelopmentMember 2016-01-01 2016-03-31 0001550020 us-gaap:FairValueInputsLevel1Member 2016-03-31 0001550020 us-gaap:FairValueInputsLevel2Member 2016-03-31 0001550020 us-gaap:FairValueInputsLevel3Member 2016-03-31 0001550020 DGT:NonConvertibleNotePayableOneMember 2015-10-10 2015-10-11 0001550020 DGT:NonConvertibleNotePayableOneMember us-gaap:MaximumMember 2015-10-11 0001550020 DGT:NonConvertibleNotePayableOneMember 2015-10-04 2015-10-05 0001550020 DGT:NonConvertibleNotePayableThreeMember 2015-10-10 2015-10-11 0001550020 DGT:NonConvertibleNotePayableThreeMember 2015-10-11 0001550020 DGT:NonConvertibleNotePayableThreeMember 2015-12-05 2015-12-06 0001550020 DGT:NonConvertibleNotePayableThreeMember 2015-12-06 0001550020 DGT:ConvertibleNotesPayablesMember 2015-12-07 0001550020 DGT:ConvertibleNotesPayablesMember 2016-03-31 0001550020 DGT:ConvertibleNotesPayablesMember 2016-01-01 2016-03-31 0001550020 2015-09-29 2015-10-02 0001550020 2015-11-10 2015-11-11 0001550020 2015-12-16 2015-12-17 0001550020 us-gaap:MinimumMember 2016-03-31 0001550020 us-gaap:MaximumMember 2016-03-31 0001550020 2015-12-05 2015-12-07 0001550020 us-gaap:WarrantMember 2016-01-01 2016-03-31 0001550020 2015-03-31 0001550020 2014-12-31 0001550020 DGT:ShareExchangeAgreementMember 2016-03-31 0001550020 DGT:NonConvertibleNotePayableOneMember us-gaap:MaximumMember 2015-07-15 0001550020 DGT:NonConvertibleNotePayableThreeMember 2015-09-16 0001550020 DGT:NonConvertibleNotePayableThreeMember 2016-03-13 2016-03-14 0001550020 DGT:NonConvertibleNotePayableThreeMember 2016-03-14 0001550020 DGT:NonConvertibleNotePayableThreeMember 2016-01-01 2016-03-31 0001550020 DGT:ConvertibleNotesPayablesMember us-gaap:MaximumMember 2016-03-31 0001550020 DGT:ConvertibleNotesPayableTwoMember 2016-03-31 0001550020 us-gaap:WarrantMember 2016-03-31 0001550020 2016-01-19 2016-01-20 0001550020 2016-02-28 2016-02-29 0001550020 2016-03-02 2016-03-03 0001550020 2016-03-10 2016-03-11 0001550020 DGT:StockOptionPlanMember 2016-02-19 0001550020 DGT:StockOptionPlanMember 2016-02-18 2016-02-19 0001550020 DGT:StockOptionPlanMember 2016-01-01 2016-03-31 0001550020 2016-03-13 2016-03-14 0001550020 DGT:MavericksCapitalSecuritiesLlcMember 2015-09-27 2015-09-28 0001550020 DGT:ConsultingFirmMember 2016-01-19 2016-01-20 0001550020 DGT:ConsultingFirmMember DGT:ConsultingServicesAgreementMember 2016-01-19 2016-01-20 0001550020 DGT:ConsultingFirmMember DGT:ConsultingServicesAgreementMember DGT:JulyTwoThousandAndSixteenMember 2016-01-19 2016-01-20 0001550020 DGT:ConsultingFirmMember 2016-01-30 2016-02-01 0001550020 DGT:ConsultingFirmMember 2016-03-02 2016-03-03 0001550020 DGT:PromissoryNoteExtensionMember 2016-03-13 2016-03-14 0001550020 DGT:PromissoryNoteExtensionMember 2016-03-14 0001550020 DGT:PromissoryNoteExtensionMember 2016-03-31 0001550020 us-gaap:SubsequentEventMember DGT:MrMillsMember 2016-04-13 0001550020 us-gaap:SubsequentEventMember DGT:PromissoryNoteExtensionMember 2016-05-01 2016-05-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure DGT:Segments 18697770 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 2. Summary of Significant Accounting Policies</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><u>Basis of Presentation</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The interim financial information of the Company as of periods ended March 31, 2016 and March 31, 2015 is unaudited. The balance sheet as of December 31, 2015 is derived from audited financial statements of eWellness Healthcare Corporation. The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial statements. Accordingly, they omit or condense footnotes and certain other information normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles. The accounting policies followed for quarterly financial reporting conform to the accounting policies disclosed in ASU 2014-10. In the opinion of management, all adjustments which are necessary for a fair presentation of the financial information for the interim periods reported have been made. All such adjustments are of a normal recurring nature. The results of operations for the three months ended March 31, 2016 are not necessarily indicative of the results that can be expected for the entire year ending December 31, 2016. The unaudited financial statements should be read in conjunction with the financial statements and the notes thereto included in the Company&#146;s annual report on Form 10-K for the year ended December 31, 2015.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><u>Use of Estimates</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from these good faith estimates and judgments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><u>Going Concern</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For the period ended March 31, 2016, the Company has no revenues and no operations. The Company has an accumulated loss of $3,881,795. In view of these matters, there is substantive doubt about the Company&#146;s ability to continue as a going concern. The Company&#146;s ability to continue operations is dependent upon the Company&#146;s ability to raise additional capital and to ultimately achieve sustainable revenues and profitable operations, of which there can be no guarantee. The Company intends to finance its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><u>Deferred Offering and Acquisition Costs</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company defers as other assets the direct incremental costs of raising capital until such time as the offering is completed. At the time of the completion of the offering, the costs will be charged against the capital raised. Should the offering be terminated, the deferred offering costs will be charged to operations during the period in which the offering is terminated. Direct acquisition costs will be expensed as incurred.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><u>Fair Value of Financial Instruments</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company complies with the accounting guidance under Financial Accounting Standards Board (&#147;FASB&#148;) Accounting Standards Codification (&#147;ASC&#148;) 820-10, <i>Fair Value Measurements,</i> as well as certain related FASB staff positions. This guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact business and considers assumptions that marketplace participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The guidance also establishes a fair value hierarchy for measurements of fair value as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Level 1 &#150; quoted market prices in active markets for identical assets or liabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Level 2 &#150; inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Level 3 &#150; unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of March 31, 2016, the Company had the following assets and liabilities measured at fair value on a recurring basis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Total</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Level 1</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Level 2</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Level 3</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 48%; padding-bottom: 1.5pt"><font style="font-size: 10pt">Derivative liability</font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">2,802</font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">2,802</font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total liabilities measure at fair value</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2,802</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2,802</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><u>Cash and Cash Equivalents</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Cash and cash equivalents includes all cash deposits and highly liquid financial instruments with an original maturity to the Company of three months or less.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Property and Equipment</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Property and equipment are recorded at historical cost. Minor additions and renewals are expensed in the year incurred. Major additions and renewals are capitalized and depreciated over their estimated useful lives. Depreciation is recorded over the estimated useful lives of the related assets using the straight-line method for financial statement purposes. The Company uses other depreciation methods (generally accelerated) for tax purposes where appropriate. The estimated useful lives for significant property and equipment categories are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 50%"><font style="font-size: 10pt">Furniture and Fixtures</font></td> <td style="width: 1%">&#160;</td> <td style="width: 49%"><font style="font-size: 10pt">5-7 Years</font></td></tr> <tr style="vertical-align: top"> <td><font style="font-size: 10pt">Computer Equipment</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">5-7 Years</font></td></tr> <tr style="vertical-align: top"> <td><font style="font-size: 10pt">Software</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">3 Years</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company regularly evaluates whether events or circumstances have occurred that indicate the carrying value of long-lived assets may not be recoverable. If factors indicate the asset may not be recoverable, we compare the related undiscounted future net cash flows to the carrying value of the asset to determine if impairment exists. If the expected future net cash flows are less than the carrying value, an impairment charge is recognized based on the fair value of the asset.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><u>Revenue Recognition</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company has yet to realize revenues from operations. Once the Company has commenced operations, it will recognize revenues when delivery of goods or completion of services has occurred provided there is persuasive evidence of an agreement, acceptance has been approved by its customers, the fee is fixed or determinable based on the completion of stated terms and conditions, and collection of any related receivable is probable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><u>Loss per Common Share</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company follows ASC Topic 260 to account for the loss per share. Basic loss per common share calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per common share calculations are determined by dividing net loss by the weighted average number of common shares and dilutive common share equivalents outstanding. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation. As the Company has no common stock equivalents and has incurred losses for the period ended March 31, 2016, no dilutive shares are added into the loss per share calculations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><u>Recent Accounting Pronouncements</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#147;FASB&#148;) that are adopted by the Company as of the specified date. The Company has elected to the early adoption of ASU 2015-03 that simplifies the presentation of debt issuance costs. The Company had previously used the methodology in this standard and has adopted the pronouncement for current and future debt instruments.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 9. Equity Transactions</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><u>Preferred Stock</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The total number of shares of preferred stock which the Company shall have authority to issue is 10,000,000 shares with a par value of $0.001 per share. There have been no preferred shares issued as of March 31, 2016.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><u>Common Stock</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The total number of shares of common stock which the Company shall have authority to issue is 100,000,000 shares with a par value of $0.001 per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On January 24, 2015, the Company authorized the issuance of 400,000 shares of common stock for consulting services at a value of $40,000. This value was amortized over the life of the contract.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 23, 2015, the Company authorized the issuance of 60,000 shares of common stock for consulting services for a value of $6,000. This value was amortized over the life of the contract</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On July 14, 2015, the Company authorized the issuance of 250,000 shares of common stock for the conversion of convertible debt of $87,500.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 19, 2015, the Company authorized the issuance of 96,000 shares of common stock for conversion of convertible debt of $33,600.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On September 10, 2015, the Company authorized the issuance of 663,277 shares of common stock for conversion of convertible debt of $232,147.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On October 1, 2015, the Company authorized the issuance of 50,272 shares of common stock for the accrued interest totaling $17,595 on convertible debt previously converted.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On November 11, 2015, the Company authorized the issuance of 179,989 shares of common stock for conversion of convertible debt and accrued interest of $62,996.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On December 17, 2015, the Company authorized the issuance of 50,000 shares of comon stock as part of a provision of the convertible debt note payable signed on December 7, 2015. (See Note 9 - Convertible Notes Payable)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On January 20, 2016, the Company authorized the issuance of 50,000 shares for consulting services for a value of $5,000 that is being amortized over the life of the contract.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 29, 2016, the Company authorized the issuance of 227,232 shares for conversion of convertible debt of $69,500.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On March 3, 2016, the Company authorized the issuance of 100,000 shares for consulting services for a value of $10,100 that is being amortized over the life of the contract.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On March 11, 2016, the Company authorized the issuance of 150,000 shares for consulting services for a value of $15,000 that is being amortized over the life of the contract.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of the period ended March 31, 2016, the Company has 18,697,770 shares of common stock issued and outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Holders of shares of common stock are entitled to cast one vote for each share held at all stockholders&#146; meetings for all purposes including the election of directors. The common stock does not have cumulative voting rights.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">No holder of shares of stock of any class is entitled as a matter of right to subscribe for or purchase or receive any part of any new or additional issue of shares of stock of any class or of securities convertible into shares of stock of any class, whether now hereafter authorized or whether issued for money, for consideration other than money, or by way of dividend.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On February 22, 2016, the Company received the common stock trading symbol of EWLL.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Stock Options</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 6, 2015, the Board of Directors approved the 2015 Stock Option Plan, pursuant to which certain directors, officers, employees and consultants will be eligible for certain stock options and grants. The Plan is effective as of August 1, 2015 and the maximum number of shares reserved and available for granting awards under the Plan shall be an aggregate of 3,000,000 shares of common stock, provided however that on each January 1, starting with January 1, 2016, an additional number of shares equal to the lesser of (A) 2% of the outstanding number of shares (on a fully-diluted basis) on the immediately preceding December 31 and (B) such lower number of shares as may be determined by the Board or committee charged with administering the plan. This plan may be amended at any time by the Board or appointed plan Committee.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 19, 2016, the Board of Directors authorized the issuance of stock options under this plan to selected employees, directors and consultants. The stock options vest immediately upon the grant date and authorize the recipient to purchase shares of common stock at $.80 per share within five years of the grant date.. The Company valued the issuance of these warrants using the Black Scholes valuation model assuming a 2.0% risk free rate and an 61.4% volatility. At the three months ended March 31, 2016, the vested value of the options was $4,633. This was recorded as compensation expense.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following is a summary of the status of all Company&#146;s stock options as of March 31, 2016 and changes during the three months ended on that date:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Number</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Weighted</font></td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">of Stock</font><br /> <font style="font-size: 10pt">Options</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Average Exercise Price</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 72%"><font style="font-size: 10pt">Oustanding at January 1, 2016</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: right"><font style="font-size: 10pt">0</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 11%; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Granted</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">2,850,000</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">0.80</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Exercised</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">0</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-size: 10pt">Cancelled</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">0</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Outstanding at March 31, 2016</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2,850,000</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.80</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Options exercisable at March 31, 2016</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2,850,000</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.80</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><u>Warrants</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On March 14, 2016, the Company authorized the issuance of 400,000 warrants that were issued as part of the extension of a promissory note dated December 6, 2015. The fair value of the warrants is $794.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following is a summary of the status of all of the Company&#146;s warrants as of March 31, 2016 and changes during the three months ended on that date:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Weighted</font></td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Number of</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Average</font></td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Warrants</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Exercise Price</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Outstanding at January 1, 2015</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">609,533</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">0.35</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Granted</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">5,021,658</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">0.63</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Exercised</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Cancelled</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 61%"><font style="font-size: 10pt">Outstanding at December 31, 2015</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">5,631,191</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">0.61</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Granted</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">400,000</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">0.80</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Exercised</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-size: 10pt">Cancelled</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Outstanding at March 31, 2016</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">6,031,191</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.62</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For purpose of determining the fair market value of the warrants and options issued during the three months ended March 31, 2016, we used the Black Scholes option valuation model. These valuations were done throughout the period at the date of issuance and not necessary as of the reporting date. As there is no current market for the Company&#146;s shares, we used $0.10 as the stock price at valuation date to be consistent with prior issuances and the stock prices of comparable companies to determine volatility. The significant assumptions used in the Black Scholes valuation of the date of issuance are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 82%"><font style="font-size: 10pt">Stock price on the valuation date</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 15%; text-align: right"><font style="font-size: 10pt">0.10</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Exercise price of warrants</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">.35 and .80 </font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Dividend yield</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">0.00</font></td> <td><font style="font-size: 10pt">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Years to maturity</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#160;2.5 </font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Risk free rate</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">2.0%</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Expected volatility</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">61%</font></td> <td>&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 10. Commitments, Contingencies</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company may be subject to lawsuits, administrative proceedings, regulatory reviews or investigations associated with its business and other matters arising in the normal conduct of its business. The following is a description of an uncertainty that is considered other than ordinary, routine and incidental to the business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The closing of the Initial Exchange Agreement with Private Co. was conditioned upon certain, limited customary representations and warranties, as well as, among other things, our compliance with Rule 419 (&#147;Rule 419&#148;) of Regulation C under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;) and the consent of our shareholders as required under Rule 419. Accordingly, we conducted a &#147;Blank Check&#148; offering subject to Rule 419 (the &#147;Rule 419 Offering&#148;) and filed a Registration Statement on Form S-1 to register the shares of such offering; the Registration Statement was declared effective on September 14, 2012. We used 10% of the subscription proceeds as permitted under Rule 419 and the amount remaining in the escrow trust as of the date of the closing of the Share Exchange was $90,000 (the &#147;Trust Account Balance&#148;).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Rule 419 required that the Share Exchange occur on or before March 18, 2014, but due to normal negotiations regarding the transactions and the parties&#146; efforts to satisfy all of the closing conditions, the Share Exchange did not close on such date. Accordingly, after numerous discussions with management of both parties, they entered into an Amended and Restated Share Exchange Agreement (the &#147;Share Exchange Agreement&#148;) to reflect a revised business combination structure, pursuant to which we would: (i) file a registration statement on Form 8-A (&#147;Form 8A&#148;) to register our common stock pursuant to Section 12(g) of the Exchange Act, which we did on May 1, 2014 and (ii) seek to convert the participants of the Rule 419 Offering into participants of a similarly termed private offering (the &#147;Converted Offering&#148;), to be conducted pursuant to Regulation D, as promulgated under the Securities Act.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Fifty-two persons participated in the Rule 419 Offering and each of them gave the Company his/her/its consent to use his/her/its escrowed funds to purchase shares of the Company&#146;s restricted common stock in the Converted Offering (the &#147;Consent&#148;) rather than have their funds returned. To avoid further administrative work for the investors, we believe that we took reasonable steps to inform investors of the situation and provided them with an appropriate opportunity to maintain their investment in the Company, if they so choose, or have their funds physically returned. Management believed the steps it took constituted a constructive return of the funds and therefore met the requirements of Rule 419.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">However, pursuant to Rule 419(e)(2)(iv), &#147;funds held in the escrow or trust account<sup> </sup>shall be returned by first class mail or equally prompt means to the purchaser within five business days [if the related acquisition transaction does not occur by a date that is 18 months after the effective date of the related registration statement].&#148; As set forth above, rather than physically return the funds, we sought consent from the investors of the Rule 419 Offering to direct their escrowed funds to the Company to instead purchase shares in the Converted Offering. The consent document (which was essentially a form of rescission) was given to the investors along with a private placement memorandum describing the Converted Offering and stated that any investor who elected not to participate in the Converted Offering would get 90% of their funds physically returned. Pursuant to Rule 419(b)(2)(vi), a blank check company is entitled to use 10% of the proceed/escrowed funds; therefore, if a return of funds is required, only 90% of the proceed/escrowed funds need be returned. The Company received $100,000 proceeds and used $10,000 as per Rule 419(b)(2)(vi); therefore, only $90,000 was subject to possible return.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As disclosed therein, we filed the amendments to the initial Form 8-K in response to comments from the SEC regarding the Form 8-K and many of those comments pertain to an alleged violation of Rule 419. The Company continued to provide the SEC with information and analysis as to why it believes it did not violate Rule 419, but was unable to satisfy the SEC&#146;s concerns. Comments and communications indicate that Rule 419 requires a physical return of funds if a 419 offering cannot be completed because a business combination was not consummated within the required time frame; constructive return is not permitted.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As a result of these communications and past comments, we are disclosing that we did not comply with the requirements of Rule 419, which required us to physically return the funds previously submitted to escrow pursuant to the Rule 419 Offering. As a result of our failure to comply with Rule 419, the SEC may bring an enforcement action or commence litigation against us for failure to strictly comply with Rule 419. If any claims or actions were to be brought against us relating to our lack of compliance with Rule 419, we could be subject to penalties (including criminal penalties), required to pay fines, make damages payments or settlement payments. In addition, any claims or actions could force us to expend significant financial resources to defend ourselves, could divert the attention of our management from our core business and could harm our reputation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Ultimately, the SEC determined to terminate its review of the Initial Form 8-K and related amendments, rather than provide us with additional opportunities to address their concerns and therefore, we did not clear their comments. It is not possible at this time to predict whether or when the SEC may initiate any proceedings, when this issue may be resolved or what, if any, penalties or other remedies may be imposed, and whether any such penalties or remedies would have a material adverse effect on our consolidated financial position, results of operations, or cash flows. Litigation and enforcement actions are inherently unpredictable, the outcome of any potential lawsuit or action is subject to significant uncertainties and, therefore, determining at this time the likelihood of a loss, any SEC enforcement action and/or the measurement of the amount of any loss is complex. Consequently, we are unable to estimate the range of reasonably possible loss. Our assessment is based on an estimate and assumption that has been deemed reasonable by management, but the assessment process relies heavily on an estimate and assumption that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change that estimate and assumption. In light of the uncertainty of this issue and while Management evaluates the best and most appropriate way to resolve same, management determined to create a reserve on the Company&#146;s Balance Sheet for the $90,000 that was subject to the Consent.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company rents its Culver City, CA office space from a company owned by our CEO. The rental agreement provides for the value of the rent of $500 per month be recorded as contributed towards the founding eWellness and its operations. During the period ended March 31, 2016, we have recorded this rent payment in the Consolidated Statements of Operations and Additional Paid in Capital on the Balance Sheet.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On April 1, 2015, the Company entered into an Operating Agreement with Evolution Physical Therapy (&#147;EPT&#148;), a company owned by one of the Company&#146;s officers, wherein it is agreed that EPT would be able to operate the Company&#146;s telemedicine platform <u>www.phzio.com</u> and offer it to selected physical therapy patients of EPT. The Company is to receive 75% of the net insurance reimbursements from the patient for use of the platform. The Company will advance capital requested by EPT for costs specifically associated with operating the <u>www.phzio,com</u> platform and associated physical therapy treatments &#150; computer equipment, office or facilities rental payments, physical therapist or physical therapy assistant, administrative staff, patient induction equipment, office supplies, utilities and other associated operating costs. It is anticipated that the operation of the platform by EPT will generate positive cash flow within 90 days from the start of patient induction.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On May 20, 2015, the Company entered into an agreement with Mavericks Capital Securities LLC (&#147;Mavericks&#148;). The term of the contract begins on the effective date and can be terminated within 30 days upon written notice by either party. The Company is to pay Mavericks a monthly retainer fee of $10,000 that is deferred until the Company raises $250,000 in new investor funds from the effective date. In addition, the Company granted Mavericks 250,000 warrants to purchase Company common stock at $.35 per share. On September 28, 2015, the Company and Mavericks entered into an amendment to the consultant agreement pursuant to which Mavericks will also assist the Company in the acquisition of new customers, for which the Company shall pay Mavericks 10% of the revenue received by the Company, net of any pass through costs, from any such customers introduced to the Company by Mavericks; payment shall be made upon the Company&#146;s receipt of such revenues. In the amendment, the parties also further clarified the definition of Customer Acquisition.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On January 20, 2016, the Company entered into a one year agreement with a consulting firm to provide marketing and financial media awareness services. Compensation for this agreement is the issuance of 100,000 shares of common stock &#150; 50,000 were issued at the signing of the agreement and the other 50,000 are to be issued in July, 2016. The value of these shares is $5,000 for each issuance which is being amortized over the term of the contract.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 1, 2016, the Company entered into a six month agreement with a consulting firm for services including introductions to brokers, investment bankers, market makers and business development opportunities. Compensation for his agreement is the issuance of 100,000 shares of common stock. The value of these shares is $10,000 and is being amortized over the term of the contract. At the end of the period ending March 31, 2016, the shares had not yet been issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On March 3, 2016, the Company entered into a six month agreement with a consulting firm for management consulting, business advisory and public relations services. Compensation for this agreement is the issuance of 100,000 shares of common stock for the purchase price of $100 and a $2,500 monthly fee that is to be accrued and not payable until the Company closes a qualified financing.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On March 14, 2016, the Company entered into a 45-day Promissory Note Extension at an interest rate of 12% per annum. As an inducement for this extension of previous promissory notes, the Company issued 400,000 warrants to purchase Company common stock at $.80 per share. The fair value of the warrants is $794. For the period ended March 31, 2016, the Company recorded $629 of accrued interest for this note.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">From time to time the Company may become a party to litigation matters involving claims against the Company. Except as may be outlined above, management believes that there are no current matters that would have a material effect on the Company&#146;s financial position or results of operations.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 5. Related Party Transactions</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Through the period ended March 31, 2016, a related party, a company for which the Company&#146;s former Secretary-Treasurer and CFO is also serving as CFO, has paid $96,831 on the Company&#146;s behalf for various operating expenses. The amount outstanding as of March 31, 2016 and December 31, 2015 was $50,362 and $43,717, respectively. The Company recorded $897 and $1,078 imputed interest on the amount owed to the related party based on an interest rate of 8% for the three months ended March 31, 2016 and March 31, 2015, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During 2014, the Company entered into a license agreement with a programming company in which one of our directors is Chief Marketing Officer. Through the licensing agreement, we obtained a perpetual license to use the programming code created by a video management platform as a base to develop our telemedicine video service for a license fee of $20,000. The license fee is recorded as an Intangible Asset and Accounts Payable on the Balance Sheet.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On April 1, 2015, the Company entered into an operating agreement with a physical therapy company (&#147;EPT&#148;) which is owned by the Company&#146;s President and Chief Executive Officer. Through the agreement the Company agrees to provide operating capital advances in order for EPT to offer the Company&#146;s PHIZIO platform to physical therapy patients. For accounting and tax purposes, the net profits or losses generated by EPA shall be allocated on a monthly basis. The Company will receive 75% of the net patient insurance reimbursements associated with the operation of the PHIZIO platform.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company rents its Culver City, CA office space from a company owned by our CEO. The imputed rent expense of $500 per month is recorded in the Consolidated Statement of Operations and Additional Paid in Capital in the Balance Sheet.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The officers of the Company incur business expenses on behalf of the Company. The amounts outstanding as of March 31, 2016 and December 31, 2015 were $49,226 and $33,090, respectively.</p> 0.001 0.001 0.001 96831 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><u>Basis of Presentation</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The interim financial information of the Company as of periods ended March 31, 2016 and March 31, 2015 is unaudited. The balance sheet as of December 31, 2015 is derived from audited financial statements of eWellness Healthcare Corporation. The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial statements. Accordingly, they omit or condense footnotes and certain other information normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles. The accounting policies followed for quarterly financial reporting conform to the accounting policies disclosed in ASU 2014-10. In the opinion of management, all adjustments which are necessary for a fair presentation of the financial information for the interim periods reported have been made. All such adjustments are of a normal recurring nature. The results of operations for the three months ended March 31, 2016 are not necessarily indicative of the results that can be expected for the entire year ending December 31, 2016. The unaudited financial statements should be read in conjunction with the financial statements and the notes thereto included in the Company&#146;s annual report on Form 10-K for the year ended December 31, 2015.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><u>Use of Estimates</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from these good faith estimates and judgments.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 13. Subsequent Events</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On April 13, 2016, we entered into a one-year renewable advisory agreement with Dan Mills, MPT to become the Company&#146;s chairman of the to-be-formed committee known as the eWellness Physical Therapy Clinical Advisory Board and to act as the Company&#146;s national spokesperson at the American Physical Therapy Association (&#147;APTA&#148;).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As inducement for Mr. Mills to enter the Agreement, we agreed to issue to 250,000 immediately vesting common stock purchase warrants at a price of $1.00 per share. The common stock underlying the Warrants has piggy-back registration rights. In addition, 10,000 shares of common stock are to be issued to Mr. Mills upon the signing of the Agreement. Per the agreement Mr. Mills will receive $0.50 cents per PHZIO session that an APTA members uses, $500 per month in consulting fees and $2,500 paid within ten days of signing the Agreement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On May 2, 2016, the Company entered into a 45-day Promissory Note Extension at an interest rate of 12% per annum. As an inducement for this extension of previous promissory notes, the Company issued 400,000 warrants to purchase Company common stock at $.80 per share.</p> 9200000 2500000 11700000 2100000 5964 5543 8421 8421 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 3. Property and Equipment</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Property and equipment consists of computer equipment that is stated at cost $8,421 and $8,421 less accumulated depreciation of $2,878 and $2,457 at March 31, 2016 and December 31, 2015, respectively. Depreciation expense was $421 for the three months ended March 31, 2016 and $211 for the three months ended March 31, 2015, respectively.</p> 20000 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 8. Convertible Notes Payable</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On December 23, 2014 the Company issued $213,337 convertible promissory notes and warrants to purchase shares of common stock to four individual investors. The overall terms of the Notes are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px; text-align: justify">&#160;</td> <td style="width: 24px; text-align: justify"><font style="font-size: 10pt">&#9679;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">Interest rate: 12% per annum. As of March 31, 2016, the Company had recorded $464 of accrued interest.</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><font style="font-size: 10pt">&#9679;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">Due date: December 31, 2015. The Company is to pay the principal amount and all accrued and unpaid interest on or before the due date. One of the convertible notes totaling $3,000 is in default.</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><font style="font-size: 10pt">&#9679;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">Redemption right: Any time the closing price of the Company&#146;s common stock has been at or above $1.50 for 20 consecutive trading days, the Company has the right to redeem all or any part of the principal and accrued interest of the notes, following written notice to the holders of the notes.</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><font style="font-size: 10pt">&#9679;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">Optional Conversion: At the option of the holders, the notes may be converted into shares of the Company&#146;s common stock at a conversion price equal to $0.35 per share.</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><font style="font-size: 10pt">&#9679;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">Additionally, if the Company elects to exercise the redemption right, the holders have the opportunity to elect to take the cash payment or to convert all or any portion of the notes into shares of the Company&#146;s common stock.</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><font style="font-size: 10pt">&#9679;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">The conversion price is subject to proportional adjustment in the event of stock splits, stock dividends and similar corporate events.</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><font style="font-size: 10pt">&#9679;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">The notes are senior in rank to any other debt held by our officers, directors or affiliates and may not be subordinated to any other debt issued by the Company without the written consent of the holders.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td>&#160;</td> <td><font style="font-size: 10pt">&#9679;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">Warrants: The holders of the notes are granted the right through December 23, 2017 to purchase 609,534 additional shares of common stock at $.35 per share.</font></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><font style="font-size: 10pt">&#9679;</font></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the time that any portion of these Notes are outstanding, if any Event of Default, as defined in the notes, occurs and such Default is not cured by the Company within sixty (60) days of the occurrence of the Event of Default (the &#147;Cure Period&#148;), the amount equal to one hundred fifty percent (150%) of the outstanding principal amount of this Note, together with accrued interest and other amounts owing shall become at the holder&#146;s election, immediately due and payable in cash. The</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">holders at its option have the right, with three (3) business days advance written notice to the Company after the expiration of the Cure Period, to elect to convert the Notes into shares of the Company&#146;s common stock pursuant to the Optional Conversion rights disclosed above.</p></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><font style="font-size: 10pt">&#9679;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">The Company valued the cash conversion feature as the difference in the value of the note at its stated annual interest rate of 12% and the fair value of the note at its discounted value using an expected borrowing rate of 18%.</font></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><font style="font-size: 10pt">&#9679;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">The Company&#146;s Condensed Consolidated Balance Sheets report the following related to the convertible promissory notes:</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">March 31, 2016</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%"><font style="font-size: 10pt">Principal amount</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">3,000</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Unamortized debt discount</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Net carrying amount</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">3,000</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 20, 2016, a convertible promissory note with the principal value of $69,500 was converted to 227,332 shares of common stock at a conversion price of $.35 per share. The warrants associated with this note were not exercised. See Note 9 below &#150; Equity Transactions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On April 9, 2015, the Company issued $270,080 convertible promissory notes (including an aggregate of $123,980 that was converted from certain other outstanding notes, including accrued interest, and future contractual cash consulting fees) and warrants to purchase shares of common stock to eight individual investors. The overall terms of the notes are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><font style="font-size: 10pt">&#9679;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">Interest rate: 12% per annum. As of March 31, 2016, the Company recorded $13,274 of accrued interest.</font></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><font style="font-size: 10pt">&#9679;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">Due date: April 30, 2016. The Company is to pay the principal amount and all accrued and unpaid interest on or before the due date.</font></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><font style="font-size: 10pt">&#9679;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">Redemption right: Any time the closing price of the Company&#146;s common stock has been at or above $1.50 for 20 consecutive trading days, the Company has the right to redeem all or any part of the principal and accrued interest of the notes, following written notice to the holders of the Notes.</font></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><font style="font-size: 10pt">&#9679;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">Optional Conversion: At the option of the holders, the notes may be converted into shares of the Company&#146;s common stock at a conversion price equal to $0.35 per share.</font></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><font style="font-size: 10pt">&#9679;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">Additionally, if the Company elects to exercise the redemption right, the holders have the opportunity to elect to take the cash payment or to convert all or any portion of the Notes into shares of the Company&#146;s common stock.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><font style="font-size: 10pt">&#9679;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">The conversion price is subject to proportional adjustment in the event of stock splits, stock dividends and similar corporate events.</font></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><font style="font-size: 10pt">&#9679;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">The notes are senior in rank to any other debt held by our officers, directors or affiliates and may not be subordinated to any other debt issued by us without the written consent of the holders.</font></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><font style="font-size: 10pt">&#9679;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">Warrants: The holders of the notes are granted the right through April 30, 2016 to purchase 771,658 additional shares of common stock at $.35 per share. The fair value of the warrants is $1,132.</font></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><font style="font-size: 10pt">&#9679;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">During the time that any portion of these notes are outstanding, if any Event of Default, as defined in the notes, occurs and such Default is not cured by the Company within sixty (60) days of the occurrence of the Event of Default (the &#147;Cure Period&#148;), the amount equal to one hundred fifty percent (150%) of the outstanding principal amount of this Note, together with accrued interest and other amounts owing shall become at the holder&#146;s election, immediately due and payable in cash. The holders at its option have the right, with three (3) business days advance written notice to the Company after the expiration of the Cure Period, to elect to convert the Notes into shares of the Company&#146;s common stock pursuant to the Optional Conversion rights disclosed above.</font></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><font style="font-size: 10pt">&#9679;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">The Company&#146;s Condensed Consolidated Balance Sheets report the following related to the convertible promissory notes:</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">March 31, 2016</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%"><font style="font-size: 10pt">Principal amount</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Unamortized debt discount</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Net carrying amount</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><font style="font-size: 10pt">&#9679;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">The Company valued the cash conversion feature as the difference in the value of the note at its stated interest rate of 12% and the fair value of the note at its discounted value using an expected borrowing rate of 18%. The value of the cash conversion feature at inception of the notes was $44,189.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On December 7, 2015, the Company issued a $275,000 senior convertible promissory note with a 10% original issue discount and warrants to purchase shares of common stock. The overall terms of the notes are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><font style="font-size: 10pt">&#9679;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">Interest rate: 8% per annum. As of the period ended March 31, 2016, the Company had recorded $5,561 of interest expense. The interest rate increases to 15% per annum on any unpaid and overdue principal and interest.</font></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><font style="font-size: 10pt">&#9679;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">Due date: June 2, 2016. The Company is to pay the principal amount and all accrued and unpaid interest on or before the due date.</font></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><font style="font-size: 10pt">&#9679;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">Redemption right: Within three trading days, prior written notice of the Company has the right to redeem all the note equal to the sum of 115% of the principal plus accrued and unpaid interest on the principal amount.</font></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><font style="font-size: 10pt">&#9679;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">Optional Conversion: At the option of the holder, the note may be converted into shares of the Company&#146;s common stock at a conversion price equal to 75% of the lowest per share purchase price, conversion price or exercise price of securities that the Company issues in the next financing transaction.</font></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><font style="font-size: 10pt">&#9679;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">The note is senior in rank to any other debt of the Company as of the issuance date of the note and to any indebtedness incurred following the issuance date.</font></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><font style="font-size: 10pt">&#9679;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">Warrants: The holders of the notes are granted the right to purchase 250,000 additional shares of common stock at $.80 per share.</font></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><font style="font-size: 10pt">&#9679;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">The Company shall be considered to be in Default if the Company fails to obtain a listing of its common stock on at least one of OTCBB, OTCQB, Nasdaq or NYSE within 90 days of the date of the note or fails to maintain the listing of its common stock; the Company fails to comply with the reporting requirements of the 1934 Act and/or ceases to be subject to the reporting requirements of the 1934 Act; the restatement of any financial statements for any date or period from two years prior to the date of the note and until this note is no longer outstanding results in a material adverse effect on the rights of the note holder; the DTC places a &#147;chill&#148; on any of the Company&#146;s securities; the Company&#146;s common stock becomes not eligible for trading through the DTC&#146;s FAST Automated Securities Transfer or Deposit/Withdrawal at Custodian programs; the Company fails to raise at least $1,000,000 in a Primary Offering within 120 days following the list date; the Company fails to appoint VStock Transfer LLC as the transfer agent for its common stock within 30 days of list date. </font></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><font style="font-size: 10pt">&#9679;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">The Company&#146;s Balance Sheets report the following related to the December 7, 2015, convertible promissory note:</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">March 31, 2016</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%"><font style="font-size: 10pt">Principal amount</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">275,000</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Unamortized debt discount</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(16,273</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Net carrying amount</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">258,727</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Under the guidance of ASC 470-20 Debt With Conversion and Other Options, the common shares of the Company, pending being listed on the OTC, and the net settlement requirements of the warrants will be analyzed at the end of each quarter to determine if the conversion does become readily convertible to cash which would require derivative accounting calculations and recording.</p> 0.7697 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><u>Cash and Cash Equivalents</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Cash and cash equivalents includes all cash deposits and highly liquid financial instruments with an original maturity to the Company of three months or less.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><u>Recent Accounting Pronouncements</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#147;FASB&#148;) that are adopted by the Company as of the specified date. The Company has elected to the early adoption of ASU 2015-03 that simplifies the presentation of debt issuance costs. The Company had previously used the methodology in this standard and has adopted the pronouncement for current and future debt instruments.</p> P5Y P7Y P5Y P7Y P3Y 500 90000 0.10 0.90 eWELLNESS HEALTHCARE Corp 0001550020 10-Q 2016-03-31 false --12-31 Q1 19862 19123 24770 24770 4908 5647 0.35 0.35 .35 .35 .80 .80 .35 .80 0.80 1.00 1.50 0.12 0.12 0.05 0.05 0.12 0.12 1.50 0.12 0.12 0.12 0.12 0.75 0.12 0.12 0.12 0.12 0.08 0.12 0.12 0.12 0.10 0.08 0.08 0.15 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company&#146;s Condensed Consolidated Balance Sheets report the following related to the convertible promissory notes:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">March 31, 2016</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%"><font style="font-size: 10pt">Principal amount</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">3,000</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Unamortized debt discount</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Net carrying amount</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">3,000</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company&#146;s Condensed Consolidated Balance Sheets report the following related to the convertible promissory notes:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">March 31, 2016</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%"><font style="font-size: 10pt">Principal amount</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Unamortized debt discount</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Net carrying amount</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company&#146;s Balance Sheets report the following related to the December 7, 2015, convertible promissory note:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">March 31, 2016</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%"><font style="font-size: 10pt">Principal amount</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">275,000</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Unamortized debt discount</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(16,273</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Net carrying amount</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">258,727</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p> 213337 3000 270080 275000 275000 5000000 421 211 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 4. Intangible Assets</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company recognizes the cost of a software license and a license for use of a programming code as intangible assets. The stated cost of these assets were $24,770 and $24,770 less accumulated amortization of $5,647 and $4,908 for the periods ended March 31, 2016 and December 31, 2015, respectively. For the periods ended March 31, 2016 and March 31, 2015, the amortization expense recorded was $739 and $739, respectively.</p> Redemption right: Any time the closing price of the Company’s common stock has been at or above $1.50 for 20 consecutive trading days, the Company has the right to redeem all or any part of the principal and accrued interest of the notes, following written notice to the holders of the notes. Redemption right: Any time the closing price of the Company’s common stock has been at or above $1.50 for 20 consecutive trading days, the Company has the right to redeem all or any part of the principal and accrued interest of the notes, following written notice to the holders of the Notes. With three trading days prior written notice of the Company has the right to redeem all the note equal to the sum of 115% of the principal plus accrued and unpaid interest on the principal amount. 2015-12-31 2015-04-23 2016-04-30 2015-12-14 2015-12-14 2015-12-14 2016-06-02 2016-05-01 0.35 0.35 0.10 0.90 100000 10000 90000 40000 6000 5000 10100 15000 5000 10000 100 2878 2457 3980 629 69500 87500 33600 232147 17595 62996 69500 400000 60000 50000 100000 150000 100000 50000 50000 100000 100000 609533 5631191 6031191 5021658 400000 0.63 0.80 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following is a summary of the status of all of the Company&#146;s warrants as of March 31, 2016 and changes during the three months ended on that date:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Weighted</font></td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Number of</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Average</font></td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Warrants</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Exercise Price</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Outstanding at January 1, 2015</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">609,533</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">0.35</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Granted</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">5,021,658</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">0.63</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Exercised</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Cancelled</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 61%"><font style="font-size: 10pt">Outstanding at December 31, 2015</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">5,631,191</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">0.61</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Granted</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">400,000</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">0.80</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Exercised</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-size: 10pt">Cancelled</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Outstanding at March 31, 2016</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">6,031,191</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.62</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p> 20000 10000 2500 123980 2500000 70000 0.10 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 11. Segment Reporting</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company has one operating segment, which was identified based upon the availability of discrete financial information and the chief operating decision makers&#146; regular review of financial information.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><u>Revenue Recognition</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company has yet to realize revenues from operations. Once the Company has commenced operations, it will recognize revenues when delivery of goods or completion of services has occurred provided there is persuasive evidence of an agreement, acceptance has been approved by its customers, the fee is fixed or determinable based on the completion of stated terms and conditions, and collection of any related receivable is probable.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Property and Equipment</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Property and equipment are recorded at historical cost. Minor additions and renewals are expensed in the year incurred. Major additions and renewals are capitalized and depreciated over their estimated useful lives. Depreciation is recorded over the estimated useful lives of the related assets using the straight-line method for financial statement purposes. The Company uses other depreciation methods (generally accelerated) for tax purposes where appropriate. The estimated useful lives for significant property and equipment categories are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 50%"><font style="font-size: 10pt">Furniture and Fixtures</font></td> <td style="width: 1%">&#160;</td> <td style="width: 49%"><font style="font-size: 10pt">5-7 Years</font></td></tr> <tr style="vertical-align: top"> <td><font style="font-size: 10pt">Computer Equipment</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">5-7 Years</font></td></tr> <tr style="vertical-align: top"> <td><font style="font-size: 10pt">Software</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">3 Years</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company regularly evaluates whether events or circumstances have occurred that indicate the carrying value of long-lived assets may not be recoverable. If factors indicate the asset may not be recoverable, we compare the related undiscounted future net cash flows to the carrying value of the asset to determine if impairment exists. If the expected future net cash flows are less than the carrying value, an impairment charge is recognized based on the fair value of the asset.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><u>Fair Value of Financial Instruments</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company complies with the accounting guidance under Financial Accounting Standards Board (&#147;FASB&#148;) Accounting Standards Codification (&#147;ASC&#148;) 820-10, <i>Fair Value Measurements,</i> as well as certain related FASB staff positions. This guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact business and considers assumptions that marketplace participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The guidance also establishes a fair value hierarchy for measurements of fair value as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Level 1 &#150; quoted market prices in active markets for identical assets or liabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Level 2 &#150; inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Level 3 &#150; unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of March 31, 2016, the Company had the following assets and liabilities measured at fair value on a recurring basis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Total</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Level 1</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Level 2</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Level 3</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 48%; padding-bottom: 1.5pt"><font style="font-size: 10pt">Derivative liability</font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">2,802</font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">2,802</font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total liabilities measure at fair value</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2,802</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2,802</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><u>Deferred Offering and Acquisition Costs</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company defers as other assets the direct incremental costs of raising capital until such time as the offering is completed. At the time of the completion of the offering, the costs will be charged against the capital raised. Should the offering be terminated, the deferred offering costs will be charged to operations during the period in which the offering is terminated. Direct acquisition costs will be expensed as incurred.</p> Smaller Reporting Company <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><u>Loss per Common Share</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company follows ASC Topic 260 to account for the loss per share. Basic loss per common share calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per common share calculations are determined by dividing net loss by the weighted average number of common shares and dilutive common share equivalents outstanding. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation. As the Company has no common stock equivalents and has incurred losses for the period ended March 31, 2016, no dilutive shares are added into the loss per share calculations.</p> 10000000 10000000 .001 .001 0 0 0 0 100000000 100000000 18170538 18697770 18170538 18697770 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 7. Non-Convertible Notes Payable</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On January 27, 2015, the Company issued a promissory note of $20,000 with a shareholder/consultant at an annual interest rate of 12% due and payable on April 23, 2015. On April 9, 2015, as part of the second closing of the convertible debt discussed in Note 8 below, the note for $20,000, together with accrued interest for $3,980 through March 31, 2015 and future consulting fees due and payable through October 2015 of $100,000 were converted to a convertible note of $123,980.11. The consulting fees for future months were booked to prepaid expense and were amortized over the remaining term of the consulting agreement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On May 30, 2015, the Company received $25,000 in exchange for a 90-day Promissory Note at an interest rate of 5% per annum. As an inducement for this promissory note, the Company issued 150,000 warrants to purchase Company common stock at $.35 per share. The fair value of the warrants is $768. On August 26, 2015, the Company entered into an extension of this note for another 90 days to October 23, 2015. As an inducement for this extension, the Company issued 150,000 warrants to purchase Company common stock at $.80 per share. The fair value of the warrants if $158. On October 11, 2015 the Company entered into a second extension of this note to be due on December 14, 2015. As an inducement for this extension, the Company issued 150,000 warrants to purchase Company common stock at $.80 per share. The fair value of the warrants is $300. In addition the interest rate on the note was increased to 12% from the original note date of May 27 plus a risky loan fee of $6,250.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On July 15, 2015, the Company received $18,000 in exchange for a 90-day Promissory Note at an interest rate of 5% per annum. As an inducement for this promissory note, the Company issued 150,000 warrants to purchase Company common stock at $.80 per share. The fair value of the warrants is $310. On October 5, 2015 the Company entered into an extension of this note to be due on December 14, 2015. As an inducement for this extension, the Company issued 150,000 warrants to purchase Company common stock at $.80 per share. The fair value of the warrants is $300. In addition the interest rate on the note was increased to 12% from the original note date of July 15 plus a risky loan fee of $4,500.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On September 16, 2015, the Company received $22,500 in exchange for a 90-day Promissory Note at an interest rate of 12% per annum plus a risky note fee of $5,625. As an inducement for this promissory note, the Company issued 450,000 warrants to purchase Company common stock at $.80 per share. The fair value of the warrants is $908.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On September 16, 2015, the Company received $12,500 in exchange for a 90-day Promissory Note at an interest rate of 12% per annum plus a risky loan fee of $3,125 which was amortized over the term of the loan. As an inducement for this promissory note, the Company issued 250,000 warrants to purchase Company common stock at $.80 per share. The fair value of the warrants is $504. This note, accrued interest and risky loan fee were paid on December 9, 2015.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On September 16, 2015, the Company received $2,500 in exchange for a 90-day Promissory Note at an interest rate of 12% per annum plus a risky loan fee of $625 which was amortized over the term of the loan. As an inducement for this promissory note, the Company issued 50,000 warrants to purchase Company common stock at $.80 per share. The fair value of the warrants is $101. This note, accrued interest and risky loan fee were paid on December 9, 2015.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On October 11, 2015, the Company received $10,000 in exchange for a Promissory Note which matures on December 14, 2015; however if the Company receives $100,000 or more in its current private placement of up to $2,500,000 convertible note with warrants, the note will be due within three business days of such funds settling in the Company&#146;s account. The note has an interest rate of 12% per annum plus a risky loan fee of $2,500 which was amortized over the term of the loan. As an inducement for this promissory note, the Company issued 200,000 warrants to purchase Company common stock at $.80 per share. The fair value of the warrants is $385.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On December 6, 2015, the Company entered into a 90-day Promissory Note for $70,000 at an interest rate of 12% per annum plus a risky loan fee of $17,500 which is being amortized over the term of the loan. As an inducement the Company issued 1,400,000 warrants to purchase Company common stock at $.80 per share. The fair value of the warrants is $2,800. The Company further agreed to repay the loan within three days of the Company receiving $500,000 or more in the current private placement of up to $2,500,000 convertible note with warrants. This Promissory Note resulted from the principal payment to the note holder of $28,222.94 and the holder cancelling the notes originally signed on May 27, 2015 plus extensions, July 15, 2015 plus extensions, September 16, 2015 and October 11, 2015.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On March 14, 2016, the Company issued a 45-day promissory note to a shareholder of $112,550 as an extension for notes with a shareholder dated May 30 2015, July 15, 2015, September 16, 2015, October 11, 2015, and December 6, 2015. The amount of the note includes interest accrued on the previous notes, risky loan fee and a default fee. The note has an annual interest rate of 12% due and payable on May 1, 2016. As an inducement for this promissory note, the Company issued 400,000 warrants to purchase Company common stock at $.80 per share. The fair value of the warrants is $794. For the period ended March 31, 2016, the Company recorded $2,470 of interest expense for this note.</p> 20000 112550 100000 25000 18000 22500 12500 2500 10000 150000 150000 150000 450000 250000 50000 150000 150000 200000 1400000 400000 0.35 0.80 0.80 .80 0.80 .80 .80 .80 .80 .80 .80 768 158 310 908 504 101 1132 300 300 385 2800 794 794 794 0.18 0.18 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The significant assumptions used in the Black Scholes valuation of the date of issuance are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 82%"><font style="font-size: 10pt">Stock price on the valuation date</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 15%; text-align: right"><font style="font-size: 10pt">0.10</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Exercise price of warrants</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">.35 and .80 </font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Dividend yield</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">0.00</font></td> <td><font style="font-size: 10pt">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Years to maturity</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#160;2.5 </font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Risk free rate</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">2.0%</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Expected volatility</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">61%</font></td> <td>&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p> 0.00 P2Y6M 0.020 0.020 0.61 0.614 0.75 2850000 250000 227332 250000 96000 663277 50272 179989 50000 227232 0.35 0.61 0.62 190633 186000 -425608 -316879 6250 4500 5625 3125 625 2500 17500 41951 13582 900 through March 31, 2015 and future consulting fees due and payable through October 2015 464 13274 123980 0.02 739 739 500 44189 -1404634 -1606786 2802 2802 2802 2802 100000 500000 2500000 3000 During the time that any portion of these Notes are outstanding, if any Event of Default, as defined in the notes, occurs and such Default is not cured by the Company within sixty (60) days of the occurrence of the Event of Default (the “Cure Period”), the amount equal to one hundred fifty percent (150%) of the outstanding principal amount of this Note, together with accrued interest and other amounts owing shall become at the holder’s election, immediately due and payable in cash. The holders at its option have the right, with three (3) business days advance written notice to the Company after the expiration of the Cure Period, to elect to convert the Notes into shares of the Company’s common stock pursuant to the Optional Conversion rights disclosed above. During the time that any portion of these notes are outstanding, if any Event of Default, as defined in the notes, occurs and such Default is not cured by the Company within sixty (60) days of the occurrence of the Event of Default (the “Cure Period”), the amount equal to one hundred fifty percent (150%) of the outstanding principal amount of this Note, together with accrued interest and other amounts owing shall become at the holder’s election, immediately due and payable in cash. The holders at its option have the right, with three (3) business days advance written notice to the Company after the expiration of the Cure Period, to elect to convert the Notes into shares of the Company’s common stock pursuant to the Optional Conversion rights disclosed above. holder cancelling the notes originally signed on May 27, 2015 plus extensions, July 15, 2015 plus extensions, September 16, 2015 and October 11, 2015. On March 14, 2016, the Company issued a 45-day promissory note to a shareholder of $112,550 as an extension for notes with a shareholder dated May 30 2015, July 15, 2015, September 16, 2015, October 11, 2015, and December 6, 2015. 22494 7153 5561 2470 250000 1000000 275000 2802 0.0167 0.6282 0.80 P5Y 0.00 16273 309945 261727 3000 258727 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The estimated useful lives for significant property and equipment categories are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 50%"><font style="font-size: 10pt">Furniture and Fixtures</font></td> <td style="width: 1%">&#160;</td> <td style="width: 49%"><font style="font-size: 10pt">5-7 Years</font></td></tr> <tr style="vertical-align: top"> <td><font style="font-size: 10pt">Computer Equipment</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">5-7 Years</font></td></tr> <tr style="vertical-align: top"> <td><font style="font-size: 10pt">Software</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">3 Years</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of March 31, 2016, the Company had the following assets and liabilities measured at fair value on a recurring basis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Total</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Level 1</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Level 2</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Level 3</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 48%; padding-bottom: 1.5pt"><font style="font-size: 10pt">Derivative liability</font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">2,802</font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">2,802</font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total liabilities measure at fair value</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2,802</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2,802</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The significant assumptions used in the Black Scholes valuation of the derivative are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%"><font style="font-size: 10pt">Stock price at valuation date</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">.10</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Exercise price of warrants</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">.80</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Risk free interest rate</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1.67</font></td> <td><font style="font-size: 10pt">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Stock volatility factor</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">62.82</font></td> <td><font style="font-size: 10pt">%</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Years to Maturity</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">5</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Expected dividend yield</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">None</font></td> <td>&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 12. Derivative Valuation</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The warrants granted with the $275,000 senior convertible promissory note (the &#147;Note&#148;) issued on December 7, 2015 (described in Note 8) have a Most Favored Nation clause resulting in the exercise price of the warrants not being fixed. Therefore, this feature has been characterized as a derivate liability to be re-measured at the end of every reporting period with the change in value reported in the statement of operations. At March 31, 2016, the outstanding fair value of the warrants accounted for as a derivative liability amounted to $2,802. As of March e31, 2016. no gain or loss was recognized in the statement of operations as the change in valuation from inception was clearly trivial to the financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For purposes of determining the fair market value of the derivative liability for the warrants, the Company used Black Scholes option valuation model. The significant assumptions used in the Black Scholes valuation of the derivative are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%"><font style="font-size: 10pt">Stock price at valuation date</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">.10</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Exercise price of warrants</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">.80</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Risk free interest rate</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1.67</font></td> <td><font style="font-size: 10pt">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Stock volatility factor</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">62.82</font></td> <td><font style="font-size: 10pt">%</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Years to Maturity</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">5</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Expected dividend yield</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">None</font></td> <td>&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p> 2016 4053 42824 46004 56406 71830 81072 71605 112048 2802 2802 90000 90000 677000 767000 33090 49226 43717 50362 248305 354693 1476464 1687858 1476464 1687858 -3456187 -3881795 2033383 2246311 10000 18171 18698 71830 81072 111288 90394 500 51526 34588 353447 310982 -353447 -310982 71264 16142 11323 -425608 -316879 -0.02 -0.02 18352696 16740778 -1500 37470 8726 4633 897 1078 9389 96000 97500 1160 950 90000 85000 16137 -5105 6645 -13100 118974 -34880 -1329 -16074 -7054 -28369 -137040 -4207 4207 146100 20000 166100 -28369 24853 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 1. The Company</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><u>The Company and Nature of Business</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">eWellness Healthcare Corporation (f/k/a Dignyte, Inc.), (the &#147;Company&#148;, &#147;we&#148;, &#147;us&#148;, &#147;our&#148;) was incorporated in the State of Nevada on April 7, 2011, to engage in any lawful corporate undertaking, including, but not limited to, selected mergers and acquisitions. The Company has generated no revenues to date. Prior to the Share Exchange Agreement discussed below, other than issuing shares to its original shareholder, the Company never commenced any operational activities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The eWellness strategy as a first-to-market enterprise in the Physical Therapy based telemedicine industry is to deliver a telemedicine physical therapy service augmenting corporate wellness programs and also expand nationally through a Software as a Service (SaaS) business model that enables existing physical therapy practices to extend their offerings via our telemedicine solution. Our objective is to provide Distance Monitored Physical Therapy (PHZIO) Programs to pre diabetic, cardiac and health challenged patients and knee and hip surgery rehabilitation. For corporate wellness program our services are designed to deliver significant healthcare savings to the company while charging a very small relative incremental cost.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Share Exchange Agreement</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On April 11, 2014, Digntye, Inc. (&#147;Dignyte&#148;), a publicly held Nevada corporation and eWellness Corporation (&#147;Private Co&#148;), a privately held company incorporated in Nevada, executed a Share Exchange Agreement (or &#147;Initial Exchange Agreement&#148;). Prior to the execution and delivery of the final Amended and Restated Share Exchange Agreement (the &#147;Agreement&#148;), the Board of Directors of Dignyte approved the Agreement and the transactions contemplated thereby. Similarly, the Board of Directors of the Private Co. approved the exchange. On April 25, 2014, immediately prior to the execution and delivery of the Agreement, Dignyte amended its certificate of incorporation to change its corporate name from &#147;Dignyte, Inc.&#148; to &#147;eWellness Healthcare Corporation.&#148;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Pursuant to the Agreement, eWellness Healthcare Corporation issued 9,200,000 shares of unregistered common stock, $.001 par value per share (the &#147;common stock&#148;) to the shareholders of the Private Co. in exchange for all outstanding shares of the Private Co.&#146;s common stock. In addition, our former chief executive officer agreed: (i) to tender 5,000,000 shares of common stock of Dignyte back to the Company for cancellation; (ii) assign from his holdings, an additional 2,500,000 shares of Dignyte to the shareholders of the Private Co. resulting in a total of 11,700,000 shares owned by those shareholders; and, (iii) to a further assignment of an additional 2,100,000 shares of Dignyte to other parties as stated therein (collectively, the &#147;CEO Stock Actions&#148;).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As the parties satisfied all of the closing conditions, on April 30, 2014, we closed the Share Exchange. As a result, the Private Co. shareholders own approximately 76.97% of our issued and outstanding common stock, after giving effect to CEO Stock Actions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Following the Share Exchange, we abandoned our prior business plan and we are now pursuing the Private Co.&#146;s historical businesses and proposed businesses. The Private Co. is the surviving company under the share exchange and became a wholly owned subsidiary of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For financial reporting purposes, the Share Exchange represents a &#147;reverse merger&#148; rather than a business combination. Consequently, the transaction is accounted for as a reverse-merger and recapitalization. eWellness Corporation is the acquirer for financial reporting purposes and Dignyte, Inc. is the acquired company. Consequently, the assets and liabilities and the operations that are reflected in the historical financial statements prior to the transactions are those of eWellness Corporation and are recorded at the historical cost basis of eWellness</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Corporation,and the consolidated financial statements after completion of the transaction include the assets, liabilities and operations of eWellness Healthcare Corporation, and eWellness Corporation from the closing date of the transaction. Additionally all historical equity accounts and awards of eWellness Corporation, including par value per share, share and per share numbers, have been adjusted to reflect the number of shares received in the transaction.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The foregoing description of the Share Exchange Agreement does not purport to be complete and is qualified in its entirety by the Share Exchange Agreement, a copy of which is attached to the Company&#146;s Current Report on Form 8-K/A as filed with the Securities and Exchange Commission on August 6, 2014. At the execution of the Share Exchange Agreement, the number of total shares of common stock outstanding was 15,200,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On July 22, 2015, the Company&#146;s wholly owned subsidiary, eWellness Corporation, was merged into the Company and, therefore, no longer exists as a separate entity.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 6. Income Taxes</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The tax provision for interim periods is determined using an estimate of the Company&#146;s effective tax rate for the full year adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter the Company updates its estimate of the annual effective tax rate, and if the estimated tax rate changes, the Company makes a cumulative adjustment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">At March 31, 2016 and December 31, 2015, the Company had a full valuation allowance against its deferred tax assets, net of expected reversals of existing deferred tax liabilities, as it believes it is more likely than not that these benefits will not be realized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company does not identify any material uncertain tax positions of the Company on returns that have been filed or that will be filed. The Company has not had operations and has deferred items consisting entirely of unused Net Operating Losses. Since the Company does not believe that this Net Operating Loss will ever produce a tax benefit, even if examined by taxing authorities and disallowed entirely, there would be no effect on the financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company&#146;s policy is to recognize potential interest and penalties accrued related to unrecognized tax benefits within income tax expense. For the periods ended March 31, 2016, and March 31, 2015, the Company did not recognize nor accrue for any interest or penalties.</p> 15200000 28223 609534 771658 0 2850000 0 0 2850000 0.80 0.80 0.80 3000000 0.80 4633 400000 250000 250000 400000 400000 0.50 0.10 P1Y P6M P6M 1 10000 2500 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><u>Going Concern</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For the period ended March 31, 2016, the Company has no revenues and no operations. The Company has an accumulated loss of $3,881,795. In view of these matters, there is substantive doubt about the Company&#146;s ability to continue as a going concern. The Company&#146;s ability to continue operations is dependent upon the Company&#146;s ability to raise additional capital and to ultimately achieve sustainable revenues and profitable operations, of which there can be no guarantee. The Company intends to finance its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following is a summary of the status of all Company&#146;s stock options as of March 31, 2016 and changes during the three months ended on that date:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Number</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Weighted</font></td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">of Stock</font><br /> <font style="font-size: 10pt">Options</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Average Exercise Price</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 72%"><font style="font-size: 10pt">Oustanding at January 1, 2016</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: right"><font style="font-size: 10pt">0</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 11%; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Granted</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">2,850,000</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">0.80</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Exercised</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">0</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-size: 10pt">Cancelled</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">0</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Outstanding at March 31, 2016</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2,850,000</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.80</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Options exercisable at March 31, 2016</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2,850,000</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.80</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p> 0.75 EX-101.SCH 8 dgt-20160331.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - The Company link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Non-Convertible Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Convertible Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Equity Transactions link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Commitments, Contingencies link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Segment Reporting link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Derivative Valuation link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Convertible Notes Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Equity Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Derivative Valuation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - The Company (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Summary of Significant Accounting Policies - Summary of Assets and Liabilities Fair Value Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives for Significant Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Property and Equipment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Intangible Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Non-Convertible Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Convertible Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Convertible Notes Payable - Schedule of Convertible Promissory Note (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Equity Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Equity Transactions - Summary of Stock Options Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Equity Transactions - Summary of Warrant Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Equity Transactions - Schedule of Valuation Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Commitments, Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Segment Reporting (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Derivate Valuation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Derivate Valuation - Schedule of Assumptions Used Black Scholes Valuation of Derivative (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 dgt-20160331_cal.xml XBRL CALCULATION FILE EX-101.DEF 10 dgt-20160331_def.xml XBRL DEFINITION FILE EX-101.LAB 11 dgt-20160331_lab.xml XBRL LABEL FILE Chief Financial Officer [Member] Related Party Transactions By Related Party [Axis] Convertible Notes Payable [Member] Debt Instrument [Axis] Escrow Trust [Member] Consulting Services Agreement [Member] Scenario [Axis] April 20, 2015 To October 20, 2015 [Member] Report Date [Axis] Share Exchange Agreement [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Computer Equipment [Member] Property, Plant and Equipment, Type [Axis] SoftwareLlicense [Member] Finite-Lived Intangible Assets by Major Class [Axis] Warrant [Member] Equity Components [Axis] Bistromatics Corp., [Member] BMT Inc., [Member] Chief Marketing Officer [Member] MHI Patients [Member] Promissory Note One [Member] Convertible Notes Payable One [Member] Warrant One [Member] Minimum [Member] Range [Axis] Maximum [Member] Akash Bajaj [Member] Title of Individual [Axis] Mavericks Capital Securities Llc [Member] Agreement [Axis] Non-Convertible Notes Payable [Member] Non-Convertible Notes Payable [Member] Non-Convertible Notes Payable [Member] Convertible Notes Payable Three [Member] Stock Option Plan [Member] Promissory Note Two [Member] Ms Rochelle Pleskow [Member] Promissory Note Three [Member] Promissory Note Four [Member] Promissory Note Five [Member] Subsequent Event [Member] Subsequent Event Type [Axis] Mr. Mills [Member] Promissory Note Extension [Member] Preferred Stock [Member] Common Stock [Member] Additional Paid-In Capital [Member] Accumulated Deficit [Member] Furniture and Fixtures [Member] Software [Member] Level 1 [Member] Fair Value, Hierarchy [Axis] Level 2 [Member] Level 3 [Member] Convertible Notes Payables [Member] Promissory Note Six [Member] Convertible Notes Payable Two [Member] Consulting Firm [Member] July, 2016 [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS CURRENT ASSETS Cash Prepaid Expenses Total current assets Property & equipment, net Intangible assets, net TOTAL ASSETS LIABILITIES AND STOCKHOLDERS’ DEFICIT CURRENT LIABILITIES Accounts payable and accrued expenses Accounts payable - related party Accrued expenses - related party Accrued compensation Contingent liability Convertible debt, net of discount Derivative liability Short term note and liabilities Total current liabilities Total Liabilities STOCKHOLDERS' DEFICIT Preferred stock, authorized, 10,000,000 shares, $.001 value, 0 shares issued and outstanding Common stock, authorized 100,000,000 shares, $.001 par value, 18,697,770 and 18,170,538 issued and outstanding, respectively Shares to be issued Additional paid in capital Accumulated deficit Total Stockholders' Deficit TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT Preferred stock, shares authorized Preferred stock, par value Preferred stock, shares issued Preferred stock, shares outstanding Common stock, shares authorized Common stock, par value Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] OPERATING EXPENSES Executive compensation General and administrative Professional fees Total Operating Expenses Loss from Operations OTHER INCOME (EXPENSE) Gain on extinguishmment of debt Interest expense, related parties Interest expense Net Loss before Income Taxes Income tax expense Net Loss Basic and diluted (loss) per share Basic and diluted weighted average shares outstanding Statement of Cash Flows [Abstract] Cash flows from operating activities Net loss Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization Contributed services Shares issued for consulting services Imputed interest - related party Option expense Interest on debt extension Amortization of debt discount to interest expense Rent contributed by officer Changes in operating assets and liabilities Advances - related parties Prepaid expense Accounts payable and accrued expenses Accounts payable - related party Accrued expenses - related party Accrued compensation Net cash used in operating activities Cash flows from investing activities Purchase of equipment Net cash used in investing activities Cash flows from financing activities Convertible loan payable proceeds Common stock subscribed Net cash provided by financing activities Net increase in cash Cash, beginning of period Cash, end of period Supplemental Information: Cash paid for: Taxes Interest Expense Organization, Consolidation and Presentation of Financial Statements [Abstract] The Company Accounting Policies [Abstract] Summary of Significant Accounting Policies Property, Plant and Equipment [Abstract] Property and Equipment Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets Related Party Transactions [Abstract] Related Party Transactions Income Tax Disclosure [Abstract] Income Taxes Debt Disclosure [Abstract] Non-Convertible Notes Payable Convertible Notes Payable Equity [Abstract] Equity Transactions Commitments and Contingencies Disclosure [Abstract] Commitments, Contingencies Segment Reporting [Abstract] Segment Reporting Derivative Valuation Derivative Valuation Subsequent Events [Abstract] Subsequent Events Basis of Presentation Use of Estimates Going Concern Deferred Offering and Acquisition Costs Fair Value of Financial Instruments Cash and Cash Equivalents Property and Equipment Revenue Recognition Loss per Common Share Recent Accounting Pronouncements Summary of Assets and Liabilities Fair Value Recurring Basis Estimated Useful Lives for Significant Property and Equipment Schedule of Convertible Promissory Note Summary of Stock Options Activity Schedule of Warrant Activity Schedule of Valuation Assumptions Derivative Valuation Tables Schedule of Assumptions Used Black Scholes Valuation of Derivative Statement [Table] Statement [Line Items] Unregistered common stock issued Number of common stock returned to company by the officer Number of shares assigned to shareholders from the holdings of officer Number of shares owned by the shareholders, total Additional number of common shares assigned to other parties Percentage of issued and outstanding common stock own by shareholders of subsidiary Number of shares of common stock outstanding Accumulated deficit Derivative liability Total liabilities measure at fair value Estimated useful lives Property and equipment Accumulated depreciation Depreciation expense Intangible assets Accumulated amortization Amortization expense Related Party [Axis] Amount paid by related parties Accounts payable-related party Percentage of interest rate of related party License fee Percenage of patient insurance reimbursements received Rent expense Deferred tax assets, net valuation allowance Interest or penalties Promissory note Debt instrumenst interest rate Debt instruments maturity date Notes payable Accrued interest Debt maturity descriptions Non convertible debt converted into convertible debt Convertible debt total Debt receivable Issuance of warrants to purchase of commn stock Warrants issuance price per share Fair value of warrants Loans payable risky fee Receiving from private placement Maximum of private placement Promissory note from principal payment Note payable description Interest expense note Issuance of convertible promissory notes Interest rate Accrued interest Convertible notes payable Redemption right Common stock conversion price per share Warrants to purchase of common stock shares Purchase of common stock purchase price per share Convertible note payable description Debt instrument accrued interest rate Percentage of expected borrowing rate Converted debt into shares amount Number of converted commnon stock Beneficial conversion feature Purchase of warrants exercised Interest expense Fail to raise in primary offering Principal amount Unamortized debt discount Net carrying amount Shares issued during period for consulting services, shares Shares issued during period for consulting services Shares issued during period for conversion of convertible debt, shares Shares issued during period for conversion of convertible debt Number of reserved shares available for grants Percentage of outstanding shares diluted basis stock options vest to purchase shares of common stock price per share Risk free rate Volatility rate Vested value of options Number of warrants issued as part of extension of promissory note Stock price on the valuation date Number of Stock Options Oustanding , Beginning Balance Number of Stock Options Oustanding , Granted Number of Stock Options Oustanding , Exercised Number of Stock Options Oustanding , Cancelled Number of Stock Options Oustanding , Ending Balance Number of Stock Options Oustanding , Exercisable Weighted Average Exercise Price, Beginning Weighted Average Exercise Price, Granted Weighted Average Exercise Price, Exercised Weighted Average Exercise Price, Cancelled Weighted Average Exercise Price, Ending Weighted Average Exercise Price, Exercisable Number of Warrants Outstanding, Beginning Balance Number of Warrants Granted Number of Warrants Exercised Number of Warrants Cancelled Number of Warrants outstanding, Ending Balance Weighted Average Exercise Price, Warrants Outstanding, Beginning Balance Weighted Average Exercise Price, Warrants Granted Weighted Average Exercise Price, Warrants Exercised Weighted Average Exercise Price, Warrants Cancelled Weighted Average Exercise Price, Warrants outstanding, Ending Balance Exercise price of warrants Dividend yield Years to maturity Expected volatility AgreementAxiAxis [Axis] Percentage of subscription proceeds Trust account balance Percentage of returned funds Percentage of funds proceed Percentage of required funds Escrowed funds Proceeds from escrowed funds Return of escrowed funds Rent expense Percentage of insurance reimbursement Consulting fee Proceeds from related party Issuance of warrants to purchase of commn stock shares Warrants price per share Percentage of revenue received Consulting agreement term Number of operating segment Derivate Valuation Details Narrative Warrants granted Derivative liability Derivate Valuation - Schedule Of Assumptions Used Black Scholes Valuation Of Derivative Details Stock price at valuation date Exercise price of warrants Risk free interest rate Stock volatility factor Years to Maturity Expected dividend yield Number of common stock shares issued during the period Shares issued price per share Consulting fees Payment of consulting fees Accrued Liabilities Related Parties Current. Additional number of common shares assigned to other parties. Agreement Axis. Akash Bajaj [Member] April Twenty One Two Thousand Fifteen to October Twenty Two Thousand Fifteen [Member] BMT Inc [Member] Bistromatics Corp [Member] Chief Marketing Officer [Member] Consulting fee. Consulting services agreement [Member] Contributed services. Convertible Notes Payable One [Member]. Convertible Notes Payable [Member] Convertible Notes Payable Two [Member]. Convertible Notes Payables [Member] Derivative Valuation [Text Block] Escrow Trust [Member] Fail raise in primary offering. Going Concern [Policy Text Block] Increase Decrease in Accrued Liabilities Related Parties. Issuance Of Warrants To Purchase Of Common Stock. Loans payable risky fee. MHI Patients [Member] Mavericks Capital Securities Llc [Member] Maximum of private placement. MsRochelle Pleskow [Member]. Non Convertible Debt Converted Into Convertible Debt. Non-Convertible Notes Payable [Member] Non-Convertible Notes Payable [Member] Non-Convertible Notes Payable [Member] Non convertible Notes Payable Text Block. Number of shares assigned to shareholders form the holdings of officer. Number of shares owned by the shareholders, total. Option expense. Percenage of patient insurance reimbursements received. Percentage Of Expected Borrowing Rate. Percentage of funds proceed. Percentage Of Insurance Reimbursement. Percentage of issued and outstanding common stock own by shareholders of subsidiary. Percentage of outstanding shares diluted basis. Percentage of required funds. Percentage of returned funds. Percentage of subscription proceeds. Proceeds from escrowed funds. Promissory Note Five [Member] Promissory Note Four [Member] Promissory Note One [Member] Promissory Note Six [Member] Promissory Note Three [Member] Promissory Note Two [Member] Purchase of warrants exercised. Rent contributed by officer. Return of escrowed funds. Schedule Of Assumptions Used Black Scholes Valuation Of Derivative [Table Text Block] Share Based Compensation Arrangement By Share Based Payment Award Non Option Exercised In Period Weighted Average Exercise Price. Share Based Compensation Arrangement By Share Based Payment Award Non Option Forfeited Or Expired In Period Weighted Average Exercise Price. Share Based Compensation Arrangement By Share Based Payment Award Non Option Grand In Period Weighted Average Exercise Price. Share Based Compensation Arrangement By Share Based Payment Award Non Option Outstanding Weighted Average Number Of Share. Share Exchange Agreement [Member] Shares issued for consulting services. Unregistered common stock issued during the period, shares. Stock Option Plan [Member] Warrant One [Member]. Warrants granted. Warrants Issuance Price Per Share. Warrants to purchase of common stock shares. Vested value of options. Issuance of warrants to purchase of commn stock shares Percentage of revenue received. Consulting Firm [Member] July, 2016 [Member] Consulting agreement term. Promissory Note Extension [Member] Mr. Mills [Member] Payment of consulting fees. NonConvertibleNotePayableTwoMember NonConvertibleNotePayableThreeMember Assets, Current Assets Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Interest Expense, Other Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income Tax Expense (Benefit) RentContributedByOfficer Increase (Decrease) in Due from Related Parties, Current Increase (Decrease) in Prepaid Expense Increase (Decrease) in Accounts Payable and Accrued Liabilities Increase (Decrease) in Accounts Payable, Related Parties IncreaseDecreaseInAccruedLiabilitiesRelatedParties Increase (Decrease) in Employee Related Liabilities Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Financing Activities Cash and Cash Equivalents, Period Increase (Decrease) DerivativeValuationTextBlock Property, Plant and Equipment, Policy [Policy Text Block] Derivative Assets (Liabilities), at Fair Value, Net Interest Payable, Current Debt Instrument, Unamortized Discount Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare Payments for Rent Derivative Liability EX-101.PRE 12 dgt-20160331_pre.xml XBRL PRESENTATION FILE XML 13 R1.htm IDEA: XBRL DOCUMENT v3.4.0.3
Document and Entity Information - shares
3 Months Ended
Mar. 31, 2016
May. 12, 2016
Document And Entity Information    
Entity Registrant Name eWELLNESS HEALTHCARE Corp  
Entity Central Index Key 0001550020  
Document Type 10-Q  
Document Period End Date Mar. 31, 2016  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   18,697,770
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2016  
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.4.0.3
Condensed Balance Sheets - USD ($)
Mar. 31, 2016
Dec. 31, 2015
CURRENT ASSETS    
Cash $ 13,582 $ 41,951
Prepaid Expenses 42,824 4,053
Total current assets 56,406 46,004
Property & equipment, net 5,543 5,964
Intangible assets, net 19,123 19,862
TOTAL ASSETS 81,072 71,830
CURRENT LIABILITIES    
Accounts payable and accrued expenses 354,693 248,305
Accounts payable - related party 50,362 43,717
Accrued expenses - related party 49,226 33,090
Accrued compensation 767,000 677,000
Contingent liability 90,000 90,000
Convertible debt, net of discount 261,727 309,945
Derivative liability 2,802 2,802
Short term note and liabilities 112,048 71,605
Total current liabilities 1,687,858 1,476,464
Total Liabilities $ 1,687,858 $ 1,476,464
STOCKHOLDERS' DEFICIT    
Preferred stock, authorized, 10,000,000 shares, $.001 value, 0 shares issued and outstanding
Common stock, authorized 100,000,000 shares, $.001 par value, 18,697,770 and 18,170,538 issued and outstanding, respectively $ 18,698 $ 18,171
Shares to be issued 10,000
Additional paid in capital 2,246,311 $ 2,033,383
Accumulated deficit (3,881,795) (3,456,187)
Total Stockholders' Deficit (1,606,786) (1,404,634)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT $ 81,072 $ 71,830
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.4.0.3
Condensed Balance Sheets (Parenthetical) - $ / shares
Mar. 31, 2016
Dec. 31, 2015
Statement of Financial Position [Abstract]    
Preferred stock, shares authorized 10,000,000 10,000,000
Preferred stock, par value $ .001 $ .001
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, shares authorized 100,000,000 100,000,000
Common stock, par value $ 0.001 $ 0.001
Common stock, shares issued 18,697,770 18,170,538
Common stock, shares outstanding 18,697,770 18,170,538
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.4.0.3
Condensed Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
OPERATING EXPENSES    
Executive compensation $ 190,633 $ 186,000
General and administrative 51,526 34,588
Professional fees 111,288 90,394
Total Operating Expenses 353,447 310,982
Loss from Operations $ (353,447) (310,982)
OTHER INCOME (EXPENSE)    
Gain on extinguishmment of debt 11,323
Interest expense, related parties $ (897) (1,078)
Interest expense (71,264) (16,142)
Net Loss before Income Taxes $ (425,608) $ (316,879)
Income tax expense
Net Loss $ (425,608) $ (316,879)
Basic and diluted (loss) per share $ (0.02) $ (0.02)
Basic and diluted weighted average shares outstanding 18,352,696 16,740,778
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.4.0.3
Condensed Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Cash flows from operating activities    
Net loss $ (425,608) $ (316,879)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 1,160 950
Contributed services $ 96,000 97,500
Shares issued for consulting services 9,389
Imputed interest - related party $ 897 $ 1,078
Option expense 4,633
Interest on debt extension 22,494 $ 7,153
Amortization of debt discount to interest expense 37,470 $ 8,726
Rent contributed by officer $ 1,500
Changes in operating assets and liabilities    
Advances - related parties $ 7,054
Prepaid expense $ 1,329 16,074
Accounts payable and accrued expenses 118,974 (34,880)
Accounts payable - related party 6,645 (13,100)
Accrued expenses - related party 16,137 (5,105)
Accrued compensation 90,000 85,000
Net cash used in operating activities $ (28,369) (137,040)
Cash flows from investing activities    
Purchase of equipment (4,207)
Net cash used in investing activities (4,207)
Cash flows from financing activities    
Convertible loan payable proceeds 20,000
Common stock subscribed 146,100
Net cash provided by financing activities 166,100
Net increase in cash $ (28,369) 24,853
Cash, beginning of period 41,951 $ 900
Cash, end of period $ 13,582  
Supplemental Information:    
Taxes
Interest Expense
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.4.0.3
The Company
3 Months Ended
Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
The Company

Note 1. The Company

 

The Company and Nature of Business

 

eWellness Healthcare Corporation (f/k/a Dignyte, Inc.), (the “Company”, “we”, “us”, “our”) was incorporated in the State of Nevada on April 7, 2011, to engage in any lawful corporate undertaking, including, but not limited to, selected mergers and acquisitions. The Company has generated no revenues to date. Prior to the Share Exchange Agreement discussed below, other than issuing shares to its original shareholder, the Company never commenced any operational activities.

 

The eWellness strategy as a first-to-market enterprise in the Physical Therapy based telemedicine industry is to deliver a telemedicine physical therapy service augmenting corporate wellness programs and also expand nationally through a Software as a Service (SaaS) business model that enables existing physical therapy practices to extend their offerings via our telemedicine solution. Our objective is to provide Distance Monitored Physical Therapy (PHZIO) Programs to pre diabetic, cardiac and health challenged patients and knee and hip surgery rehabilitation. For corporate wellness program our services are designed to deliver significant healthcare savings to the company while charging a very small relative incremental cost.

 

Share Exchange Agreement

 

On April 11, 2014, Digntye, Inc. (“Dignyte”), a publicly held Nevada corporation and eWellness Corporation (“Private Co”), a privately held company incorporated in Nevada, executed a Share Exchange Agreement (or “Initial Exchange Agreement”). Prior to the execution and delivery of the final Amended and Restated Share Exchange Agreement (the “Agreement”), the Board of Directors of Dignyte approved the Agreement and the transactions contemplated thereby. Similarly, the Board of Directors of the Private Co. approved the exchange. On April 25, 2014, immediately prior to the execution and delivery of the Agreement, Dignyte amended its certificate of incorporation to change its corporate name from “Dignyte, Inc.” to “eWellness Healthcare Corporation.”

 

Pursuant to the Agreement, eWellness Healthcare Corporation issued 9,200,000 shares of unregistered common stock, $.001 par value per share (the “common stock”) to the shareholders of the Private Co. in exchange for all outstanding shares of the Private Co.’s common stock. In addition, our former chief executive officer agreed: (i) to tender 5,000,000 shares of common stock of Dignyte back to the Company for cancellation; (ii) assign from his holdings, an additional 2,500,000 shares of Dignyte to the shareholders of the Private Co. resulting in a total of 11,700,000 shares owned by those shareholders; and, (iii) to a further assignment of an additional 2,100,000 shares of Dignyte to other parties as stated therein (collectively, the “CEO Stock Actions”).

 

As the parties satisfied all of the closing conditions, on April 30, 2014, we closed the Share Exchange. As a result, the Private Co. shareholders own approximately 76.97% of our issued and outstanding common stock, after giving effect to CEO Stock Actions.

 

Following the Share Exchange, we abandoned our prior business plan and we are now pursuing the Private Co.’s historical businesses and proposed businesses. The Private Co. is the surviving company under the share exchange and became a wholly owned subsidiary of the Company.

 

For financial reporting purposes, the Share Exchange represents a “reverse merger” rather than a business combination. Consequently, the transaction is accounted for as a reverse-merger and recapitalization. eWellness Corporation is the acquirer for financial reporting purposes and Dignyte, Inc. is the acquired company. Consequently, the assets and liabilities and the operations that are reflected in the historical financial statements prior to the transactions are those of eWellness Corporation and are recorded at the historical cost basis of eWellness

Corporation,and the consolidated financial statements after completion of the transaction include the assets, liabilities and operations of eWellness Healthcare Corporation, and eWellness Corporation from the closing date of the transaction. Additionally all historical equity accounts and awards of eWellness Corporation, including par value per share, share and per share numbers, have been adjusted to reflect the number of shares received in the transaction.

 

The foregoing description of the Share Exchange Agreement does not purport to be complete and is qualified in its entirety by the Share Exchange Agreement, a copy of which is attached to the Company’s Current Report on Form 8-K/A as filed with the Securities and Exchange Commission on August 6, 2014. At the execution of the Share Exchange Agreement, the number of total shares of common stock outstanding was 15,200,000.

 

On July 22, 2015, the Company’s wholly owned subsidiary, eWellness Corporation, was merged into the Company and, therefore, no longer exists as a separate entity.

XML 19 R7.htm IDEA: XBRL DOCUMENT v3.4.0.3
Summary of Significant Accounting Policies
3 Months Ended
Mar. 31, 2016
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

Note 2. Summary of Significant Accounting Policies

 

Basis of Presentation

 

The interim financial information of the Company as of periods ended March 31, 2016 and March 31, 2015 is unaudited. The balance sheet as of December 31, 2015 is derived from audited financial statements of eWellness Healthcare Corporation. The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial statements. Accordingly, they omit or condense footnotes and certain other information normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles. The accounting policies followed for quarterly financial reporting conform to the accounting policies disclosed in ASU 2014-10. In the opinion of management, all adjustments which are necessary for a fair presentation of the financial information for the interim periods reported have been made. All such adjustments are of a normal recurring nature. The results of operations for the three months ended March 31, 2016 are not necessarily indicative of the results that can be expected for the entire year ending December 31, 2016. The unaudited financial statements should be read in conjunction with the financial statements and the notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2015.

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from these good faith estimates and judgments.

 

Going Concern

 

For the period ended March 31, 2016, the Company has no revenues and no operations. The Company has an accumulated loss of $3,881,795. In view of these matters, there is substantive doubt about the Company’s ability to continue as a going concern. The Company’s ability to continue operations is dependent upon the Company’s ability to raise additional capital and to ultimately achieve sustainable revenues and profitable operations, of which there can be no guarantee. The Company intends to finance its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

 

Deferred Offering and Acquisition Costs

 

The Company defers as other assets the direct incremental costs of raising capital until such time as the offering is completed. At the time of the completion of the offering, the costs will be charged against the capital raised. Should the offering be terminated, the deferred offering costs will be charged to operations during the period in which the offering is terminated. Direct acquisition costs will be expensed as incurred.

 

Fair Value of Financial Instruments

 

The Company complies with the accounting guidance under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820-10, Fair Value Measurements, as well as certain related FASB staff positions. This guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact business and considers assumptions that marketplace participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance.

 

The guidance also establishes a fair value hierarchy for measurements of fair value as follows:

 

Level 1 – quoted market prices in active markets for identical assets or liabilities.

 

Level 2 – inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

 

Level 3 – unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

 

As of March 31, 2016, the Company had the following assets and liabilities measured at fair value on a recurring basis.

 

    Total     Level 1     Level 2     Level 3  
Derivative liability   $ 2,802     $ -     $ -     $ 2,802  
Total liabilities measure at fair value   $ 2,802     $ -     $ -     $ 2,802  

 

Cash and Cash Equivalents

 

Cash and cash equivalents includes all cash deposits and highly liquid financial instruments with an original maturity to the Company of three months or less.

 

Property and Equipment

 

Property and equipment are recorded at historical cost. Minor additions and renewals are expensed in the year incurred. Major additions and renewals are capitalized and depreciated over their estimated useful lives. Depreciation is recorded over the estimated useful lives of the related assets using the straight-line method for financial statement purposes. The Company uses other depreciation methods (generally accelerated) for tax purposes where appropriate. The estimated useful lives for significant property and equipment categories are as follows:

 

Furniture and Fixtures   5-7 Years
Computer Equipment   5-7 Years
Software   3 Years

 

The Company regularly evaluates whether events or circumstances have occurred that indicate the carrying value of long-lived assets may not be recoverable. If factors indicate the asset may not be recoverable, we compare the related undiscounted future net cash flows to the carrying value of the asset to determine if impairment exists. If the expected future net cash flows are less than the carrying value, an impairment charge is recognized based on the fair value of the asset.

 

Revenue Recognition

 

The Company has yet to realize revenues from operations. Once the Company has commenced operations, it will recognize revenues when delivery of goods or completion of services has occurred provided there is persuasive evidence of an agreement, acceptance has been approved by its customers, the fee is fixed or determinable based on the completion of stated terms and conditions, and collection of any related receivable is probable.

 

Loss per Common Share

 

The Company follows ASC Topic 260 to account for the loss per share. Basic loss per common share calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per common share calculations are determined by dividing net loss by the weighted average number of common shares and dilutive common share equivalents outstanding. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation. As the Company has no common stock equivalents and has incurred losses for the period ended March 31, 2016, no dilutive shares are added into the loss per share calculations.

 

Recent Accounting Pronouncements

 

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) that are adopted by the Company as of the specified date. The Company has elected to the early adoption of ASU 2015-03 that simplifies the presentation of debt issuance costs. The Company had previously used the methodology in this standard and has adopted the pronouncement for current and future debt instruments.

XML 20 R8.htm IDEA: XBRL DOCUMENT v3.4.0.3
Property and Equipment
3 Months Ended
Mar. 31, 2016
Property, Plant and Equipment [Abstract]  
Property and Equipment

Note 3. Property and Equipment

 

Property and equipment consists of computer equipment that is stated at cost $8,421 and $8,421 less accumulated depreciation of $2,878 and $2,457 at March 31, 2016 and December 31, 2015, respectively. Depreciation expense was $421 for the three months ended March 31, 2016 and $211 for the three months ended March 31, 2015, respectively.

XML 21 R9.htm IDEA: XBRL DOCUMENT v3.4.0.3
Intangible Assets
3 Months Ended
Mar. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets

Note 4. Intangible Assets

 

The Company recognizes the cost of a software license and a license for use of a programming code as intangible assets. The stated cost of these assets were $24,770 and $24,770 less accumulated amortization of $5,647 and $4,908 for the periods ended March 31, 2016 and December 31, 2015, respectively. For the periods ended March 31, 2016 and March 31, 2015, the amortization expense recorded was $739 and $739, respectively.

XML 22 R10.htm IDEA: XBRL DOCUMENT v3.4.0.3
Related Party Transactions
3 Months Ended
Mar. 31, 2016
Related Party Transactions [Abstract]  
Related Party Transactions

Note 5. Related Party Transactions

 

Through the period ended March 31, 2016, a related party, a company for which the Company’s former Secretary-Treasurer and CFO is also serving as CFO, has paid $96,831 on the Company’s behalf for various operating expenses. The amount outstanding as of March 31, 2016 and December 31, 2015 was $50,362 and $43,717, respectively. The Company recorded $897 and $1,078 imputed interest on the amount owed to the related party based on an interest rate of 8% for the three months ended March 31, 2016 and March 31, 2015, respectively.

 

During 2014, the Company entered into a license agreement with a programming company in which one of our directors is Chief Marketing Officer. Through the licensing agreement, we obtained a perpetual license to use the programming code created by a video management platform as a base to develop our telemedicine video service for a license fee of $20,000. The license fee is recorded as an Intangible Asset and Accounts Payable on the Balance Sheet.

 

On April 1, 2015, the Company entered into an operating agreement with a physical therapy company (“EPT”) which is owned by the Company’s President and Chief Executive Officer. Through the agreement the Company agrees to provide operating capital advances in order for EPT to offer the Company’s PHIZIO platform to physical therapy patients. For accounting and tax purposes, the net profits or losses generated by EPA shall be allocated on a monthly basis. The Company will receive 75% of the net patient insurance reimbursements associated with the operation of the PHIZIO platform.

 

The Company rents its Culver City, CA office space from a company owned by our CEO. The imputed rent expense of $500 per month is recorded in the Consolidated Statement of Operations and Additional Paid in Capital in the Balance Sheet.

 

The officers of the Company incur business expenses on behalf of the Company. The amounts outstanding as of March 31, 2016 and December 31, 2015 were $49,226 and $33,090, respectively.

XML 23 R11.htm IDEA: XBRL DOCUMENT v3.4.0.3
Income Taxes
3 Months Ended
Mar. 31, 2016
Income Tax Disclosure [Abstract]  
Income Taxes

Note 6. Income Taxes

 

The tax provision for interim periods is determined using an estimate of the Company’s effective tax rate for the full year adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter the Company updates its estimate of the annual effective tax rate, and if the estimated tax rate changes, the Company makes a cumulative adjustment.

 

At March 31, 2016 and December 31, 2015, the Company had a full valuation allowance against its deferred tax assets, net of expected reversals of existing deferred tax liabilities, as it believes it is more likely than not that these benefits will not be realized.

 

The Company does not identify any material uncertain tax positions of the Company on returns that have been filed or that will be filed. The Company has not had operations and has deferred items consisting entirely of unused Net Operating Losses. Since the Company does not believe that this Net Operating Loss will ever produce a tax benefit, even if examined by taxing authorities and disallowed entirely, there would be no effect on the financial statements.

 

The Company’s policy is to recognize potential interest and penalties accrued related to unrecognized tax benefits within income tax expense. For the periods ended March 31, 2016, and March 31, 2015, the Company did not recognize nor accrue for any interest or penalties.

XML 24 R12.htm IDEA: XBRL DOCUMENT v3.4.0.3
Non-Convertible Notes Payable
3 Months Ended
Mar. 31, 2016
Debt Disclosure [Abstract]  
Non-Convertible Notes Payable

Note 7. Non-Convertible Notes Payable

 

On January 27, 2015, the Company issued a promissory note of $20,000 with a shareholder/consultant at an annual interest rate of 12% due and payable on April 23, 2015. On April 9, 2015, as part of the second closing of the convertible debt discussed in Note 8 below, the note for $20,000, together with accrued interest for $3,980 through March 31, 2015 and future consulting fees due and payable through October 2015 of $100,000 were converted to a convertible note of $123,980.11. The consulting fees for future months were booked to prepaid expense and were amortized over the remaining term of the consulting agreement.

 

On May 30, 2015, the Company received $25,000 in exchange for a 90-day Promissory Note at an interest rate of 5% per annum. As an inducement for this promissory note, the Company issued 150,000 warrants to purchase Company common stock at $.35 per share. The fair value of the warrants is $768. On August 26, 2015, the Company entered into an extension of this note for another 90 days to October 23, 2015. As an inducement for this extension, the Company issued 150,000 warrants to purchase Company common stock at $.80 per share. The fair value of the warrants if $158. On October 11, 2015 the Company entered into a second extension of this note to be due on December 14, 2015. As an inducement for this extension, the Company issued 150,000 warrants to purchase Company common stock at $.80 per share. The fair value of the warrants is $300. In addition the interest rate on the note was increased to 12% from the original note date of May 27 plus a risky loan fee of $6,250.

 

On July 15, 2015, the Company received $18,000 in exchange for a 90-day Promissory Note at an interest rate of 5% per annum. As an inducement for this promissory note, the Company issued 150,000 warrants to purchase Company common stock at $.80 per share. The fair value of the warrants is $310. On October 5, 2015 the Company entered into an extension of this note to be due on December 14, 2015. As an inducement for this extension, the Company issued 150,000 warrants to purchase Company common stock at $.80 per share. The fair value of the warrants is $300. In addition the interest rate on the note was increased to 12% from the original note date of July 15 plus a risky loan fee of $4,500.

 

On September 16, 2015, the Company received $22,500 in exchange for a 90-day Promissory Note at an interest rate of 12% per annum plus a risky note fee of $5,625. As an inducement for this promissory note, the Company issued 450,000 warrants to purchase Company common stock at $.80 per share. The fair value of the warrants is $908.

 

On September 16, 2015, the Company received $12,500 in exchange for a 90-day Promissory Note at an interest rate of 12% per annum plus a risky loan fee of $3,125 which was amortized over the term of the loan. As an inducement for this promissory note, the Company issued 250,000 warrants to purchase Company common stock at $.80 per share. The fair value of the warrants is $504. This note, accrued interest and risky loan fee were paid on December 9, 2015.

 

On September 16, 2015, the Company received $2,500 in exchange for a 90-day Promissory Note at an interest rate of 12% per annum plus a risky loan fee of $625 which was amortized over the term of the loan. As an inducement for this promissory note, the Company issued 50,000 warrants to purchase Company common stock at $.80 per share. The fair value of the warrants is $101. This note, accrued interest and risky loan fee were paid on December 9, 2015.

 

On October 11, 2015, the Company received $10,000 in exchange for a Promissory Note which matures on December 14, 2015; however if the Company receives $100,000 or more in its current private placement of up to $2,500,000 convertible note with warrants, the note will be due within three business days of such funds settling in the Company’s account. The note has an interest rate of 12% per annum plus a risky loan fee of $2,500 which was amortized over the term of the loan. As an inducement for this promissory note, the Company issued 200,000 warrants to purchase Company common stock at $.80 per share. The fair value of the warrants is $385.

 

On December 6, 2015, the Company entered into a 90-day Promissory Note for $70,000 at an interest rate of 12% per annum plus a risky loan fee of $17,500 which is being amortized over the term of the loan. As an inducement the Company issued 1,400,000 warrants to purchase Company common stock at $.80 per share. The fair value of the warrants is $2,800. The Company further agreed to repay the loan within three days of the Company receiving $500,000 or more in the current private placement of up to $2,500,000 convertible note with warrants. This Promissory Note resulted from the principal payment to the note holder of $28,222.94 and the holder cancelling the notes originally signed on May 27, 2015 plus extensions, July 15, 2015 plus extensions, September 16, 2015 and October 11, 2015.

 

On March 14, 2016, the Company issued a 45-day promissory note to a shareholder of $112,550 as an extension for notes with a shareholder dated May 30 2015, July 15, 2015, September 16, 2015, October 11, 2015, and December 6, 2015. The amount of the note includes interest accrued on the previous notes, risky loan fee and a default fee. The note has an annual interest rate of 12% due and payable on May 1, 2016. As an inducement for this promissory note, the Company issued 400,000 warrants to purchase Company common stock at $.80 per share. The fair value of the warrants is $794. For the period ended March 31, 2016, the Company recorded $2,470 of interest expense for this note.

XML 25 R13.htm IDEA: XBRL DOCUMENT v3.4.0.3
Convertible Notes Payable
3 Months Ended
Mar. 31, 2016
Debt Disclosure [Abstract]  
Convertible Notes Payable

Note 8. Convertible Notes Payable

 

On December 23, 2014 the Company issued $213,337 convertible promissory notes and warrants to purchase shares of common stock to four individual investors. The overall terms of the Notes are as follows:

 

  Interest rate: 12% per annum. As of March 31, 2016, the Company had recorded $464 of accrued interest.
     
  Due date: December 31, 2015. The Company is to pay the principal amount and all accrued and unpaid interest on or before the due date. One of the convertible notes totaling $3,000 is in default.
     
  Redemption right: Any time the closing price of the Company’s common stock has been at or above $1.50 for 20 consecutive trading days, the Company has the right to redeem all or any part of the principal and accrued interest of the notes, following written notice to the holders of the notes.
     
  Optional Conversion: At the option of the holders, the notes may be converted into shares of the Company’s common stock at a conversion price equal to $0.35 per share.
     
  Additionally, if the Company elects to exercise the redemption right, the holders have the opportunity to elect to take the cash payment or to convert all or any portion of the notes into shares of the Company’s common stock.
     
  The conversion price is subject to proportional adjustment in the event of stock splits, stock dividends and similar corporate events.
     
  The notes are senior in rank to any other debt held by our officers, directors or affiliates and may not be subordinated to any other debt issued by the Company without the written consent of the holders.

 

 

  Warrants: The holders of the notes are granted the right through December 23, 2017 to purchase 609,534 additional shares of common stock at $.35 per share.
     
 

During the time that any portion of these Notes are outstanding, if any Event of Default, as defined in the notes, occurs and such Default is not cured by the Company within sixty (60) days of the occurrence of the Event of Default (the “Cure Period”), the amount equal to one hundred fifty percent (150%) of the outstanding principal amount of this Note, together with accrued interest and other amounts owing shall become at the holder’s election, immediately due and payable in cash. The

holders at its option have the right, with three (3) business days advance written notice to the Company after the expiration of the Cure Period, to elect to convert the Notes into shares of the Company’s common stock pursuant to the Optional Conversion rights disclosed above.

     
  The Company valued the cash conversion feature as the difference in the value of the note at its stated annual interest rate of 12% and the fair value of the note at its discounted value using an expected borrowing rate of 18%.
     
  The Company’s Condensed Consolidated Balance Sheets report the following related to the convertible promissory notes:

 

    March 31, 2016  
Principal amount   $ 3,000  
Unamortized debt discount     -  
Net carrying amount   $ 3,000  

 

On February 20, 2016, a convertible promissory note with the principal value of $69,500 was converted to 227,332 shares of common stock at a conversion price of $.35 per share. The warrants associated with this note were not exercised. See Note 9 below – Equity Transactions.

 

On April 9, 2015, the Company issued $270,080 convertible promissory notes (including an aggregate of $123,980 that was converted from certain other outstanding notes, including accrued interest, and future contractual cash consulting fees) and warrants to purchase shares of common stock to eight individual investors. The overall terms of the notes are as follows:

 

  Interest rate: 12% per annum. As of March 31, 2016, the Company recorded $13,274 of accrued interest.
     
  Due date: April 30, 2016. The Company is to pay the principal amount and all accrued and unpaid interest on or before the due date.
     
  Redemption right: Any time the closing price of the Company’s common stock has been at or above $1.50 for 20 consecutive trading days, the Company has the right to redeem all or any part of the principal and accrued interest of the notes, following written notice to the holders of the Notes.
     
  Optional Conversion: At the option of the holders, the notes may be converted into shares of the Company’s common stock at a conversion price equal to $0.35 per share.
     
  Additionally, if the Company elects to exercise the redemption right, the holders have the opportunity to elect to take the cash payment or to convert all or any portion of the Notes into shares of the Company’s common stock.

 

  The conversion price is subject to proportional adjustment in the event of stock splits, stock dividends and similar corporate events.
     
  The notes are senior in rank to any other debt held by our officers, directors or affiliates and may not be subordinated to any other debt issued by us without the written consent of the holders.
     
  Warrants: The holders of the notes are granted the right through April 30, 2016 to purchase 771,658 additional shares of common stock at $.35 per share. The fair value of the warrants is $1,132.
     
  During the time that any portion of these notes are outstanding, if any Event of Default, as defined in the notes, occurs and such Default is not cured by the Company within sixty (60) days of the occurrence of the Event of Default (the “Cure Period”), the amount equal to one hundred fifty percent (150%) of the outstanding principal amount of this Note, together with accrued interest and other amounts owing shall become at the holder’s election, immediately due and payable in cash. The holders at its option have the right, with three (3) business days advance written notice to the Company after the expiration of the Cure Period, to elect to convert the Notes into shares of the Company’s common stock pursuant to the Optional Conversion rights disclosed above.
     
  The Company’s Condensed Consolidated Balance Sheets report the following related to the convertible promissory notes:

 

      March 31, 2016  
Principal amount   $ -  
Unamortized debt discount     -  
Net carrying amount   $ -  

 

  The Company valued the cash conversion feature as the difference in the value of the note at its stated interest rate of 12% and the fair value of the note at its discounted value using an expected borrowing rate of 18%. The value of the cash conversion feature at inception of the notes was $44,189.

 

On December 7, 2015, the Company issued a $275,000 senior convertible promissory note with a 10% original issue discount and warrants to purchase shares of common stock. The overall terms of the notes are as follows:

 

  Interest rate: 8% per annum. As of the period ended March 31, 2016, the Company had recorded $5,561 of interest expense. The interest rate increases to 15% per annum on any unpaid and overdue principal and interest.
     
  Due date: June 2, 2016. The Company is to pay the principal amount and all accrued and unpaid interest on or before the due date.
     
  Redemption right: Within three trading days, prior written notice of the Company has the right to redeem all the note equal to the sum of 115% of the principal plus accrued and unpaid interest on the principal amount.
     
  Optional Conversion: At the option of the holder, the note may be converted into shares of the Company’s common stock at a conversion price equal to 75% of the lowest per share purchase price, conversion price or exercise price of securities that the Company issues in the next financing transaction.
     
  The note is senior in rank to any other debt of the Company as of the issuance date of the note and to any indebtedness incurred following the issuance date.
     
  Warrants: The holders of the notes are granted the right to purchase 250,000 additional shares of common stock at $.80 per share.
     
  The Company shall be considered to be in Default if the Company fails to obtain a listing of its common stock on at least one of OTCBB, OTCQB, Nasdaq or NYSE within 90 days of the date of the note or fails to maintain the listing of its common stock; the Company fails to comply with the reporting requirements of the 1934 Act and/or ceases to be subject to the reporting requirements of the 1934 Act; the restatement of any financial statements for any date or period from two years prior to the date of the note and until this note is no longer outstanding results in a material adverse effect on the rights of the note holder; the DTC places a “chill” on any of the Company’s securities; the Company’s common stock becomes not eligible for trading through the DTC’s FAST Automated Securities Transfer or Deposit/Withdrawal at Custodian programs; the Company fails to raise at least $1,000,000 in a Primary Offering within 120 days following the list date; the Company fails to appoint VStock Transfer LLC as the transfer agent for its common stock within 30 days of list date.
     
  The Company’s Balance Sheets report the following related to the December 7, 2015, convertible promissory note:

 

    March 31, 2016  
Principal amount   $ 275,000  
Unamortized debt discount     (16,273 )
Net carrying amount   $ 258,727  

 

Under the guidance of ASC 470-20 Debt With Conversion and Other Options, the common shares of the Company, pending being listed on the OTC, and the net settlement requirements of the warrants will be analyzed at the end of each quarter to determine if the conversion does become readily convertible to cash which would require derivative accounting calculations and recording.

XML 26 R14.htm IDEA: XBRL DOCUMENT v3.4.0.3
Equity Transactions
3 Months Ended
Mar. 31, 2016
Equity [Abstract]  
Equity Transactions

Note 9. Equity Transactions

 

Preferred Stock

 

The total number of shares of preferred stock which the Company shall have authority to issue is 10,000,000 shares with a par value of $0.001 per share. There have been no preferred shares issued as of March 31, 2016.

 

Common Stock

 

The total number of shares of common stock which the Company shall have authority to issue is 100,000,000 shares with a par value of $0.001 per share.

 

On January 24, 2015, the Company authorized the issuance of 400,000 shares of common stock for consulting services at a value of $40,000. This value was amortized over the life of the contract.

 

On February 23, 2015, the Company authorized the issuance of 60,000 shares of common stock for consulting services for a value of $6,000. This value was amortized over the life of the contract

 

On July 14, 2015, the Company authorized the issuance of 250,000 shares of common stock for the conversion of convertible debt of $87,500.

 

On August 19, 2015, the Company authorized the issuance of 96,000 shares of common stock for conversion of convertible debt of $33,600.

 

On September 10, 2015, the Company authorized the issuance of 663,277 shares of common stock for conversion of convertible debt of $232,147.

 

On October 1, 2015, the Company authorized the issuance of 50,272 shares of common stock for the accrued interest totaling $17,595 on convertible debt previously converted.

 

On November 11, 2015, the Company authorized the issuance of 179,989 shares of common stock for conversion of convertible debt and accrued interest of $62,996.

 

On December 17, 2015, the Company authorized the issuance of 50,000 shares of comon stock as part of a provision of the convertible debt note payable signed on December 7, 2015. (See Note 9 - Convertible Notes Payable)

 

On January 20, 2016, the Company authorized the issuance of 50,000 shares for consulting services for a value of $5,000 that is being amortized over the life of the contract.

 

On February 29, 2016, the Company authorized the issuance of 227,232 shares for conversion of convertible debt of $69,500.

 

On March 3, 2016, the Company authorized the issuance of 100,000 shares for consulting services for a value of $10,100 that is being amortized over the life of the contract.

 

On March 11, 2016, the Company authorized the issuance of 150,000 shares for consulting services for a value of $15,000 that is being amortized over the life of the contract.

 

As of the period ended March 31, 2016, the Company has 18,697,770 shares of common stock issued and outstanding.

 

Holders of shares of common stock are entitled to cast one vote for each share held at all stockholders’ meetings for all purposes including the election of directors. The common stock does not have cumulative voting rights.

 

No holder of shares of stock of any class is entitled as a matter of right to subscribe for or purchase or receive any part of any new or additional issue of shares of stock of any class or of securities convertible into shares of stock of any class, whether now hereafter authorized or whether issued for money, for consideration other than money, or by way of dividend.

 

On February 22, 2016, the Company received the common stock trading symbol of EWLL.

 

Stock Options

 

On August 6, 2015, the Board of Directors approved the 2015 Stock Option Plan, pursuant to which certain directors, officers, employees and consultants will be eligible for certain stock options and grants. The Plan is effective as of August 1, 2015 and the maximum number of shares reserved and available for granting awards under the Plan shall be an aggregate of 3,000,000 shares of common stock, provided however that on each January 1, starting with January 1, 2016, an additional number of shares equal to the lesser of (A) 2% of the outstanding number of shares (on a fully-diluted basis) on the immediately preceding December 31 and (B) such lower number of shares as may be determined by the Board or committee charged with administering the plan. This plan may be amended at any time by the Board or appointed plan Committee.

 

On February 19, 2016, the Board of Directors authorized the issuance of stock options under this plan to selected employees, directors and consultants. The stock options vest immediately upon the grant date and authorize the recipient to purchase shares of common stock at $.80 per share within five years of the grant date.. The Company valued the issuance of these warrants using the Black Scholes valuation model assuming a 2.0% risk free rate and an 61.4% volatility. At the three months ended March 31, 2016, the vested value of the options was $4,633. This was recorded as compensation expense.

 

The following is a summary of the status of all Company’s stock options as of March 31, 2016 and changes during the three months ended on that date:

 

    Number     Weighted  
    of Stock
Options
    Average Exercise Price  
Oustanding at January 1, 2016     0     $ -  
Granted     2,850,000     $ 0.80  
Exercised     0     $ -  
Cancelled     0     $ -  
Outstanding at March 31, 2016     2,850,000     $ 0.80  
Options exercisable at March 31, 2016     2,850,000     $ 0.80  

 

Warrants

 

On March 14, 2016, the Company authorized the issuance of 400,000 warrants that were issued as part of the extension of a promissory note dated December 6, 2015. The fair value of the warrants is $794.

 

The following is a summary of the status of all of the Company’s warrants as of March 31, 2016 and changes during the three months ended on that date:

 

            Weighted  
      Number of     Average  
      Warrants     Exercise Price  
Outstanding at January 1, 2015       609,533     $ 0.35  
Granted       5,021,658     $ 0.63  
Exercised       -     $ -  
Cancelled       -     $ -  
Outstanding at December 31, 2015       5,631,191     $ 0.61  
Granted       400,000     $ 0.80  
Exercised       -     $ -  
Cancelled       -     $ -  
Outstanding at March 31, 2016       6,031,191     $ 0.62  

 

For purpose of determining the fair market value of the warrants and options issued during the three months ended March 31, 2016, we used the Black Scholes option valuation model. These valuations were done throughout the period at the date of issuance and not necessary as of the reporting date. As there is no current market for the Company’s shares, we used $0.10 as the stock price at valuation date to be consistent with prior issuances and the stock prices of comparable companies to determine volatility. The significant assumptions used in the Black Scholes valuation of the date of issuance are as follows:

 

Stock price on the valuation date   $ 0.10  
Exercise price of warrants   $ .35 and .80  
Dividend yield     0.00 %
Years to maturity      2.5  
Risk free rate     2.0%  
Expected volatility     61%  

XML 27 R15.htm IDEA: XBRL DOCUMENT v3.4.0.3
Commitments, Contingencies
3 Months Ended
Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]  
Commitments, Contingencies

Note 10. Commitments, Contingencies

 

The Company may be subject to lawsuits, administrative proceedings, regulatory reviews or investigations associated with its business and other matters arising in the normal conduct of its business. The following is a description of an uncertainty that is considered other than ordinary, routine and incidental to the business.

 

The closing of the Initial Exchange Agreement with Private Co. was conditioned upon certain, limited customary representations and warranties, as well as, among other things, our compliance with Rule 419 (“Rule 419”) of Regulation C under the Securities Act of 1933, as amended (the “Securities Act”) and the consent of our shareholders as required under Rule 419. Accordingly, we conducted a “Blank Check” offering subject to Rule 419 (the “Rule 419 Offering”) and filed a Registration Statement on Form S-1 to register the shares of such offering; the Registration Statement was declared effective on September 14, 2012. We used 10% of the subscription proceeds as permitted under Rule 419 and the amount remaining in the escrow trust as of the date of the closing of the Share Exchange was $90,000 (the “Trust Account Balance”).

 

Rule 419 required that the Share Exchange occur on or before March 18, 2014, but due to normal negotiations regarding the transactions and the parties’ efforts to satisfy all of the closing conditions, the Share Exchange did not close on such date. Accordingly, after numerous discussions with management of both parties, they entered into an Amended and Restated Share Exchange Agreement (the “Share Exchange Agreement”) to reflect a revised business combination structure, pursuant to which we would: (i) file a registration statement on Form 8-A (“Form 8A”) to register our common stock pursuant to Section 12(g) of the Exchange Act, which we did on May 1, 2014 and (ii) seek to convert the participants of the Rule 419 Offering into participants of a similarly termed private offering (the “Converted Offering”), to be conducted pursuant to Regulation D, as promulgated under the Securities Act.

 

Fifty-two persons participated in the Rule 419 Offering and each of them gave the Company his/her/its consent to use his/her/its escrowed funds to purchase shares of the Company’s restricted common stock in the Converted Offering (the “Consent”) rather than have their funds returned. To avoid further administrative work for the investors, we believe that we took reasonable steps to inform investors of the situation and provided them with an appropriate opportunity to maintain their investment in the Company, if they so choose, or have their funds physically returned. Management believed the steps it took constituted a constructive return of the funds and therefore met the requirements of Rule 419.

 

However, pursuant to Rule 419(e)(2)(iv), “funds held in the escrow or trust account shall be returned by first class mail or equally prompt means to the purchaser within five business days [if the related acquisition transaction does not occur by a date that is 18 months after the effective date of the related registration statement].” As set forth above, rather than physically return the funds, we sought consent from the investors of the Rule 419 Offering to direct their escrowed funds to the Company to instead purchase shares in the Converted Offering. The consent document (which was essentially a form of rescission) was given to the investors along with a private placement memorandum describing the Converted Offering and stated that any investor who elected not to participate in the Converted Offering would get 90% of their funds physically returned. Pursuant to Rule 419(b)(2)(vi), a blank check company is entitled to use 10% of the proceed/escrowed funds; therefore, if a return of funds is required, only 90% of the proceed/escrowed funds need be returned. The Company received $100,000 proceeds and used $10,000 as per Rule 419(b)(2)(vi); therefore, only $90,000 was subject to possible return.

 

As disclosed therein, we filed the amendments to the initial Form 8-K in response to comments from the SEC regarding the Form 8-K and many of those comments pertain to an alleged violation of Rule 419. The Company continued to provide the SEC with information and analysis as to why it believes it did not violate Rule 419, but was unable to satisfy the SEC’s concerns. Comments and communications indicate that Rule 419 requires a physical return of funds if a 419 offering cannot be completed because a business combination was not consummated within the required time frame; constructive return is not permitted.

 

As a result of these communications and past comments, we are disclosing that we did not comply with the requirements of Rule 419, which required us to physically return the funds previously submitted to escrow pursuant to the Rule 419 Offering. As a result of our failure to comply with Rule 419, the SEC may bring an enforcement action or commence litigation against us for failure to strictly comply with Rule 419. If any claims or actions were to be brought against us relating to our lack of compliance with Rule 419, we could be subject to penalties (including criminal penalties), required to pay fines, make damages payments or settlement payments. In addition, any claims or actions could force us to expend significant financial resources to defend ourselves, could divert the attention of our management from our core business and could harm our reputation.

 

Ultimately, the SEC determined to terminate its review of the Initial Form 8-K and related amendments, rather than provide us with additional opportunities to address their concerns and therefore, we did not clear their comments. It is not possible at this time to predict whether or when the SEC may initiate any proceedings, when this issue may be resolved or what, if any, penalties or other remedies may be imposed, and whether any such penalties or remedies would have a material adverse effect on our consolidated financial position, results of operations, or cash flows. Litigation and enforcement actions are inherently unpredictable, the outcome of any potential lawsuit or action is subject to significant uncertainties and, therefore, determining at this time the likelihood of a loss, any SEC enforcement action and/or the measurement of the amount of any loss is complex. Consequently, we are unable to estimate the range of reasonably possible loss. Our assessment is based on an estimate and assumption that has been deemed reasonable by management, but the assessment process relies heavily on an estimate and assumption that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change that estimate and assumption. In light of the uncertainty of this issue and while Management evaluates the best and most appropriate way to resolve same, management determined to create a reserve on the Company’s Balance Sheet for the $90,000 that was subject to the Consent.

 

The Company rents its Culver City, CA office space from a company owned by our CEO. The rental agreement provides for the value of the rent of $500 per month be recorded as contributed towards the founding eWellness and its operations. During the period ended March 31, 2016, we have recorded this rent payment in the Consolidated Statements of Operations and Additional Paid in Capital on the Balance Sheet.

 

On April 1, 2015, the Company entered into an Operating Agreement with Evolution Physical Therapy (“EPT”), a company owned by one of the Company’s officers, wherein it is agreed that EPT would be able to operate the Company’s telemedicine platform www.phzio.com and offer it to selected physical therapy patients of EPT. The Company is to receive 75% of the net insurance reimbursements from the patient for use of the platform. The Company will advance capital requested by EPT for costs specifically associated with operating the www.phzio,com platform and associated physical therapy treatments – computer equipment, office or facilities rental payments, physical therapist or physical therapy assistant, administrative staff, patient induction equipment, office supplies, utilities and other associated operating costs. It is anticipated that the operation of the platform by EPT will generate positive cash flow within 90 days from the start of patient induction.

 

On May 20, 2015, the Company entered into an agreement with Mavericks Capital Securities LLC (“Mavericks”). The term of the contract begins on the effective date and can be terminated within 30 days upon written notice by either party. The Company is to pay Mavericks a monthly retainer fee of $10,000 that is deferred until the Company raises $250,000 in new investor funds from the effective date. In addition, the Company granted Mavericks 250,000 warrants to purchase Company common stock at $.35 per share. On September 28, 2015, the Company and Mavericks entered into an amendment to the consultant agreement pursuant to which Mavericks will also assist the Company in the acquisition of new customers, for which the Company shall pay Mavericks 10% of the revenue received by the Company, net of any pass through costs, from any such customers introduced to the Company by Mavericks; payment shall be made upon the Company’s receipt of such revenues. In the amendment, the parties also further clarified the definition of Customer Acquisition.

 

On January 20, 2016, the Company entered into a one year agreement with a consulting firm to provide marketing and financial media awareness services. Compensation for this agreement is the issuance of 100,000 shares of common stock – 50,000 were issued at the signing of the agreement and the other 50,000 are to be issued in July, 2016. The value of these shares is $5,000 for each issuance which is being amortized over the term of the contract.

 

On February 1, 2016, the Company entered into a six month agreement with a consulting firm for services including introductions to brokers, investment bankers, market makers and business development opportunities. Compensation for his agreement is the issuance of 100,000 shares of common stock. The value of these shares is $10,000 and is being amortized over the term of the contract. At the end of the period ending March 31, 2016, the shares had not yet been issued.

 

On March 3, 2016, the Company entered into a six month agreement with a consulting firm for management consulting, business advisory and public relations services. Compensation for this agreement is the issuance of 100,000 shares of common stock for the purchase price of $100 and a $2,500 monthly fee that is to be accrued and not payable until the Company closes a qualified financing.

 

On March 14, 2016, the Company entered into a 45-day Promissory Note Extension at an interest rate of 12% per annum. As an inducement for this extension of previous promissory notes, the Company issued 400,000 warrants to purchase Company common stock at $.80 per share. The fair value of the warrants is $794. For the period ended March 31, 2016, the Company recorded $629 of accrued interest for this note.

 

From time to time the Company may become a party to litigation matters involving claims against the Company. Except as may be outlined above, management believes that there are no current matters that would have a material effect on the Company’s financial position or results of operations.

XML 28 R16.htm IDEA: XBRL DOCUMENT v3.4.0.3
Segment Reporting
3 Months Ended
Mar. 31, 2016
Segment Reporting [Abstract]  
Segment Reporting

Note 11. Segment Reporting

 

The Company has one operating segment, which was identified based upon the availability of discrete financial information and the chief operating decision makers’ regular review of financial information.

XML 29 R17.htm IDEA: XBRL DOCUMENT v3.4.0.3
Derivative Valuation
3 Months Ended
Mar. 31, 2016
Derivative Valuation  
Derivative Valuation

Note 12. Derivative Valuation

 

The warrants granted with the $275,000 senior convertible promissory note (the “Note”) issued on December 7, 2015 (described in Note 8) have a Most Favored Nation clause resulting in the exercise price of the warrants not being fixed. Therefore, this feature has been characterized as a derivate liability to be re-measured at the end of every reporting period with the change in value reported in the statement of operations. At March 31, 2016, the outstanding fair value of the warrants accounted for as a derivative liability amounted to $2,802. As of March e31, 2016. no gain or loss was recognized in the statement of operations as the change in valuation from inception was clearly trivial to the financial statements.

 

For purposes of determining the fair market value of the derivative liability for the warrants, the Company used Black Scholes option valuation model. The significant assumptions used in the Black Scholes valuation of the derivative are as follows:

 

Stock price at valuation date   $ .10  
Exercise price of warrants   $ .80  
Risk free interest rate     1.67 %
Stock volatility factor     62.82 %
Years to Maturity     5  
Expected dividend yield     None  

XML 30 R18.htm IDEA: XBRL DOCUMENT v3.4.0.3
Subsequent Events
3 Months Ended
Mar. 31, 2016
Subsequent Events [Abstract]  
Subsequent Events

Note 13. Subsequent Events

 

On April 13, 2016, we entered into a one-year renewable advisory agreement with Dan Mills, MPT to become the Company’s chairman of the to-be-formed committee known as the eWellness Physical Therapy Clinical Advisory Board and to act as the Company’s national spokesperson at the American Physical Therapy Association (“APTA”).

 

As inducement for Mr. Mills to enter the Agreement, we agreed to issue to 250,000 immediately vesting common stock purchase warrants at a price of $1.00 per share. The common stock underlying the Warrants has piggy-back registration rights. In addition, 10,000 shares of common stock are to be issued to Mr. Mills upon the signing of the Agreement. Per the agreement Mr. Mills will receive $0.50 cents per PHZIO session that an APTA members uses, $500 per month in consulting fees and $2,500 paid within ten days of signing the Agreement.

 

On May 2, 2016, the Company entered into a 45-day Promissory Note Extension at an interest rate of 12% per annum. As an inducement for this extension of previous promissory notes, the Company issued 400,000 warrants to purchase Company common stock at $.80 per share.

XML 31 R19.htm IDEA: XBRL DOCUMENT v3.4.0.3
Summary of Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2016
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

 

The interim financial information of the Company as of periods ended March 31, 2016 and March 31, 2015 is unaudited. The balance sheet as of December 31, 2015 is derived from audited financial statements of eWellness Healthcare Corporation. The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial statements. Accordingly, they omit or condense footnotes and certain other information normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles. The accounting policies followed for quarterly financial reporting conform to the accounting policies disclosed in ASU 2014-10. In the opinion of management, all adjustments which are necessary for a fair presentation of the financial information for the interim periods reported have been made. All such adjustments are of a normal recurring nature. The results of operations for the three months ended March 31, 2016 are not necessarily indicative of the results that can be expected for the entire year ending December 31, 2016. The unaudited financial statements should be read in conjunction with the financial statements and the notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2015.

Use of Estimates

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from these good faith estimates and judgments.

Going Concern

Going Concern

 

For the period ended March 31, 2016, the Company has no revenues and no operations. The Company has an accumulated loss of $3,881,795. In view of these matters, there is substantive doubt about the Company’s ability to continue as a going concern. The Company’s ability to continue operations is dependent upon the Company’s ability to raise additional capital and to ultimately achieve sustainable revenues and profitable operations, of which there can be no guarantee. The Company intends to finance its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

Deferred Offering and Acquisition Costs

Deferred Offering and Acquisition Costs

 

The Company defers as other assets the direct incremental costs of raising capital until such time as the offering is completed. At the time of the completion of the offering, the costs will be charged against the capital raised. Should the offering be terminated, the deferred offering costs will be charged to operations during the period in which the offering is terminated. Direct acquisition costs will be expensed as incurred.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

The Company complies with the accounting guidance under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820-10, Fair Value Measurements, as well as certain related FASB staff positions. This guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact business and considers assumptions that marketplace participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance.

 

The guidance also establishes a fair value hierarchy for measurements of fair value as follows:

 

Level 1 – quoted market prices in active markets for identical assets or liabilities.

 

Level 2 – inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

 

Level 3 – unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

 

As of March 31, 2016, the Company had the following assets and liabilities measured at fair value on a recurring basis.

 

    Total     Level 1     Level 2     Level 3  
Derivative liability   $ 2,802     $ -     $ -     $ 2,802  
Total liabilities measure at fair value   $ 2,802     $ -     $ -     $ 2,802  

Cash and Cash Equivalents

Cash and Cash Equivalents

 

Cash and cash equivalents includes all cash deposits and highly liquid financial instruments with an original maturity to the Company of three months or less.

Property and Equipment

Property and Equipment

 

Property and equipment are recorded at historical cost. Minor additions and renewals are expensed in the year incurred. Major additions and renewals are capitalized and depreciated over their estimated useful lives. Depreciation is recorded over the estimated useful lives of the related assets using the straight-line method for financial statement purposes. The Company uses other depreciation methods (generally accelerated) for tax purposes where appropriate. The estimated useful lives for significant property and equipment categories are as follows:

 

Furniture and Fixtures   5-7 Years
Computer Equipment   5-7 Years
Software   3 Years

 

The Company regularly evaluates whether events or circumstances have occurred that indicate the carrying value of long-lived assets may not be recoverable. If factors indicate the asset may not be recoverable, we compare the related undiscounted future net cash flows to the carrying value of the asset to determine if impairment exists. If the expected future net cash flows are less than the carrying value, an impairment charge is recognized based on the fair value of the asset.

Revenue Recognition

Revenue Recognition

 

The Company has yet to realize revenues from operations. Once the Company has commenced operations, it will recognize revenues when delivery of goods or completion of services has occurred provided there is persuasive evidence of an agreement, acceptance has been approved by its customers, the fee is fixed or determinable based on the completion of stated terms and conditions, and collection of any related receivable is probable.

Loss per Common Share

Loss per Common Share

 

The Company follows ASC Topic 260 to account for the loss per share. Basic loss per common share calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per common share calculations are determined by dividing net loss by the weighted average number of common shares and dilutive common share equivalents outstanding. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation. As the Company has no common stock equivalents and has incurred losses for the period ended March 31, 2016, no dilutive shares are added into the loss per share calculations.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) that are adopted by the Company as of the specified date. The Company has elected to the early adoption of ASU 2015-03 that simplifies the presentation of debt issuance costs. The Company had previously used the methodology in this standard and has adopted the pronouncement for current and future debt instruments.

XML 32 R20.htm IDEA: XBRL DOCUMENT v3.4.0.3
Summary of Significant Accounting Policies (Tables)
3 Months Ended
Mar. 31, 2016
Property, Plant and Equipment [Abstract]  
Summary of Assets and Liabilities Fair Value Recurring Basis

As of March 31, 2016, the Company had the following assets and liabilities measured at fair value on a recurring basis.

 

    Total     Level 1     Level 2     Level 3  
Derivative liability   $ 2,802     $ -     $ -     $ 2,802  
Total liabilities measure at fair value   $ 2,802     $ -     $ -     $ 2,802  

Estimated Useful Lives for Significant Property and Equipment

The estimated useful lives for significant property and equipment categories are as follows:

 

Furniture and Fixtures   5-7 Years
Computer Equipment   5-7 Years
Software   3 Years

XML 33 R21.htm IDEA: XBRL DOCUMENT v3.4.0.3
Convertible Notes Payable (Tables)
3 Months Ended
Mar. 31, 2016
Debt Disclosure [Abstract]  
Schedule of Convertible Promissory Note

The Company’s Condensed Consolidated Balance Sheets report the following related to the convertible promissory notes:

 

    March 31, 2016  
Principal amount   $ 3,000  
Unamortized debt discount     -  
Net carrying amount   $ 3,000  

 

The Company’s Condensed Consolidated Balance Sheets report the following related to the convertible promissory notes:

 

      March 31, 2016  
Principal amount   $ -  
Unamortized debt discount     -  
Net carrying amount   $ -  

 

The Company’s Balance Sheets report the following related to the December 7, 2015, convertible promissory note:

 

    March 31, 2016  
Principal amount   $ 275,000  
Unamortized debt discount     (16,273 )
Net carrying amount   $ 258,727  

XML 34 R22.htm IDEA: XBRL DOCUMENT v3.4.0.3
Equity Transactions (Tables)
3 Months Ended
Mar. 31, 2016
Equity [Abstract]  
Summary of Stock Options Activity

The following is a summary of the status of all Company’s stock options as of March 31, 2016 and changes during the three months ended on that date:

 

    Number     Weighted  
    of Stock
Options
    Average Exercise Price  
Oustanding at January 1, 2016     0     $ -  
Granted     2,850,000     $ 0.80  
Exercised     0     $ -  
Cancelled     0     $ -  
Outstanding at March 31, 2016     2,850,000     $ 0.80  
Options exercisable at March 31, 2016     2,850,000     $ 0.80  

Schedule of Warrant Activity

The following is a summary of the status of all of the Company’s warrants as of March 31, 2016 and changes during the three months ended on that date:

 

            Weighted  
      Number of     Average  
      Warrants     Exercise Price  
Outstanding at January 1, 2015       609,533     $ 0.35  
Granted       5,021,658     $ 0.63  
Exercised       -     $ -  
Cancelled       -     $ -  
Outstanding at December 31, 2015       5,631,191     $ 0.61  
Granted       400,000     $ 0.80  
Exercised       -     $ -  
Cancelled       -     $ -  
Outstanding at March 31, 2016       6,031,191     $ 0.62  

Schedule of Valuation Assumptions

The significant assumptions used in the Black Scholes valuation of the date of issuance are as follows:

 

Stock price on the valuation date   $ 0.10  
Exercise price of warrants   $ .35 and .80  
Dividend yield     0.00 %
Years to maturity      2.5  
Risk free rate     2.0%  
Expected volatility     61%  

XML 35 R23.htm IDEA: XBRL DOCUMENT v3.4.0.3
Derivative Valuation (Tables)
3 Months Ended
Mar. 31, 2016
Derivative Valuation Tables  
Schedule of Assumptions Used Black Scholes Valuation of Derivative

The significant assumptions used in the Black Scholes valuation of the derivative are as follows:

 

Stock price at valuation date   $ .10  
Exercise price of warrants   $ .80  
Risk free interest rate     1.67 %
Stock volatility factor     62.82 %
Years to Maturity     5  
Expected dividend yield     None  

XML 36 R24.htm IDEA: XBRL DOCUMENT v3.4.0.3
The Company (Details Narrative) - $ / shares
Apr. 30, 2014
Apr. 11, 2014
Mar. 31, 2016
Dec. 31, 2015
Common stock, par value     $ 0.001 $ 0.001
Share Exchange Agreement [Member]        
Unregistered common stock issued   9,200,000    
Common stock, par value   $ 0.001    
Number of common stock returned to company by the officer   5,000,000    
Number of shares assigned to shareholders from the holdings of officer   2,500,000    
Number of shares owned by the shareholders, total   11,700,000    
Additional number of common shares assigned to other parties   2,100,000    
Percentage of issued and outstanding common stock own by shareholders of subsidiary 76.97%      
Number of shares of common stock outstanding     15,200,000  
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.4.0.3
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
Mar. 31, 2016
Dec. 31, 2015
Accounting Policies [Abstract]    
Accumulated deficit $ 3,881,795 $ 3,456,187
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.4.0.3
Summary of Significant Accounting Policies - Summary of Assets and Liabilities Fair Value Recurring Basis (Details)
Mar. 31, 2016
USD ($)
Derivative liability $ 2,802
Total liabilities measure at fair value $ 2,802
Level 1 [Member]  
Derivative liability
Total liabilities measure at fair value
Level 2 [Member]  
Derivative liability
Total liabilities measure at fair value
Level 3 [Member]  
Derivative liability $ 2,802
Total liabilities measure at fair value $ 2,802
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.4.0.3
Summary of Significant Accounting Policies - Estimated Useful Lives for Significant Property and Equipment (Details)
3 Months Ended
Mar. 31, 2016
Furniture and Fixtures [Member] | Minimum [Member]  
Estimated useful lives 5 years
Furniture and Fixtures [Member] | Maximum [Member]  
Estimated useful lives 7 years
Computer Equipment [Member] | Minimum [Member]  
Estimated useful lives 5 years
Computer Equipment [Member] | Maximum [Member]  
Estimated useful lives 7 years
Software [Member]  
Estimated useful lives 3 years
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.4.0.3
Property and Equipment (Details Narrative) - USD ($)
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Dec. 31, 2015
Property and equipment $ 5,543   $ 5,964
Depreciation expense 421 $ 211  
Computer Equipment [Member]      
Property and equipment 8,421   8,421
Accumulated depreciation $ 2,878   $ 2,457
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.4.0.3
Intangible Assets (Details Narrative) - USD ($)
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Dec. 31, 2015
Intangible assets $ 19,123   $ 19,862
Amortization expense 739 $ 739  
SoftwareLlicense [Member]      
Intangible assets 24,770   24,770
Accumulated amortization $ 5,647   $ 4,908
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.4.0.3
Related Party Transactions (Details Narrative) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Dec. 31, 2014
Dec. 31, 2015
Accounts payable-related party $ 50,362     $ 43,717
Imputed interest - related party $ 897 $ 1,078    
Percentage of interest rate of related party 8.00% 8.00%    
Percenage of patient insurance reimbursements received 75.00%      
Rent expense $ 500      
Accrued expenses - related party 49,226     $ 33,090
Chief Financial Officer [Member]        
Amount paid by related parties $ 96,831      
Chief Marketing Officer [Member]        
License fee     $ 20,000  
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.4.0.3
Income Taxes (Details Narrative) - USD ($)
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Dec. 31, 2015
Income Tax Disclosure [Abstract]      
Deferred tax assets, net valuation allowance  
Interest or penalties  
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.4.0.3
Non-Convertible Notes Payable (Details Narrative) - USD ($)
3 Months Ended
Mar. 14, 2016
Dec. 06, 2015
Oct. 11, 2015
Oct. 05, 2015
Sep. 16, 2015
Aug. 26, 2015
Jul. 15, 2015
May. 30, 2015
Apr. 09, 2015
Jan. 27, 2015
Mar. 31, 2016
Mar. 31, 2015
Promissory note                   $ 20,000    
Debt instrumenst interest rate                   12.00%    
Debt instruments maturity date                   Apr. 23, 2015    
Notes payable                 $ 20,000      
Accrued interest                 $ 3,980      
Debt maturity descriptions                 through March 31, 2015 and future consulting fees due and payable through October 2015      
Non convertible debt converted into convertible debt                 $ 100,000      
Convertible debt total                 $ 123,980      
Fair value of warrants $ 794                      
Interest expense note                     $ 22,494 $ 7,153
Non-Convertible Notes Payable [Member]                        
Debt instrumenst interest rate         12.00%   5.00% 5.00%        
Debt instruments maturity date     Dec. 14, 2015 Dec. 14, 2015                
Debt receivable         $ 22,500   $ 18,000 $ 25,000        
Issuance of warrants to purchase of commn stock     150,000 150,000 450,000 150,000 150,000 150,000        
Warrants issuance price per share     $ .80 $ .80 $ .80 $ 0.80 $ 0.80 $ 0.35        
Fair value of warrants     $ 300 $ 300 $ 908 $ 158 $ 310 $ 768        
Loans payable risky fee         $ 5,625   $ 4,500 $ 6,250        
Non-Convertible Notes Payable [Member] | Maximum [Member]                        
Debt instrumenst interest rate     12.00%       12.00%          
Non-Convertible Notes Payable [Member]                        
Debt instrumenst interest rate         12.00%              
Debt receivable         $ 12,500              
Issuance of warrants to purchase of commn stock         250,000              
Warrants issuance price per share         $ 0.80              
Fair value of warrants         $ 504              
Loans payable risky fee         $ 3,125              
Non-Convertible Notes Payable [Member]                        
Debt instrumenst interest rate 12.00% 12.00% 12.00%   12.00%              
Debt instruments maturity date May 01, 2016   Dec. 14, 2015                  
Notes payable $ 112,550                      
Convertible debt total   $ 70,000 $ 2,500,000                  
Debt receivable     $ 10,000   $ 2,500              
Issuance of warrants to purchase of commn stock 400,000 1,400,000 200,000   50,000              
Warrants issuance price per share $ .80 $ .80 $ .80   $ .80              
Fair value of warrants $ 794 $ 2,800 $ 385   $ 101              
Loans payable risky fee   17,500 2,500   $ 625              
Receiving from private placement   500,000 $ 100,000                  
Maximum of private placement   2,500,000                    
Promissory note from principal payment   $ 28,223                    
Note payable description On March 14, 2016, the Company issued a 45-day promissory note to a shareholder of $112,550 as an extension for notes with a shareholder dated May 30 2015, July 15, 2015, September 16, 2015, October 11, 2015, and December 6, 2015. holder cancelling the notes originally signed on May 27, 2015 plus extensions, July 15, 2015 plus extensions, September 16, 2015 and October 11, 2015.                    
Interest expense note                     $ 2,470  
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.4.0.3
Convertible Notes Payable (Details Narrative) - USD ($)
3 Months Ended
Mar. 14, 2016
Feb. 29, 2016
Feb. 20, 2016
Dec. 17, 2015
Nov. 11, 2015
Oct. 02, 2015
Sep. 10, 2015
Aug. 19, 2015
Jul. 14, 2015
Apr. 09, 2015
Jan. 27, 2015
Dec. 23, 2014
Dec. 23, 2014
Mar. 31, 2016
Mar. 31, 2015
Dec. 07, 2015
Interest rate                           8.00% 8.00%  
Debt instruments maturity date                     Apr. 23, 2015          
Debt instrument accrued interest rate                     12.00%          
Converted debt into shares amount   $ 69,500     $ 62,996 $ 17,595 $ 232,147 $ 33,600 $ 87,500              
Number of converted commnon stock   227,232   50,000 179,989 50,272 663,277 96,000 250,000              
Fair value of warrants $ 794                              
Interest expense                           $ 22,494 $ 7,153  
Maximum [Member]                                
Purchase of common stock purchase price per share                           $ .80    
Convertible Notes Payable [Member]                                
Issuance of convertible promissory notes                   $ 270,080   $ 213,337 $ 213,337      
Interest rate                   12.00%   12.00% 12.00%      
Accrued interest                   $ 123,980       $ 464    
Debt instruments maturity date                   Apr. 30, 2016     Dec. 31, 2015      
Convertible notes payable                       $ 3,000 $ 3,000      
Redemption right                   Redemption right: Any time the closing price of the Company’s common stock has been at or above $1.50 for 20 consecutive trading days, the Company has the right to redeem all or any part of the principal and accrued interest of the notes, following written notice to the holders of the Notes.     Redemption right: Any time the closing price of the Company’s common stock has been at or above $1.50 for 20 consecutive trading days, the Company has the right to redeem all or any part of the principal and accrued interest of the notes, following written notice to the holders of the notes.      
Common stock conversion price per share                   $ 0.35   $ 0.35 $ 0.35      
Purchase of common stock purchase price per share     $ .35                          
Convertible note payable description                   During the time that any portion of these notes are outstanding, if any Event of Default, as defined in the notes, occurs and such Default is not cured by the Company within sixty (60) days of the occurrence of the Event of Default (the “Cure Period”), the amount equal to one hundred fifty percent (150%) of the outstanding principal amount of this Note, together with accrued interest and other amounts owing shall become at the holder’s election, immediately due and payable in cash. The holders at its option have the right, with three (3) business days advance written notice to the Company after the expiration of the Cure Period, to elect to convert the Notes into shares of the Company’s common stock pursuant to the Optional Conversion rights disclosed above.     During the time that any portion of these Notes are outstanding, if any Event of Default, as defined in the notes, occurs and such Default is not cured by the Company within sixty (60) days of the occurrence of the Event of Default (the “Cure Period”), the amount equal to one hundred fifty percent (150%) of the outstanding principal amount of this Note, together with accrued interest and other amounts owing shall become at the holder’s election, immediately due and payable in cash. The holders at its option have the right, with three (3) business days advance written notice to the Company after the expiration of the Cure Period, to elect to convert the Notes into shares of the Company’s common stock pursuant to the Optional Conversion rights disclosed above.      
Debt instrument accrued interest rate                       150.00% 150.00%      
Percentage of expected borrowing rate                       18.00% 18.00%      
Converted debt into shares amount     $ 69,500                          
Number of converted commnon stock     227,332                          
Beneficial conversion feature                           44,189    
Convertible Notes Payable [Member] | Warrant [Member]                                
Warrants to purchase of common stock shares                   771,658   609,534        
Purchase of common stock purchase price per share                   $ .35   $ 0.35 $ 0.35      
Debt instrument accrued interest rate                   150.00%   12.00% 12.00%      
Fair value of warrants                   $ 1,132            
Convertible Notes Payable One [Member]                                
Issuance of convertible promissory notes                           3,000    
Accrued interest                           13,274    
Convertible Notes Payable Three [Member]                                
Issuance of convertible promissory notes                           $ 275,000    
Interest rate                           12.00%    
Percentage of expected borrowing rate                           18.00%    
Convertible Notes Payables [Member]                                
Issuance of convertible promissory notes                               $ 275,000
Interest rate                           8.00%   10.00%
Debt instruments maturity date                           Jun. 02, 2016    
Redemption right                           With three trading days prior written notice of the Company has the right to redeem all the note equal to the sum of 115% of the principal plus accrued and unpaid interest on the principal amount.    
Purchase of common stock purchase price per share                           $ .80    
Debt instrument accrued interest rate                           75.00%    
Purchase of warrants exercised                           $ 250,000    
Interest expense                           5,561    
Fail to raise in primary offering                           $ 1,000,000    
Convertible Notes Payables [Member] | Maximum [Member]                                
Interest rate                           15.00%    
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.4.0.3
Convertible Notes Payable - Schedule of Convertible Promissory Note (Details) - USD ($)
Mar. 31, 2016
Dec. 31, 2015
Net carrying amount $ 261,727 $ 309,945
Convertible Notes Payable One [Member]    
Principal amount $ 3,000  
Unamortized debt discount  
Net carrying amount $ 3,000  
Convertible Notes Payable Two [Member]    
Principal amount  
Unamortized debt discount  
Net carrying amount  
Convertible Notes Payable Three [Member]    
Principal amount $ 275,000  
Unamortized debt discount (16,273)  
Net carrying amount $ 258,727  
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.4.0.3
Equity Transactions (Details Narrative) - USD ($)
3 Months Ended
Mar. 14, 2016
Mar. 11, 2016
Mar. 03, 2016
Feb. 29, 2016
Feb. 19, 2016
Jan. 20, 2016
Dec. 17, 2015
Nov. 11, 2015
Oct. 02, 2015
Sep. 10, 2015
Aug. 19, 2015
Jul. 14, 2015
Feb. 23, 2015
Jan. 24, 2015
Mar. 31, 2016
Dec. 31, 2015
Aug. 06, 2015
Preferred stock, shares authorized                             10,000,000 10,000,000  
Preferred stock, par value                             $ .001 $ .001  
Preferred stock, shares issued                             0 0  
Common stock, shares authorized                             100,000,000 100,000,000  
Common stock, par value                             $ 0.001 $ 0.001  
Shares issued during period for consulting services, shares   150,000 100,000     50,000             60,000 400,000      
Shares issued during period for consulting services   $ 15,000 $ 10,100     $ 5,000             $ 6,000 $ 40,000      
Shares issued during period for conversion of convertible debt, shares       227,232     50,000 179,989 50,272 663,277 96,000 250,000          
Shares issued during period for conversion of convertible debt       $ 69,500       $ 62,996 $ 17,595 $ 232,147 $ 33,600 $ 87,500          
Common stock, shares issued                             18,697,770 18,170,538  
Common stock, shares outstanding                             18,697,770 18,170,538  
Risk free rate                             2.00%    
Volatility rate                             61.00%    
Number of warrants issued as part of extension of promissory note 400,000                                
Fair value of warrants $ 794                                
Stock price on the valuation date                             $ 0.10    
Stock Option Plan [Member]                                  
Number of reserved shares available for grants                                 3,000,000
Percentage of outstanding shares diluted basis                                 2.00%
stock options vest to purchase shares of common stock price per share         $ 0.80                        
Risk free rate         2.00%                        
Volatility rate         61.40%                        
Vested value of options                             $ 4,633    
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.4.0.3
Equity Transactions - Summary of Stock Options Activity (Details)
3 Months Ended
Mar. 31, 2016
$ / shares
shares
Equity [Abstract]  
Number of Stock Options Oustanding , Beginning Balance | shares 0
Number of Stock Options Oustanding , Granted | shares 2,850,000
Number of Stock Options Oustanding , Exercised | shares 0
Number of Stock Options Oustanding , Cancelled | shares 0
Number of Stock Options Oustanding , Ending Balance | shares 2,850,000
Number of Stock Options Oustanding , Exercisable | shares 2,850,000
Weighted Average Exercise Price, Beginning | $ / shares
Weighted Average Exercise Price, Granted | $ / shares $ 0.80
Weighted Average Exercise Price, Exercised | $ / shares
Weighted Average Exercise Price, Cancelled | $ / shares
Weighted Average Exercise Price, Ending | $ / shares $ 0.80
Weighted Average Exercise Price, Exercisable | $ / shares $ 0.80
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.4.0.3
Equity Transactions - Summary of Warrant Activity (Details) - Warrant [Member] - $ / shares
3 Months Ended 12 Months Ended
Mar. 31, 2016
Dec. 31, 2015
Number of Warrants Outstanding, Beginning Balance 5,631,191 609,533
Number of Warrants Granted 400,000 5,021,658
Number of Warrants Exercised
Number of Warrants Cancelled
Number of Warrants outstanding, Ending Balance 6,031,191 5,631,191
Weighted Average Exercise Price, Warrants Outstanding, Beginning Balance $ 0.61 $ 0.35
Weighted Average Exercise Price, Warrants Granted $ 0.80 $ 0.63
Weighted Average Exercise Price, Warrants Exercised
Weighted Average Exercise Price, Warrants Cancelled
Weighted Average Exercise Price, Warrants outstanding, Ending Balance $ 0.62 $ 0.61
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.4.0.3
Equity Transactions - Schedule of Valuation Assumptions (Details)
3 Months Ended
Mar. 31, 2016
$ / shares
Stock price on the valuation date $ 0.10
Dividend yield 0.00%
Years to maturity 2 years 6 months
Risk free rate 2.00%
Expected volatility 61.00%
Minimum [Member]  
Exercise price of warrants $ .35
Maximum [Member]  
Exercise price of warrants $ .80
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.4.0.3
Commitments, Contingencies (Details Narrative) - USD ($)
3 Months Ended
Mar. 14, 2016
Mar. 11, 2016
Mar. 03, 2016
Feb. 01, 2016
Jan. 20, 2016
Sep. 28, 2015
May. 20, 2015
Apr. 02, 2015
Feb. 23, 2015
Jan. 24, 2015
Mar. 31, 2016
Dec. 31, 2015
Apr. 09, 2015
Jan. 27, 2015
Percentage of returned funds                     90.00%      
Percentage of funds proceed                     10.00%      
Percentage of required funds                     90.00%      
Escrowed funds                     $ 100,000      
Proceeds from escrowed funds                     10,000      
Return of escrowed funds                     90,000      
Contingent liability                     90,000 $ 90,000    
Rent expense                     500      
Percentage of insurance reimbursement               75.00%            
Shares issued during period for consulting services, shares   150,000 100,000   50,000       60,000 400,000        
Shares issued during period for consulting services   $ 15,000 $ 10,100   $ 5,000       $ 6,000 $ 40,000        
Debt instrumenst interest rate                           12.00%
Fair value of warrants $ 794                          
Accrued interest                         $ 3,980  
Promissory Note Extension [Member]                            
Issuance of warrants to purchase of commn stock shares 400,000                          
Warrants price per share $ 0.80                          
Debt instrumenst interest rate 12.00%                          
Fair value of warrants $ 794                          
Accrued interest                     $ 629      
Mavericks Capital Securities Llc [Member]                            
Consulting fee             $ 10,000              
Proceeds from related party             $ 250,000              
Issuance of warrants to purchase of commn stock shares             250,000              
Warrants price per share             $ 0.35              
Percentage of revenue received           10.00%                
Escrow Trust [Member]                            
Percentage of subscription proceeds                     10.00%      
Trust account balance                     $ 90,000      
Consulting Firm [Member]                            
Consulting fee     $ 2,500                      
Consulting agreement term     6 months 6 months 1 year                  
Shares issued during period for consulting services, shares     100,000 100,000 100,000                  
Shares issued during period for consulting services     $ 100 $ 10,000 $ 5,000                  
Consulting Firm [Member] | Consulting Services Agreement [Member]                            
Shares issued during period for consulting services, shares         50,000                  
Consulting Firm [Member] | Consulting Services Agreement [Member] | July, 2016 [Member]                            
Shares issued during period for consulting services, shares         50,000                  
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.4.0.3
Segment Reporting (Details Narrative)
3 Months Ended
Mar. 31, 2016
Segments
Segment Reporting [Abstract]  
Number of operating segment 1
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.4.0.3
Derivate Valuation (Details Narrative) - USD ($)
Dec. 07, 2015
Mar. 31, 2016
Derivate Valuation Details Narrative    
Warrants granted $ 275,000  
Derivative liability   $ 2,802
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.4.0.3
Derivate Valuation - Schedule of Assumptions Used Black Scholes Valuation of Derivative (Details)
3 Months Ended
Mar. 31, 2016
$ / shares
Derivative Valuation Tables  
Stock price at valuation date $ 0.10
Exercise price of warrants $ 0.80
Risk free interest rate 1.67%
Stock volatility factor 62.82%
Years to Maturity 5 years
Expected dividend yield 0.00%
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.4.0.3
Subsequent Events (Details Narrative) - USD ($)
3 Months Ended
May. 02, 2016
Apr. 13, 2016
Mar. 14, 2016
Mar. 31, 2016
Mar. 31, 2015
Jan. 27, 2015
Consulting fees       $ 111,288 $ 90,394  
Debt instrumenst interest rate           12.00%
Promissory Note Extension [Member]            
Issuance of warrants to purchase of commn stock shares     400,000      
Warrants price per share     $ 0.80      
Debt instrumenst interest rate     12.00%      
Subsequent Event [Member] | Promissory Note Extension [Member]            
Issuance of warrants to purchase of commn stock shares 400,000          
Warrants price per share $ .80          
Debt instrumenst interest rate 12.00%          
Subsequent Event [Member] | Mr. Mills [Member]            
Issuance of warrants to purchase of commn stock shares   250,000        
Warrants price per share   $ 1.00        
Number of common stock shares issued during the period   10,000        
Shares issued price per share   $ 0.50        
Consulting fees   $ 500        
Payment of consulting fees   $ 2,500        
EXCEL 56 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 60 FilingSummary.xml IDEA: XBRL DOCUMENT 3.4.0.3 html 112 214 1 false 30 0 false 5 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://ewellnesshealth.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Balance Sheets Sheet http://ewellnesshealth.com/role/BalanceSheets Condensed Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Balance Sheets (Parenthetical) Sheet http://ewellnesshealth.com/role/BalanceSheetsParenthetical Condensed Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Statements of Operations (Unaudited) Sheet http://ewellnesshealth.com/role/StatementsOfOperations Condensed Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Statements of Cash Flows (Unaudited) Sheet http://ewellnesshealth.com/role/StatementsOfCashFlows Condensed Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Disclosure - The Company Sheet http://ewellnesshealth.com/role/Company The Company Notes 6 false false R7.htm 00000007 - Disclosure - Summary of Significant Accounting Policies Sheet http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 7 false false R8.htm 00000008 - Disclosure - Property and Equipment Sheet http://ewellnesshealth.com/role/PropertyAndEquipment Property and Equipment Notes 8 false false R9.htm 00000009 - Disclosure - Intangible Assets Sheet http://ewellnesshealth.com/role/IntangibleAssets Intangible Assets Notes 9 false false R10.htm 00000010 - Disclosure - Related Party Transactions Sheet http://ewellnesshealth.com/role/RelatedPartyTransactions Related Party Transactions Notes 10 false false R11.htm 00000011 - Disclosure - Income Taxes Sheet http://ewellnesshealth.com/role/IncomeTaxes Income Taxes Notes 11 false false R12.htm 00000012 - Disclosure - Non-Convertible Notes Payable Notes http://ewellnesshealth.com/role/Non-convertibleNotesPayable Non-Convertible Notes Payable Notes 12 false false R13.htm 00000013 - Disclosure - Convertible Notes Payable Notes http://ewellnesshealth.com/role/ConvertibleNotesPayable Convertible Notes Payable Notes 13 false false R14.htm 00000014 - Disclosure - Equity Transactions Sheet http://ewellnesshealth.com/role/EquityTransactions Equity Transactions Notes 14 false false R15.htm 00000015 - Disclosure - Commitments, Contingencies Sheet http://ewellnesshealth.com/role/CommitmentsContingencies Commitments, Contingencies Notes 15 false false R16.htm 00000016 - Disclosure - Segment Reporting Sheet http://ewellnesshealth.com/role/SegmentReporting Segment Reporting Notes 16 false false R17.htm 00000017 - Disclosure - Derivative Valuation Sheet http://ewellnesshealth.com/role/DerivativeValuation Derivative Valuation Notes 17 false false R18.htm 00000018 - Disclosure - Subsequent Events Sheet http://ewellnesshealth.com/role/SubsequentEvents Subsequent Events Notes 18 false false R19.htm 00000019 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPolicies 19 false false R20.htm 00000020 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPolicies 20 false false R21.htm 00000021 - Disclosure - Convertible Notes Payable (Tables) Notes http://ewellnesshealth.com/role/ConvertibleNotesPayableTables Convertible Notes Payable (Tables) Tables http://ewellnesshealth.com/role/ConvertibleNotesPayable 21 false false R22.htm 00000022 - Disclosure - Equity Transactions (Tables) Sheet http://ewellnesshealth.com/role/EquityTransactionsTables Equity Transactions (Tables) Tables http://ewellnesshealth.com/role/EquityTransactions 22 false false R23.htm 00000023 - Disclosure - Derivative Valuation (Tables) Sheet http://ewellnesshealth.com/role/DerivativeValuationTables Derivative Valuation (Tables) Tables http://ewellnesshealth.com/role/DerivativeValuation 23 false false R24.htm 00000024 - Disclosure - The Company (Details Narrative) Sheet http://ewellnesshealth.com/role/CompanyDetailsNarrative The Company (Details Narrative) Details http://ewellnesshealth.com/role/Company 24 false false R25.htm 00000025 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesTables 25 false false R26.htm 00000026 - Disclosure - Summary of Significant Accounting Policies - Summary of Assets and Liabilities Fair Value Recurring Basis (Details) Sheet http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPolicies-SummaryOfAssetsAndLiabilitiesFairValueRecurringBasisDetails Summary of Significant Accounting Policies - Summary of Assets and Liabilities Fair Value Recurring Basis (Details) Details 26 false false R27.htm 00000027 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives for Significant Property and Equipment (Details) Sheet http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPolicies-EstimatedUsefulLivesForSignificantPropertyAndEquipmentDetails Summary of Significant Accounting Policies - Estimated Useful Lives for Significant Property and Equipment (Details) Details 27 false false R28.htm 00000028 - Disclosure - Property and Equipment (Details Narrative) Sheet http://ewellnesshealth.com/role/PropertyAndEquipmentDetailsNarrative Property and Equipment (Details Narrative) Details http://ewellnesshealth.com/role/PropertyAndEquipment 28 false false R29.htm 00000029 - Disclosure - Intangible Assets (Details Narrative) Sheet http://ewellnesshealth.com/role/IntangibleAssetsDetailsNarrative Intangible Assets (Details Narrative) Details http://ewellnesshealth.com/role/IntangibleAssets 29 false false R30.htm 00000030 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://ewellnesshealth.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://ewellnesshealth.com/role/RelatedPartyTransactions 30 false false R31.htm 00000031 - Disclosure - Income Taxes (Details Narrative) Sheet http://ewellnesshealth.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://ewellnesshealth.com/role/IncomeTaxes 31 false false R32.htm 00000032 - Disclosure - Non-Convertible Notes Payable (Details Narrative) Notes http://ewellnesshealth.com/role/Non-convertibleNotesPayableDetailsNarrative Non-Convertible Notes Payable (Details Narrative) Details http://ewellnesshealth.com/role/Non-convertibleNotesPayable 32 false false R33.htm 00000033 - Disclosure - Convertible Notes Payable (Details Narrative) Notes http://ewellnesshealth.com/role/ConvertibleNotesPayableDetailsNarrative Convertible Notes Payable (Details Narrative) Details http://ewellnesshealth.com/role/ConvertibleNotesPayableTables 33 false false R34.htm 00000034 - Disclosure - Convertible Notes Payable - Schedule of Convertible Promissory Note (Details) Notes http://ewellnesshealth.com/role/ConvertibleNotesPayable-ScheduleOfConvertiblePromissoryNoteDetails Convertible Notes Payable - Schedule of Convertible Promissory Note (Details) Details 34 false false R35.htm 00000035 - Disclosure - Equity Transactions (Details Narrative) Sheet http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative Equity Transactions (Details Narrative) Details http://ewellnesshealth.com/role/EquityTransactionsTables 35 false false R36.htm 00000036 - Disclosure - Equity Transactions - Summary of Stock Options Activity (Details) Sheet http://ewellnesshealth.com/role/EquityTransactions-SummaryOfStockOptionsActivityDetails Equity Transactions - Summary of Stock Options Activity (Details) Details 36 false false R37.htm 00000037 - Disclosure - Equity Transactions - Summary of Warrant Activity (Details) Sheet http://ewellnesshealth.com/role/EquityTransactions-SummaryOfWarrantActivityDetails Equity Transactions - Summary of Warrant Activity (Details) Details 37 false false R38.htm 00000038 - Disclosure - Equity Transactions - Schedule of Valuation Assumptions (Details) Sheet http://ewellnesshealth.com/role/EquityTransactions-ScheduleOfValuationAssumptionsDetails Equity Transactions - Schedule of Valuation Assumptions (Details) Details 38 false false R39.htm 00000039 - Disclosure - Commitments, Contingencies (Details Narrative) Sheet http://ewellnesshealth.com/role/CommitmentsContingenciesDetailsNarrative Commitments, Contingencies (Details Narrative) Details http://ewellnesshealth.com/role/CommitmentsContingencies 39 false false R40.htm 00000040 - Disclosure - Segment Reporting (Details Narrative) Sheet http://ewellnesshealth.com/role/SegmentReportingDetailsNarrative Segment Reporting (Details Narrative) Details http://ewellnesshealth.com/role/SegmentReporting 40 false false R41.htm 00000041 - Disclosure - Derivate Valuation (Details Narrative) Sheet http://ewellnesshealth.com/role/DerivateValuationDetailsNarrative Derivate Valuation (Details Narrative) Details 41 false false R42.htm 00000042 - Disclosure - Derivate Valuation - Schedule of Assumptions Used Black Scholes Valuation of Derivative (Details) Sheet http://ewellnesshealth.com/role/DerivateValuation-ScheduleOfAssumptionsUsedBlackScholesValuationOfDerivativeDetails Derivate Valuation - Schedule of Assumptions Used Black Scholes Valuation of Derivative (Details) Details 42 false false R43.htm 00000043 - Disclosure - Subsequent Events (Details Narrative) Sheet http://ewellnesshealth.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://ewellnesshealth.com/role/SubsequentEvents 43 false false All Reports Book All Reports dgt-20160331.xml dgt-20160331.xsd dgt-20160331_cal.xml dgt-20160331_def.xml dgt-20160331_lab.xml dgt-20160331_pre.xml true true ZIP 62 0001493152-16-009703-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-16-009703-xbrl.zip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end